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Abstract 
 
Streptococcus equi subspecies equi (S. equi) is the pathogen responsible for the 
prevalent and highly contagious equine disease called strangles. Strangles has been 
reported worldwide as a cause of a high level of animal suffering and economic loss. S. 
equi is susceptible to many antibiotics in vitro, but relapse due to insufficient 
vascularity often renders such treatment ineffective. Getting effective and universally 
accepted vaccines against S. equi have been slow mainly because of safety concerns. It 
was previously reported that colonization of air interface organ cultures, after 
inoculation with a mutant strain (ΔprtM138-213) deficient in the putative maturase
 
lipoprotein (PrtM, a homologue of the pneumococcal PpmA) was less than that seen in 
cultures which were infected
 
with wild-type S. equi strain 4047 (Hamilton et al, 2006), 
indicating that PrtM is a major virulence factor in strangles. It has also been 
demonstrated by in vitro and in vivo studies that many streptococcal adhesins, for 
example, serve as colonization or virulence factors and this makes them attractive 
targets for therapeutic and preventive strategies against streptococcal infections 
(Nobbs et al., 2009). S. equi adhesins or other colonization factors may be substrates 
for PrtM.  
 
Understanding PrtM is key to designing drugs or vaccines against the equine S. equi 
infection and strangles. In this research, advanced biomolecular techniques were 
systematically applied to investigate and characterise PrtM, and to evaluate its 
potential as a therapeutic or vaccine target. Bioinformatics, microbiological, 
biochemical and molecular biology techniques were used in screening the S. equi WT 
4047 and Mutant (prtM138-213) strains to evaluate the immunogenicity and conservation 
of PrtM. Proteomics techniques: two-dimensional gel electrophoresis and mass 
spectrometry were employed in evaluating the cell-associated and secreted protein 
extracts of both the S. equi WT 4047 and mutant (prtM138-213) strains. In this study, 
genetic engineering technology involving targeted domain knock-out and/or knock-in, 
was employed in producing the central domain recombinant protein and mutant 
(prtM138-213) revertants. Following cloning, over-expression and purification of the full 
length and central domain, biochemical data on the PrtM protein (kcat/KM for S. equi 
4047 PrtM full length recombinant protein = 5.84 x 10
6
/M/s) were derived via enzyme 
(peptydylprolyl isomerase - PPIase) assay; and crystallography was applied in an 
attempt to derive structural data on the PrtM protein. Advanced biomolecular 
techniques (including Western blots and Proteomics) were employed in screening the 
complemented mutants. 
 
It has been proven from this research that the PrtM of S. equi 4047 is involved in 
adaptation to NaCl stress and in regulating sensitivity to antibiotics; PrtM may have 
roles in speeding up the synthesis of hyaluronic acid and in the folding or remodeling 
of HPr Kinase. The parvulin-type structure of PrtM elucidated by bioinformatics 
analysis, the cross reactions of the WT and mutant with a number of antisera, the 
observation that PrtM may be a multisubstrate foldase due to the detectable and 
significant differences in the proteomes of the WT, mutant and complemented 
mutants, the dimeric protein formed by the full length recombinant protein of S. equi 
4047 WT, and the PPIase-Chaperonine activities of PrtM, all observed from this study, 
validate PrtM of S. equi 4047 as a viable and novel therapeutic target which 
pharmaceutical industries should extensively evaluate for the prevention and treatment 
of S. equi infection and strangles. 
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Streptococcus equi subspecies equi is responsible for the prevalent and highly 
contagious equine respiratory infection known as strangles. Developing effective and 
universally accepted vaccines against this disease has been slow. The S. equi 
lipoprotein PrtM is a putative maturase, i.e. involved in the folding of proteins to be 
exported. It has been previously reported that PrtM is a virulence factor of S. equi, as 
demonstrated in both a mouse model and the equine host. Moreover, colonization of 
air interface organ cultures after inoculation with a maturase-deficient mutant strain 
was reduced compared to infections with the wild-type strain. In this study, we have 
performed proteomic analyses of cell-associated and secreted protein extracts from the 
maturase-deficient mutant strain and the wild type strain S. equi 4047. These data have 
revealed differentially expressed proteins. Specifically, we have found that FNE (a 
fibronectin binding protein) and IdeE2 (an immunoglobulin G endopeptidase) are 
present in the secreted protein extract of the wild type strain but not in the mutant 
strain. This suggests proteolytic degradation of misfolded secreted proteins and that 
PrtM may not be linked solely to the folding of one specific substrate, but is likely a 
multi-substrate maturase. These data have allowed us to identify potential maturase 
substrates which warrant further investigation for their contribution to the virulence of 
S. equi. 
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1 General Introduction 
 
1.1 Strangles: 
 
Streptococcus equi subspecies equi (S. equi) is the pathogen responsible for the 
prevalent and highly contagious equine disease called strangles (Hamilton et al., 2006; 
Jacobs et al. 2000; Hoopes et al., 2008; Pirie, 2013). Strangles is characterized by fever, 
followed by profuse nasal discharge and the formation of abscesses on the lymph nodes 
of the head and neck (Figure 1.1a), which eventually burst and discharge highly 
infectious pus (Kelly et al., 2006, Robinson et al., 2013) – Figures 1.1b and 1.1c. 
 
 
Figure 1.1a: Swelling around the head and neck region of a horse due to 
inflammed lymph nodes – photo adapted from America’s Horse Daily, 2011. 
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Figure 1.1b: A S. equi infected horse showing profuse purulent nasal discharge 
after rupture of retropharyngeal lymph nodes (Adapted from Brazil, 2005). 
 
 
 
 
 
Figure 1.1c: Pus draining from a retropharyngeal S. equi abscess. (Adapted from 
Professor P. Dixon in Brazil, 2005). 
 
The disease is called strangles because soon after nasopharyngeal infection, affected 
horses were sometimes suffocated due to constriction of the pharynx (resulting from 
lymph node swelling – Figure 1.1d) and airway obstruction (Sweeney et al., 2005; 
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Hamilton et al., 2006). About 50% of horses with retropharyngeal lymphadenitis 
develop some degree of empyema after abscess rupture into the guttural pouches 
(Brazil, 2005). 
 
 
 
Figure 1.1d: Pony showing prominent swelling in the throat latch area (black 
arrowheads) due to chronic guttural pouch empyema (Adapted from Brazil, 2005). 
 
 
 
Equine strangles has been reported to occur worldwide (Jacobs et al., 2000; Kelly et al., 
2006; Waller et al., 2011), incurring a lot of economic losses from treatment, quarantine 
measures and occasional death of the animals (Jacobs et al., 2000). In Australia, death 
due to strangles had been reported to account for a minimum direct loss to the horse 
industry of $6.5 million annually (Canfield et al., 2000).  It has been reported that S. equi 
was responsible for about 30% of all reported cases of equine infections worldwide 
(Chanter, 1997). Though mostly reported in equidea, S. equi infection has lately been 
reported in camelids (Yigezu et al, 1997); and a case of canine strangles was recently 
reported in a dog with enlarged lymph nodes due to infection with S. equi (Ladlow et 
al., 2006). To date there has been one report of human infection with S. equi (Duma et 
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al 1969) and one case of a human with a syndrome resembling strangles (Breiman and 
Silverblatt, 1986). 
In premises, outbreak of strangles may be initiated by the introduction of: 
 animals that are incubating the disease, 
 any horse that is still shedding bacteria after clinical recovery 
 chronic carriers that may shed bacteria intermittently (Brazil 2005). 
   
It has been known for about 100 years that S. equi can remain in the upper respiratory 
tract of previously infected horses which presently appear clinically normal and can 
consequently serve as sources of infection to other animals (Brazil, 2005).  The guttural 
pouches are the main sites of bacterial persistence in chronic carriers (Harrington et al., 
2002; Kelly et al., 2006). Although there are no detailed immunological studies, it has 
been suggested that about seventy five per cent (75%) of animals develop solid 
immunity after recovery from infection and may be protected from re-infection for 
several years (Hamlen et al., 1994; Brazil, 2005). Colostrum and milk from immune 
mares have specific immunoglobulin G (IgG) and immunoglobulin A (IgA) which is 
normally protective against foalhood strangles till the animals are weaned (Galan et al., 
1986). 
 
Younger animals, less than five years old, are more commonly and more severely 
affected by strangles (Ijaz et al., 2010). S. equi is capable of infecting the host by 
attaching to tonsillar epithelium after inhalation or ingestion of infected secretions 
(Brazil, 2005). After attachment, the organism quickly migrates to draining lymph 
nodes where it multiplies, causing lymphadenopathy with surrounding oedema within 
7-10 days (Brazil, 2005). This is closely followed by abscessation of the submandibular, 
parotid and retropharyngeal lymph nodes (Sweeney et al., 2005; Timoney and Kumar, 
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2008). The hyaluronic acid capsule of S. equi and production of antiphagocytic enzymes 
and toxins by the organism makes it highly resistant to phagocytosis by neutrophils 
(Holden et al., 2008) The result of this phagocytic resistance is uncontrolled bacterial 
multiplication which in turn gives rise to intense neutrophil accumulation, resulting in 
rapid abscess formation (Brazil, 2005; Holden et al., 2008). Nasal shedding of bacteria 
begins 2-3 days after the onset of pyrexia and persists for 2-3 weeks (Sweeney et al., 
2005).  
 
Haematogenous or lymphatic spread results in secondary abscessation of local lymph 
node chains and metastatic dissemination to remote lymph nodes and other tissues, a 
phenomenon called bastard strangles (Timoney, 2004; Brazil, 2005). Young horses are 
more likely to develop severe lymph node abscessation which eventually opens and 
drains; however outbreaks characterised by mild clinical signs (characterised by nasal 
discharge, small absceses and rapid resolution of the disease)  have been reported, often 
in older horses (Sweeney et al., 2005). The severity of the disease depends on the innate 
immune status (Sweeney et al., 2005) and the general health of the infected animals; as 
well as on the dose of the bacteria (Brazil, 2005). 
 
 
 
1.2 Streptococcus equi subspecies equi (S. equi) 4047 
 
S. equi is a member of the pyogenic group of organisms which are beta-haemolytic, 
producing true haemolysis on blood agar (Nobbs et al., 2009). A Gram positive 
bacteria, S. equi shares membership of Lancefield’s group C Streptococci (Anzai et al., 
1997) with Streptococcus zooepidemicus, Streptococcus equisimilis (Brazil, 2005; 
Harrington et al., 2002) and S. dysgalactiae (Efstratiou et al., 1994; Nobbs et al., 2009). 
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S. equi is susceptible to most antibiotics in vitro (Harrington et al., 2002; Jacks et al., 
2003). However, treatment of strangles is usually ineffective because of relapse 
resulting likely from insufficient vascularity (in the abscess) to enable antibiotic 
penetration to therapeutic levels and/or inability of antibiotic treatment to eliminate 
mucosal colonization (Harrington et al., 2002). Consequently, after treatment, it is not 
uncommon for clinical signs to abate, or for onset to be delayed until withdrawal of 
treatment (Harrington et al., 2002). Generally, there are only a small number of new 
antibiotic agents for therapy of infections caused by Gram positive organisms, and the 
pathway for the development of new antibiotics is long and higly expensive (Upton et 
al., 2012). 
 
 
Horizontal gene transfer continues to influence the virulence and pathogenicity of 
Streptococcal species (Upton et al., 1996; Lawrence, 2005). There is strong evidence 
that genetic exchange between S. equi, S. zooepidemicus and Streptococcus pyogenes 
continues to influence the pathogenicity of these important bacteria (Waller et al., 
2011). S. equi and S. zooepidemicus share more than 80% DNA sequence identity with 
S. pyogenes, a human pathogen (Waller et al, 2011). Understanding S. equi better may 
shed new light into S. pyogenes infections because both organisms apart from having a 
lot in common, are also the etiologic agents of strangles and tonsillitis (respectively) - 
diseases that share similarities as well (Waller et al., 2011). 
 
S. zooepidemicus is believed to be the ancestral parent from which S. equi evolved 
(Guss et al, 2009; Webb et al., 2008, Holden et al., 2009). The two organisms share 
97% sequence identity (Ladlow et al., 2006). The population of the S. zooepidemicus 
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group is highly diverse and is made up of at least 218 sequence types (Guss et al., 
2009). However, isolates of S. equi are either ST-179 or a single locus variant (ST-151) 
that are characteristic of S. equi isolates from the USA, Canada, Australia and Europe 
(Webb et al., 2008). The limited genetic diversity of S. equi indicates that it is possible 
for an effective vaccine to confer broad protection to horses throughout the world (Guss 
et al, 2009; Flock et al, 2012). 
 
 
The development of effective preventative vaccines against equine S. equi infection has 
been slow (Guss et al., 2009, Guss et al., 2011). Although not licensed for sale in 
Europe due to safety concerns, a non-encapsulated strain of S. equi (Pinnacle IN
TM
) has 
been used as a nasal vaccine against strangles (Guss et al., 2009). A second live 
attenuated vaccine called Equilis StrepE was marketed in Europe but was withdrawn in 
2007 due to safety concerns as well (Guss et al., 2009, Guss et al., 2011). The 
Committee for Medicinal Products for Veterinary Use (a committee of the European 
Medicine Agency, European Union) has given marketing authorisation  for Equilis 
StrepE, concluding that the benefit of this vaccine exceed the risks for immunisation of 
horses against S. equi to reduce clinical signs and occurrence of lymph-node abscesses 
(European public assessment report, for European Medicine Agency, 2013).  
 
Regarding the risk associated with Equilis Strep E vaccine, the committee for Medicinal 
Products for Veterinary Use (European public assessment report, for European 
Medicine Agency, 2013) did state that “Only healthy horses that are at risk of infection 
should be vaccinated. After injection, swelling will develop at the injection site within 
four hours and the injection site may become warm or painful. The reaction is greatest 
at two to three days after injection, but the area affected should not be larger than 3 x 8 
cm. The swelling should disappear within three weeks and should have no effect on the 
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horse’s appetite, nor cause it any discomfort. In very rare cases, an abscess and 
discharge may develop at the injection site, and the lymph nodes in the head may 
enlarge, which may be painful for a short while. An increase in body temperature of up 
to 2°C may occur on the day of vaccination. In rare cases, loss of appetite, fever and 
shivering may be observed. In very rare cases, depression may develop”. According to 
Meehan et al. (1998), a vaccine targeted against M protein (SeM a surface antigen that 
increases S. equi infection) was successful in experiments with mice. However, the 
same results were not replicated in horses (Libardoni et al., 2013). It is highly desirable 
that a safe and effective vaccine be developed against S. equi (Guss et al., 2009; Waller, 
2013). 
 
The virulent strain of S. equi 4047 (ST-179 by multilocus sequence
 
typing - MLST) was 
isolated from a horse with strangles in the New Forest, England in 1990 (Swiss Institute 
of Bioinformatics, 2010; Holden et al., 2009). Multilocus sequence typing is a 
molecular technique that is established in typing bacteria via the generation of an allelic 
profile (Smith et al., 2007).  
 
Availability of data from the S. equi genome and proteome projects (Welcome Trust 
Sanger Institute, 2013, and Swiss Institute of Bioinformatics, 2010 respectively) is a 
major development in the study of strangles and S. equi (Hamilton et al., 2006).  Access 
to such sequence data (Figure 1.2a) permit the identification of surface exposed and 
secreted proteins and is anticipated to revolutionalize vaccine design – reverse 
vaccinology (Bambini et al, 2009 and Serruto et al., 2009 in Guss et al., 2009). 
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Figure 1.2a: Schematic circular diagram of the S. equi 4047 genome (Adapted from Holden 
et al., 2009). Key (outside to inside): scale (in Mb); annotated coding sequences  (CDSs) 
coloured according to predicted function represented on a pair of concentric circles, 
representing both coding strands; orthologue matches which are shared with the Streptococcal 
species, S. equi 4047 or SzH70, SzMGCS10565, S. uberis 0140J, S. pyogenes Manfredo, S. 
mutans UA159, S. gordonii Challis CH1, S. sanguinis SK36, S. pneumoniae TIGR4, S. 
agalactiae NEM316, S. suis P1/7, S. thermophilus CNRZ1066, blue; orthologue matches that 
are shared with Lactococcus lactis subspecies lactis, green; G+C% content plot; G+C deviation 
plot (>0%, olive, <0%, purple). Colour coding for CDS functions: dark blue for 
pathogenicity/adaptation; black for energy metabolism; red for information transfer; dark green 
for surface-associated; cyan for degradation of large molecules; magenta for degradation of 
small molecules; yellow for central/intermediary metabolism; pale green for unknown; pale 
blue for regulators; orange for conserved hypothetical; brown for pseudogenes; pink for phage 
and IS elements; grey, miscellaneous. The positions of the four prophages and two ICESe, 
present in the S. equi 4047 genome, are shown (Holden et al., 2009). 
 
 
 
It is believed that the evolution of S. equi has been shaped by recent gene loss and gain 
(Holden et al., 2009). In terms of gene loss, compaired to S. zooepidemicus, S. equi 
produces less hyaluronidase which means that S. equi is less able to attach to mucosal 
surfaces (Holden et al., 2009). Hyaluronidases are enzymes which can break down 
hyaluronate and are produced by a number of pathogenic Gram-positive bacteria that 
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initiate infections at the skin or mucosal surfaces (Hynes and Walton, 2006).  S. 
zooepidemicus (SzH70) genome has a single coding sequence encoding a putative 
hyaluronate lyase, SZO06680 (Holden et al., 2009). However, SEQ1479, which is an S. 
equi 4047 orthologue, contains a 4 bp deletion (TCTC) leading to a frameshift at codon 
199 (Holden et al., 2009).  S. equi 4047 has acquired a different hyaluronate lyase 
(SEQ2045) encoded on a prophage (Holden et al., 2009). This type of phage-encoded 
enzyme usually has much lower activity and reduced substrate range (Baker et al., 
2002) compaired to orthologues of SZO06680 (Pritchard et al., 1994) and may be why 
S. equi infection rarely progresses beyond the lymphatic system (Holden et al., 2009). 
The reduced level of hyaluronidase activity provides an alternative explanation as to 
why S. equi maintains high levels of hyaluronic acid capsule (Holden et al., 2009).  
 
Comparison of the genome sequences of S. zooepidemicus and S. equi, observed a 5 kb 
deletion in the S. equi 4047 genome that partially deleted lacD and lacG and deleted 
lacE, lacF and lacT (Holden et al., 2009). S. equi 4047 also contains a deletion of sorD 
gene which is immediately upstream of SEQ0286 and a deletion between SEQ0536 and 
SEQ0537 which spans the operon required for ribose fermentation (Holden et al., 
2009). Specialization of S. equi has likely rendered these pathways redundant, resulting 
in their loss (Holden et al., 2009). Carbohydrate metabolism in streptococci is important 
in colonization of mucosal surfaces (Shelburne et al., 2008). Carbohydrate fermentation 
is also used to differentiate S. equi strains from S. zooepidemicus (Bannister et al., 
1985). 
 
Gram-positive bacteria have some cell wall-anchored proteins on their surface and these 
proteins are attached covalently through a process mediated by sortase enzymes 
(Marraffini et al., 2006). These cell wall-anchored proteins have been shown to play a 
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role in modulating host-cell interactions in many cases (Holden et al., 2009). Only two 
putative sortase coding sequences are present in the S. equi 4047 genome: srtA 
(SEQ1171) and srtC.1 (SEQ0937), whereas S. zooepidemicus H70 genome has five: 
srtA (SZO09440), srtC.1 (SZO11490), srtC.2 (SZO18270), srtC.3 (SZO18280) and 
srtC.4 (SZO18290) (Holden et al., 2009).  
 
Mutation and gene loss are likely to contribute to decreased fibronectin binding in S. 
equi compared to S. zooepidemicus (Holden et al., 2009). Pili play an important role in 
the adherence of S. pyogenes to host tissues (McElroy et al., 2002). The S. 
zooepidemicus H70 genome contains two loci that encode genes required putatively for 
pilus expression (Holden et al., 2009). The genome of S.equi 4047 lacks a putative pilus 
locus through an ISSeq3 element-mediated deletion (Holden et al., 2009). 
Diversification of pilus loci may play an important role in S. zooepidemicus ability to 
infect different hosts and tissues (Holden et al., 2009). 
 
 
The absence of prophage in S. zooepidemicus may be due to the presence of clustered 
regularly interspaced short palindromic repeat (CRISPR) arrays and competence 
proteins which confer resistance to circulating phage and maintain genome integrity 
(Holden et al., 2009). In S. equi, the acquisition of prophage plays an important 
evolutionary role through integration of cargo genes; recirculation and secretion of the 
integrated φSeq1 (Figure 1.2a) may kill susceptible competing bacteria like S. 
zooepidemicus; φSeq2 contains a gene encoding a phospholipase A2 (SlaA) that may 
enhance virulence; and φSeq3 and φSeq4 encode superantigens SeeH, SeeI, SeeL, and 
SeeM that target the equine immune system (Holden et al., 2009).  
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 In S. equi 4047, the presence of integrative conjugative elements (ICESe2) locus 
(Figure 1.2a) may enhance iron acquisition through the production of a potential 
siderophore, equibactin (Holden et al., 2009). The ICESe2 locus was absent in the S. 
zooepidemicus isolates that were examined (Holden et al., 2009). The key speciation 
event in the evolution of S. equi, due to gene gain, may be the acquisition of ICESe2, 
which is the first of its kind to be identified in streptococci (Holden et al., 2009). 
 
 
 
 
 
1.3 Molecular Basis of S. equi Infection and Disease 
 
S. equi is able to gain entrance into the horse or pony through the mouth or nose, where 
it attaches to the cells in the crypt of the lingual and palatine tonsils and to the 
follicular-associated epithelium of the pharyngeal and tubal tonsils (Sweeney et al., 
2005). The factors which are produced by S. equi and implicated in its virulence can be 
broadly grouped into the following categories: adherence, invasion, immune evasion 
and nutrient aquision factors (Harrington et al., 2002). 
 
The first step in S. equi pathogenesis entails its adhesion to the host epithelium in the 
upper respiratory tract (Slater, 2003). Some ligands that may be responsible for this 
adhesion to host tissues may include the exposed surface proteins SzPSe, Se73.9, and 
Se51.9 (Sweeney et al., 2005). A fibronectin binding protein designated FNZ in S. 
zooepidemicus, is also produced by S. equi (FNZ is designated FNE in S. equi)  but 
without a C terminal anchor and so may not be functional (Lindmark et al., 2001; 
Harrington et al., 2002; Sweeney et al., 2005; Waller et al., 2011). 
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The ability of S. equi to interact with and adhere to different surfaces may increase it’s 
chances of survival when it gets to surfaces where specific and irreversible interactions 
occur and conditions are favourable for colonization (Harrington et al., 2002). The 
hyaluronic acid capsule of S. equi may also be involved in mediating adherence to the 
host (Harrington et al., 2002). 
 
To be able to gain access to the lymphatics and blood vessels of the lamina propria, S. 
equi has to invade the respiratory epithelium of the host (Sting et al, 1990 in Slater, 
2003). To achieve this, S. equi produces degradative enzymes like hyaluronidase (Sting 
et al, 1990 in Slater, 2003) and streptolysin-S like haemolysin which is a cytolytic toxin 
(Flanagan et al., 1998). Before penetration, there is no evidence for colonization; 
however S. equi reaches the deeper tissues of the tonsil within a few hours of gaining 
entry (Sweeney et al., 2005). 
 
To be able to invade and proliferate, a pathogen has to avoid being recognized by 
immunoglobulins, which are key components of the adaptive immune response 
(Lannergard and Guss, 2006). The immune complement of the host interacts with S. 
equi peptidoglycan and attracts large numbers of polymorphonuclear neutrophils.  
 
S. pyogenes produces and secretes IdeS (streptococcal cysteine proteinase an 
immunoglobulin-degrading enzyme) which has an important impact on the ability of the 
bacteria to survive in the human host (von Pawel-Rammingen and Bjorck, 2003). S. 
equi encodes two IgG endopeptidases – IdeE and IdeE2 which share amino acid 
sequence identity with IdeZ and IdeZ2 of S. zooepidemicus and IdeS of S. pyogenes 
(von Pawel-Rammingen and Bjorck, 2003). These enzymes cleave the IgG produced by 
a number of animal species, thereby reducing IgG recognition and targeting of bacteria 
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by the host immune response (Waller et al., 2011). For S. equi, the observed 
degradation of IgG - in the presence of horse serum, but not when grown with purified 
IgG - might be due to the expression of an unknown enzyme rather than IdeE 
(Lannergard and Guss, 2006). IdeE2 and IdeZ2 cleave equine IgG more efficiently than 
IdeZ and IdeE (Hulting et al., 2009), 
 
The inability of the neutrophils to phagocytose and kill the invading S. equi may be due 
to a combination of the hyaluronic acid capsule, SeM protein [antiphagocytic, acid 
resistant, fibrillar and fibrinogen binding] (Timoney, 2004) and other undetermined 
antiphagocytic factors released by the bacteria (Sweeney et al., 2005). The resistance of 
S. equi to phagocytosis is dependent on its level of expression of hyaluronic acid 
capsule; encapsulated strains were found to be more resistant than nonencapsulated 
strains (Anzai et al, 1999; Harrington et al., 2002). The antiphagocytic capsule is 
believed to reduce the numbers of S. equi cells that get associated with the surface of 
neutrophils and are subsequently ingested and killed (Tmoney, 2004). 
 
 
Streptolysin S and streptokinase may have roles to play in abscess development and 
lysis, by damaging cell membranes and activating the proteolytic properties of 
plasminogen (Timoney, 2004). S. equi has also exhibited some mitogenic activity which 
may contribute to severe inflammation and abscess formation (Anzai et al, 1999; 
Harrington et al., 2002). At least four pyrogenic mitogens, SePE-H, SePE-I, SePE-K 
and SePE-L, are expressed by S. equi and these result in non-specific T cell stimulation, 
proliferation, proinflammatory cytokine release and production of an acute phase 
response with high fever, neutrophilia and fibrinogenemia (Timoney, 2004). Long 
chains of S. equi accumulate, surrounded by large numbers of degenerating neutrophils 
(Timoney, 2004; Sweeney et al., 2005). Only the lysis of the abscess capsule and 
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evacuation of its contents would eventually dispose of the bacteria (Sweeney et al., 
2005). 
 
A S. equi LppC (a class C acid phosphatase) homologue; and ATP-binding cassette 
(ABC) transporter MBL (a S. equi lipoprotein homologue of the PsaA protein of 
Streptococcus pneumoniae) may be involved in nutrient acquisition (Harrington et al., 
2002). Hyaluronidase activity may be involved in the utilization of the hyaluronic acid 
(an abundant carbon source) of the host and in recycling of released capsular hyaluronic 
acid (Harrington et al., 2005). HPr (histidine-containing phosphocarrier protein) is an 
important player in bacterial and streptococcal phosphoenolpyruvate (PEP) 
phosphotransferase system (PTS).   It was speculated by Dixon et al, (2001) that 
surface-localised and released HPr-1 of S. equi may also have roles to play in its  (HPr-
1) mitogenic activity which had previously been demonstrated in S. pyogenes by 
Gerlach et al., (1992). 
 
The success of S. equi pathogenesis is therefore partly attributed to the wide array of 
proteins expressed by the organism.  
 
 
1.4 Lipoproteins in Gram-Positive Bacteria 
 
In addition to providing a rigid exoskeleton for protection against mechanical and 
osmotic lysis, the cell wall of Gram-positive bacteria also serves as an attachment site 
for proteins which interact with the bacterial environment (Navarre and Schneewind, 
1999). Gram-positive bacteria can immobilize proteins on their surface by covalently 
attaching proteins to the peptidoglycan or by noncovalently binding protein to either the 
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peptidoglycan or secondary wall polymers such as teichoic acids (Navarre and 
Schneewind, 1999).  
 
Lipoproteins are proteins which contain lipids that are covalently linked to an N-
terminal cysteine residue (Braun and Wu, 1994). In Gram-positive bacteria, lipoproteins 
are cell envelope proteins that are anchored into the outer leaflet of the plasma 
membrane (Hutchings et al., 2009). An N-terminal signal sequence
 
that is synthesized 
with a lipoprotein, directs the protein into the lipoprotein-processing pathway (Denham 
et al., 2009). 
 
Most exported proteins are transported across the cytoplasmic membrane of prokaryotes 
by one of either the general secretory (Sec) pathway (which is the predominant route of 
protein transport) or the twin arginine protein transport (TAT) system which transports 
folded and even oligomeric proteins (Hutchings et al., 2009) – Figure 1.4a. 
 
 
Figure 1.4a: The lipoprotein biogenesis pathway in Gram Positive Bacteria: unfolded (red 
straight line) or folded (red filled circle) lipoproteins are directed to and translocated across the 
cytoplasmic membrane by the Sec or Tat pathways by their signal sequences (shown in blue) 
(i). A lipid group (angled black line) is covalently attached to the sulphydryl group of the 
lipobox cysteine by Lgt (prolipoprotein diacylglycerol transferase) (ii), and the signal peptide is 
cleaved by Lsp (lipoprotein or type II signal peptidase) (iii). The pathway is conserved in Gram-
positive bacteria, but does not necessarily occur in strict order (Hutchings et al., 2009).  
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In both the Sec and TAT pathways -Figure 1.4b - proteins are targeted by means of the 
N-terminal signal peptides (Hutchings et al., 2009). Several streptococci lack the TAT 
pathway (Dilks et al., 2003). It is believed that in Gram-positive bacteria, mutants that 
are defective in lipoprotein biosynthetic enzymes remain viable possibly because some 
lipoprotein precursors retain functionality (Hutchings et al., 2009). 
 
 
 
Figure 1.4b: Type I and type II signal peptides for Sec- and Tat-dependent 
transport (Adapted from Hutchings et al., 2009). Both the Sec (a) and the Tat (b) signal 
peptides are tripartite in structure with a positively charged N- (N-terminal) region, an 
H- (hydrophobic) region and a C- (cleavage) region, that contains the recognition motif 
for type I (A-X-A, where X is any amino acid) or type II (L- 3-[A/S/T]-2-[G/A]-1-C+1) 
signal peptidases. The type II cleavage site is referred to as the lipoprotein ‘lipobox’. 
Tat signal peptides have variable length N-regions and a conserved SRRXFLK sequence 
between the N- and H-regions (Petit et al., 2001 in Hutchings et al., 2009) where the 
twin arginine (RR) motif is almost completely conserved and gives the transport 
pathway its name. 
 
 
In Gram-positive bacteria, lipoproteins are believed to play  important roles in substrate 
binding for ATP-binding Cassette (ABC) transporters; adhesion;  antibiotic, lantibiotic 
and bacterioicin resistance and superinfection exclusion; cell envelope homeostasis; 
protein secretion, folding and localization, redox processes; and in sensory processes, 
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including signalling in sporulation and germination (Sutcliffe and Russel, 1995; 
Hutchings et al., 2009). Bioinformatic evaluation of microbial genomes has revealed 
that putative lipoproteins represent a notable proportion (~2%) of the typical Gram-
positive bacterial proteome; are also notable as cell envelope proteins which interact 
with membrane associated or exported proteins (Hutchings et al., 2009) and are 
predicted to have important roles in pathogenic bacteria/host interactions (Hamilton et 
al., 2006; Chimalapati et al., 2012).  
 
Apart from the surface components directly involved in adhesion and immune invasion, 
the factors which influence proper protein folding and surface composition are also 
essential for bacterial virulence (Cron et al., 2009). After translocation and cleavage of 
a signal peptide, proteins fold into their native conformation (Wahlstrom et al., 2003). 
Rapid and correct folding of secreted proteins is essential, in particular because (partly) 
unfolded proteins are very sensitive to proteases several of which are present at the 
trans side of the membrane (Tjalsma et al., 2000).  
 
Many folding factors that assist post-translocational folding have been identified and 
these include chaperones, peptidylprolyl cis/trans-isomerases (PPIase) and thiol-
disulphide oxido-reductases (Tjalsma et al., 2000). In Bacillus subtillis, one of the 
proteins (named PrsA) involved in the folding of proteins after their translocation is a 
lipoprotein that is anchored to the outer leaflet of the cytoplasmic membrane (Kotinen 
and Sarvas, 1993). PrsA belongs to the parvulin family of PPIases (Rahfeld et al., 
1994). Most PrsA-Like proteins from the gram-positive bacteria contain a peptide 
leader followed by a cysteine, suggesting that they are lipoproteins (Drouault et al., 
2002). Some other lipoproteins identified to be PPIases include SIrA of Streptoccoccus 
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pneumonia (Hermans et al., 2006) and the proteinase maturation protein, PrtM of 
Lactococcus lactis (Haandrikman et al., 1991).  
 
 
 
1.5 Peptidyl-prolyl cis/trans Isomerases 
 
To be able to achieve a functional conformation, many proteins require enzymatic 
assistance (Lazar and Kolter, 1996). Peptidyl-prolyl cis/trans isomerases (PPIases; also 
termed foldase or maturase) are found in both prokaryotic and eukaryotic cells, where 
they ensure the conformation (folding and remodeling) of proteins involved in many 
vital functions, including virulence (Reffuveille et al., 2012). PPIases are folding 
proteins which catalyze the cis/trans isomerization of peptidylprolyl (Lazar and Kolter, 
1996; Reffuveille et al., 2012; Elfaki et al., 2013) – Figure 1.5a.  The cis-trans 
isomerization of prolyl residues is a rate-limiting step in protein folding (Lazar and 
Kolter, 1996).  
 
Figure 1.5a: The cis/trans isomerization reaction of PPIases (adapted from Kay, 
1996) 
 
PPIases can be broadly divided into four different families which are unrelated in their 
amino acid sequences (Kouri et al., 2009): FK506 binding proteins (FKBPs), 
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cyclophilins, parvulins (Heikkinen et al., 2009) which bind to juglone (Gothel and 
Marahiel, 1999), protein phosphatase 2A (PP2A) and phosphatase activator [PTPA] 
(Jordens et al., 2006). Each member of the PPIase family has its own fold, substrate 
specificity and catalytic mechanism (Heikkinen et al., 2009; Jordens et al., 2006).  
 
Cyclophilins were the first PPIases to be discovered, followed by FKBPs. Both bind 
immunosuppressive drugs cyclosporin A and FK-506, respectively (Siekierka et al, 
1989; Kofron et al, 1991). Although, cyclophilins and FKBPs share no primary 
sequence similarity, and no similarities in their tertiary structure, their mode of action 
converges with PPIase activities (Freedman, 1989; Hayano et al.1991; Bose et al., 
1994).  
 
PP2A is a major serine/threonine protein phosphatase in eukaryotic cells (Janssens and 
Goris, 2001). In addition to playing an important role in cell-cycle regulation, cell 
growth control, development, regulation of multiple signal transduction pathways, 
cytoskeleton dynamics, and cell mobility (Xing et al., 2006), protein synthesis (Janssens 
and Goris, 2001), PP2A is also an important tumour-suppressor protein (Janssens et al., 
2005). PTPA, a Ppiase-like FKBP12 and cyclophilin, is an essential protein which is 
involved in the regulation of PP2A and the PP2A-like enzymes (Jordens et al., 2006). 
The PPIase activity of PTPA is inhibited by a glutamic acid in the –1 position of the 
prolyl residue (Jordens et al., 2006). 
 
The parvulins are PPiases (named after the Escherichia coli protein parvulin) which are 
not inhibited by the immunosuppressants: cyclosporin A or FK506 (Rahfeld et al, 1994; 
Hennig et al., 1998; Hani et al, 1999), but can be inactivated by juglone (Hennig et al., 
1998). Apart from PPIase activity, the prokaryotic
 
parvulins exhibit chaperone-like 
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activities (He et al., 2004). For example, SurA is found
 
in the periplasm of E. coli and 
partakes in the early stage
 
maturation of outer membrane proteins (Lazar and Kolter, 
1996). Parvulins are involved in the folding and trafficking of periplasmic and outer-
membrane proteins (Rudd et al., 1995). 
 
Gram-positive bacteria have numerous PPIase lipoproteins that most likely accelerate 
protein folding outside the cell (Hutchings et al., 2009). The lipoprotein PPIases are 
thought to be well placed to interact with unfolded substrates emerging from the Sec 
translocon and could therefore be important in processing virulence factors of Gram-
positive bacteria (Hutchings et al., 2009).  
 
For efficient murine colonization, Streptococcus pneumoniae requires the SlrA 
(streptococcal lipoprotein rotamase A) PPIase (Hermans et al., 2006). PpmA (putative 
proteinase maturation protein A) and SlrA, both belong to the chaperone family of 
PPIases and play valuable roles in S. pneumoniae colonization, avoidance of 
phagocytosis and pulmonary infection (Overweg et al., 2000a).  
 
In Bacillus subtilis, the PrsA lipoprotein (a parvulin foldase) is essential for protein 
secretion and viability (Kontinen and Sarvas, 1993). PrsA-Like proteins are formed by 3 
regions: the central domain which may confer a PPIase activity in certain PrsA-Like 
proteins, as well as the N-terminal and carboxy-terminal domains whose functions 
remain unknown (Drouault et al., 2002). In Lactococcus lactis, the proteinase 
maturation protein (PrtM) is a lipoprotein (Haandrikman et al., 1991). 
 
Bray et al., (2009) confirmed that incorrect processing of lipoproteins has pleiotropic 
effects which may be of significance to Streptococcus agalactiae colonization and 
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pathogenesis. Listeria monocytogenes PrsA2 is a chaperone implicated in the secretion 
of virulence factors and virulence within the cytosol of infected host cells (Alonzo and 
Freitag, 2010). In Enterococcus faecalis, two lipoprotein PPIases:- the parvulin family 
rotamase EF0685, together with EF1534 (belonging to the cyclophilin family), have 
been shown to be important for virulence and resistance to sodium chloride (Reffuveille 
et al., 2012).  
 
Putative lipoproteins perform a wide variety of other predicted functions, including a 
wide array of enzymatic activities (Hutchings et al., 2009). Genomic analysis has 
revealed that approximately 30% of these putative lipoproteins are conserved 
hypothetical proteins or hypothetical proteins of unknown function; it is therefore a 
challenge for the post-genomic era to assign functions to these proteins (Hutchings et 
al., 2009). 
 
 
1.6 Putative Maturase Lipoprotein (PrtM) of S. equi 
 
To date, only a few S. equi  lipoproteins have been characterized, some of which are: a 
lipoprotein acid phosphatase enzyme, LppC (Hamilton et al., 2000) ;   a putative metal-
binding lipoprotein (MBL) homologous
 
to pneumococcal PsaA which is believed to be 
involved in ABC
 
transporter-mediated uptake of manganese (Harrington et al., 2000); 
and another lipoprotein which was initially
 
identified as hyaluronate (capsule)-
associated protein – HAP (Chanter et al.,1999 in Hamilton et al., 2006), but is likely to 
act as a substrate-binding lipoprotein
 
for ABC transporter-mediated uptake of 
oligopeptides (Harrington et al., 2002 in Hamilton et al., 2006). 
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32 other putative lipoproteins have been identified by bioinformatic analysis of the draft 
of S. equi genome sequence including PrtM, a putative maturase lipoprotein (Hamilton 
et al., 2006). PrtM is a homologue of the pneumococcal vaccine candidate PpmA  
(putative proteinase maturation
 
protein A) (Hamilton et al., 2006; and Overweg et al., 
2000a). It was shown that inactivation of PpmA considerably attenuated pneumococcal 
virulence in a mouse intranasal challenge model of pneumonia; and antibodies raised to 
PpmA were opsonophagocytic (Overweg et al., 2000b). 
 
In the study of Overweg et al. (2000b), it was demonstrated that PpmA was expressed 
at higher levels in the transparent phenotype of S. pneumoniae, indicating that the 
substrate for the pneumococcal maturases may be involved in the colonization of the 
host. In 2009, Cron et al. (2009) demonstrated that PpmA contributes to the early stages 
of infection (colonization) in S. pneumoniae. They stated that the contribution of PpmA 
to virulence can be explained by its strain-specific role in adherence to epithelial cells 
and contribution to the evasion of phagocytosis. It can therefore be hypothesized that 
the substrates for both the pneumococcal PpmA and S. equi PrtM maturases may be 
bacterial adhesins or some other colonization factors. Such a role would make S. equi 
PrtM maturase and its substrate/s excellent targets for therapies that are designed to 
treat or prevent strangles.  
 
Expression studies of L. lactis subsp. cremoris clones bearing plasmids (having PrtM 
gene, the PrtP gene, or both) showed that the PrtM gene encoded a trans-acting activity 
involved in the maturation of the cell envelope located and secreted forms of SK1l 
proteinase (prtP) (Vos et al, 1989). PrtM (a trans-acting protein involved in the 
processing of precursors of serine protease PrtP into active enzymes) belong to the 
family of PPIases (Vos et al., 1989, Overweg et al, 2000a). 
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At present, there is a lack of information about the substrates of most putative 
streptococcal maturases; and information regarding their nature as true PPIases is not 
clear. It has been reported that Pneumococcal PpmA lacks significant PPIase activity 
(Hermans et al., 2006). Drouault et al. (2002) also reported that the chromosomally-
encoded putative maturase lipoprotein of L. lactis and some other streptococcal 
homologues like S. pyogenes PrsA2 and pneumococcal PpmA, do not have a complete 
PPIase sequence signature. However, an evaluation of the entire length of the proteins, 
including the unconserved signature region, by secondary structure predictions, 
suggests that the folding of these PrsA-like proteins is conserved (Drouault et al., 2002). 
Therefore, the streptococcal enzymes may have a distinctive mechanism of action 
and/or substrate specificity compared to other parvulins. Defining their PPIase 
capability will therefore be very important in defining the properties of this subgroup of 
the parvulin family and may reveal highly specific drug targets. 
 
The deletion of the single specific lipoprotein PrtM was investigated in order to 
evaluate the contribution of lipoproteins to the virulence of S. equi in its natural host 
(Hamilton et al., 2006). In their study, Hamilton et al. (2006) discovered that 
colonization of the air interface organ cultures after inoculation with a mutant strain 
deficient in the maturase
 
lipoprotein (ΔprtM138-213, with a deletion of nucleotides 138
 
to 
213, and henceforth refered to as ΔPrtM) was less than that seen in cultures which were 
infected
 
with wild-type S. equi strain 4047 or a mutant strain that was
 
unable to lipidate 
preprolipoproteins  -Δlgt190-685. 
 
The parental
 
S. equi 4047 WT strain induced disease in 57% (17 of 30) of mice models 
during a 5-day study period, as determined by changes in weight
 
gain, rate of sneezing, 
   
25 
 
and histopathological analysis (Hamilton et al., 2006). It is interesting to note that the
 
deletion of the PrtM gene significantly attenuated S. equi 4047 in
 
the mouse model of S. 
equi 4047 infection (P < 0.001) such that none of
 
the mice challenged with S. equi 4047 
ΔPrtM showed signs of disease (either reduced weight gain or sneezing) throughout the 
study
 
period, and no disease was detected histologically (Hamilton et al., 2006). It is 
very interesting to note from the study of Hamilton et al. (2006) that the virulence of the 
PrtM-deficient mutant (ΔPrtM) was also significantly attenuated in the Welsh Mountain 
ponies. The findings of Hamilton et al. (2006) suggests that the deletion of the central
 
domain of S. equi 4047 PrtM is sufficient to abrogate its function
 
in vivo, thereby 
attenuating this strain. However, further analyses of the molecular consequences
 
of the 
deletion of PrtM gene in S. equi are now required in order
 
to identify those virulence 
factors which rely on its activity
 
and which are essential to pathogenicity in the horse 
(Hamilton et al., 2006).  
 
 
 
1.7    Aim of Project 
S. equi virulence factors have only been partially identified (Anzai et al, 1999). It has 
been demonstrated by in vitro and in vivo studies that many streptococcal adhesins 
serve as colonization or virulence factors and this makes them attractive targets for 
therapeutic and preventive strategies against streptococcal infections (Nobbs et al., 
2009).  
Although it has been previously demonstrated that S. equi 4047 putative lipoprotein 
maturase (PrtM) is a major virulence factor (Hamilton et al., 2006), no functional role 
has been given to it (S. equi PrtM). Understanding S. equi PrtM therefore, would be key 
to designing drugs or vaccines against the equine S. equi infection and strangles.  
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This research was meant to systematically apply advanced biomolecular techniques in 
investigating and characterising PrtM, to identify the virulence factors which rely on its 
activity
 
and are essential to pathogenicity, as well as evaluate its potential as a 
therapeutic or vaccine target. This study was embarked on with the hope of generating 
valuable information which would be useful to pharmaceutical industries in designing 
therapies against S. equi infection and strangles. The outcome of this research would 
contribute to the body of knowledge about lipoprotein maturases in general. These 
objectives have been achieved in this study by: 
 
a) Applying bioinformatics, microbiological, biochemical and molecular biology 
techniques in screening the S. equi 4047 WT and ΔPrtM strains to evaluate the 
immunogenicity and conservation of PrtM. 
b) Using proteomics techniques: 2D-E and mass spectrometry (methods of Zhang 
et al., 2007) in evaluating the cell-associated and secreted protein extracts of 
both the S. equi WT 4047 and ΔPrtM strains. 
c) Deriving biochemical data on the PrtM protein via enzyme (peptydylprolyl 
isomerase) assay, following cloning, over-expression and purification of the full 
length and central domain. 
d) Attempting to derive structural data (via crystallography) on the PrtM protein 
after cloning, over-expression and purification of the full length and central 
domain. 
e) Producing and screening mutant (ΔPrtM) revertants. 
 
This information presented hereafter, shows how from the outcome of this research, the 
following conclusions were reached: 
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 some significant proteins are differentially expressed between the S. equi 4047 
WT and ΔPrtM strains.  
 PrtM is a peptidylprolyl isomerase which may not only be linked to the folding 
of one specific substrate but could be a multisubstrate foldase.  
 PrtM is indeed a major virulence factor in strangles and  
 PrtM is a robust therapeutic/vaccine candidate.  
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2 Materials and Methods 
 
The sources of all chemicals and reagents are given in the Appendix A1. Unless stated 
otherwise, all solutions and buffers were made up with 18.2 MΩ/cm H2O purified by a 
Milli – Q Plus 18.2 H2O purification system, and stored at room temperature. 
 
All solutions and apparatus were sterilised by autoclaving (Appendix B1) at 121°C, 
with a pressure of 1.05 bar for 20 minutes, unless otherwise stated.  
 
 
2.1 Bacterial Strains and Growth Media 
The bacterial strains and culture media used in this research are described in this 
Section (2.1) 
 
2.1.1 Bacterial Strains 
 
Bacterial strains were maintained at -80
o
C in glycerol stocks (section 2.1.2). On a 
monthly basis, bacterial stocks of E coli BL21 (DE3) were streaked onto an agar plate 
and incubated at 37
o
C overnight. The plate was stored at 4
o
C for one month so that in 
the event of contamination of bacterial stock, this could be used for re-inoculation.  
 
The Streptococcus equi subspecies equi (S. equi) strains used in this study are listed in 
Table 2.1; while the E. coli strains used are listed in Table 2.2 
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S. equi 4047 Strain 
 
Comment 
 
Source 
WT Wild type (WT) strain 4047, 
originally isolated in 1990 from a 
submandibular
 
abscess of a New 
Forest pony 
Culture collection of 
the Animal Health 
Trust, Newmarket, 
United
 
Kingdom. 
ΔPrtM PrtM-deficient mutant strain 
(ΔprtM138-213 ), with a deletion of 
nucleotides 138
 
to 213. Em
r
 
Animal Health Trust, 
United Kingdom, 
following the work of 
Hamilton et al. (2006). 
 
ΔPrtM123/pVA838 Complemented mutant: PrtM-
deficient mutant strain (ΔprtM138-
213 ),  transformed with pVA838 to 
which the N-terminal, the Central 
and the C-terminal domain genes 
of PrtM had been cloned; Cm
r
. 
This study 
ΔPrtM12/pVA838 Complemented mutant: PrtM-
deficient mutant strain (ΔprtM138-
213 ),  transformed with pVA838 to 
which only the N-terminal and  the 
Central domain genes of PrtM had 
been cloned; Cm
r
. 
This study 
ΔPrtM/pVA838 PrtM-deficient mutant strain 
(ΔprtM138-213) transformed with 
the plasmid pVA838. Cm
r
 . 
This study 
WT 4047/pVA838- Cm
r
 S. equi WT 4047 transformed with 
the plasmid pVA838. Cm
r
 
This study 
WT 4047/pVA838- Em
r
 S. equi WT 4047 transformed with 
the plasmid pVA838. Em
r
 
This study 
Table 2.1 Streptococcus equi subspecies equi strains used in this research. 
 
E. coli strain Use Characteristics Source 
One Shot
 
 
TOP10
 
Cloning host F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
Invitrogen 
BL21 
(DE3) 
 
Protein hyper 
expression 
host 
F- ompT hsdSB (rB- mB-) gal dcm 
(DE3) 
Invitrogen 
Table 2.2 E. coli strains used in this research. 
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2.1.2 Cryogenic storage of bacterial stocks 
Per 100 mL 
100 % (v/v) glycerol      50.0 mL 
 
50% (v/v) glycerol was aliquoted into 1 mL amounts in 1.5 mL microcentrifuge tubes, 
autoclaved and cooled to room temperature before use.  
 
Bacterial stocks were prepared by mixing 0.5 mL of broth culture with 1.0 mL of sterile 
50% (v/v) glycerol. These stocks were then stored at -20°C (medium-term storage) or -
80 °C (long term storage).  
 
 
2.1.3 Growth Media 
 
Culture media (Table 2.3) were prepared using distilled water, and sterilised by 
autoclaving, unless otherwise stated. Liquid culture media were stored at room 
temperature, and solid media at 4°C.  pH adjustments of solutions are stated and were 
performed using a pH meter (Appendix B2), and HCl or NaOH, unless otherwise stated. 
 
THB and THA were chosen as culture media of choice for S. equi strains according to 
the methods of Hamilton et al. (2000); and Sutcliffe et al. (2000). 
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Media Composition Sterilisation 
Todd-Hewith Broth (THB) Todd-Hewith Broth base (Oxoid): 
36.4 g per L. 
Autoclaved at 121ºC for 
15 min 
 
Todd-Hewith Agar (THA) THB, Agar (bacteriological agar 
#1) 15 g per L. 
Autoclaved at 121ºC for 
15 min 
 
THB / 0.5 M Sucrose THB, Sucrose 34.23 g per 200  mL Autoclaved at 121ºC for 
15 min 
 
THB / 0.5 M Sucrose / 
20mM MgCl2 / 2 mM 
CaCl2. 
THB, 6.846 g, MgCl2.6H2O  
0.2033 g, CaCl2 0.294 g per 50  mL 
Autoclaved at 121ºC for 
15 min 
 
THB / 90 mM glycine THB Autoclaved at 121ºC for 
15 min, glycine filter 
sterilised using a 0.2 μm 
filter 
THB / 90 mM glycine / 
0.1% Tween-80 
THB / 90 mM glycine, Tween-80 1 
g per L. 
Autoclaved at 121ºC for 
15 min, glycine filter 
sterilised using a 0.2 μm 
filter 
 
 
Luria Bertiani (LB) broth -  
Low Salt 
 
Tryptone 10 g, Yeast extract 5 g, 
Sodium Chloride 5 g - per L 
Autoclaved at 121ºC for 
15 min 
 
LB agar Tryptone 10 g, Yeast extract 5 g, 
Sodium Chloride 5 g, agar 15 g - 
per L 
Autoclaved at 121ºC for 
15 min 
 
Foetal Calf Serum (FCS) Commercially prepared (Appendix 
A5) 
Commercially pre-
sterilized stored at -20°C 
Todd Hewith broth with 
Foetal Calf Serum (THB + 
FCS) 
10% (v/v) FCS in THB (adapted 
from Hamilton et al., 2006) 
Used freshly prepared 
5% Horse blood agar 40 g of blood agar base (Merck) 
was heated in 1litre of boiling 
water and autoclaved for 15 min at 
121°C. This was left to cool to 50-
45°C. Finally, 5-6% sterile 
defibrinated horse blood was added 
and mixed carefully to avoid 
formation of bubbles. 15-20 mL 
volumes were poured onto petri 
dishes. 
Plates were stored in the 
refrigerator at 4°C until 
ready for use. 
 
Table 2.3 Growth media and supplements used in this research 
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2.1.4 Antibiotics  
 
Compositions of the stock solutions of antibiotics used in this study are shown in Table 
2.4. Appropriate volumes of the stock solutions were diluted in liquid media for 
antibiotics selection. Autoclaved media was cooled to less than 55
o
C before the addition 
of antibiotics.  Final concentrations of antibiotic used are stated in the method section 
for specific assays. 
 
 
Antibiotic 
 
Stock Concentration 
 
Solvent 
 
Storage. 
Ampicillin 10 mg/mL
 
18.2 MΩ/cm H2O -20°C 
Chloramphenicol 34 mg/mL 100% Ethanol -20°C 
Erythromycin 1 mg/mL 18.2 MΩ/cm H2O -20°C 
Gentamycin 500 mg/mL 18.2 MΩ/cm H2O -20°C 
Kanamycin 10 mg/mL 18.2 MΩ/cm H2O -20°C 
Norfloxacin 5 mg/mL 18.2 MΩ/cm H2O -20°C 
Penicillin G 6 mg/mL 18.2 MΩ/cm H2O -20°C 
Streptomycin 500 mg/mL 18.2 MΩ/cm H2O -20°C 
Vancomycin 30 mg/mL 18.2 MΩ/cm H2O -20°C 
Table 2.4 Stock concentrations of antibiotics used in this research. 
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2.2 Reagents, Buffers, Enzymes and Kits 
The reagents and buffers that were used in this study are listed in tables 2.5, 2.6 and 2.7. 
 
 
Reagent/ Buffer Composition Use 
TAE Running Buffer 50 x stock : Tris HCl 242.0 g, 
17.51 M Glacial acetic acid   
57.1  mL, 0.5 M EDTA pH 8.0 
100 mL - per L. 
Diluted to 1 x by a 1:50 
dilution for agarose gel 
electrophoresis. 
Bromophenol Blue 
Loading Buffer 
6 x sample loading buffer: 
Bromophenol Blue 0.025 g, 
glycerol 3.0 g - per 10 mL 
Dilited to 1 x with 
sample prior to loading. 
For agarose gel 
electrophoresis 
Xylene cyanol  Loading 
Buffer 
6 x sample loading buffer: 
Xylene cyanol 0.025 g, glycerol 
3.0 g - per 10 mL 
Dilited to 1 x with 
sample prior to loading. 
For agarose gel 
electrophoresis of DNA 
bands < 1Kb 
Bioline Hyperladder
  
1 (size standard) 
DNA ladder  (10, 8, 6, 5, 4, 3, 
2.5, 2, 1.5, 1.0, 0.8, 0.6, 0.4, and 
0.2 kb) (Appendix A8) 
Agarose gel 
electrophoresis 
Ethidium Bromide 10 mg/mL Diluted to 10 µg/ mL for 
agarose gel 
electrophoresis 
TE buffer, pH 7.5 0.5 M Tris-HCL pH 7.5 20  mL, 
0.5 M EDTA pH 8.0  2.0  mL - 
per L 
Elution, storage and 
agarose gel 
electrophoresis of  DNA 
STET buffer, pH 8.0 Sucrose 80 g, Triton X-100 50  
mL,  0.5 M EDTA  pH 8.0     
100  mL,    Tris-HCL 6.06 g – 
per L 
Crude plasmid 
preparation. 
 
Table 2.5: Reagents and Buffers for DNA analysis 
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Reagent Composition Use 
12% (w/v) Acrylamide 
resolving gel 
40% (w/v) solution (37.5:1 acrylamide:bisacrylamide) 3.0  
mL, Solution B (2M Tris-HCL pH 8.8  75  mL, 10% w/v 
SDS 4  mL per 100  mL) 2.5  mL, 18.2 MΩ/cm H2O 4.5  
mL, 10% w/v ammonium persulphate 50  µL,  
TEMED 10  µL 
SDS-PAGE 
13% (w/v) Acrylamide 
resolving gel 
40% (w/v) solution (37.5:1 acrylamide:bisacrylamide) 
3.25  mL, Solution B (2M Tris-HCL pH 8.8  75  mL, 
10% w/v SDS 4  mL per 100  mL) 2.5  mL, 18.2 MΩ/cm 
H2O 3.25  mL, 10% w/v ammonium persulphate 50  µL, 
TEMED 10  µL 
SDS-PAGE 
15% (w/v) Acrylamide 
resolving gel 
40% (w/v) solution (37.5:1 acrylamide:bisacrylamide) 
3.75  mL, Solution B (2M Tris-HCL pH 8.8 75  mL, 10% 
w/v SDS 4  mL per 100  mL) 2.5  mL, 18.2MΩ/cm H2O 
3.75  mL, 10% w/v ammonium persulphate 50  µL, 
TEMED 10  µL 
SDS-PAGE 
4% (w/v) Acrylamide 
stacking gel 
40% (w/v) solution (37.5:1 acrylamide:bisacrylamide) 0.5  
mL, Solution C (1M Tris-HCL pH 6.8 50  mL, 10% w/v 
SDS 4  mL per 100  mL) 1.0  mL, 18.2MΩ/cm H2O 2.5  
mL, 10% w/v ammonium persulphate 30  µL,  
TEMED 10  µL 
SDS-PAGE 
Running buffer, pH 
8.8 
10 x stock: Tris-HCl 30.3 g, Glycine 144 g,  
SDS 10 g  – per L 
Diluted 1:10 for 
SDS-PAGE and  
2D-E 
SDS-PAGE sample 
loading buffer 
5 x stock: 2 M Tris-HCl pH 6.8 0.3  mL, 50% v/v 
glycerol 5 mL, 10% w/v SDS 2  mL,  14.4 mM β-
mercaptoethanol 0.5  mL, 1% w/v bromophenol blue 1  
mL - per 10  mL. Stored in a brown bottle at 4
o
C.
 
1 volume buffer to 
4 volumes sample. 
For SDS-PAGE. 
SDS - PAGE sample 
cracking buffer 
2.4 g Urea, 7.6 mL SDS-PAGE sample loading buffer. 
Stored at 4°C. 
For protein 
extraction for 
SDS-PAGE. 
HMW Protein size 
standard 
M.W. (KDa): 205, 116, 97, 84, 66, 55, 45, 36. 
Lyophilized standard. reconstituted with 18.2 MΩ/cm 
H2O 200  µL and SDS-PAGE sample buffer (5 x) 25  µL, 
boiled for 3 min and stored at 4
o
C. 
SDS-PAGE 
LMW Protein size 
standard 
M.W. (KDa): 66, 45, 36, 29, 24, 20. Lyophilized standard 
reconstituted with 18.2 MΩ/cm H2O 200 µL and SDS-
PAGE sample buffer (5 x) 25  µL, boiled for 3 min and 
stored at 4
o
C. 
SDS-PAGE 
Coomassie blue 
staining solution 
Coomassie blue R-250 1 g, Glacial acetic acid 100 mL, 
Methanol 450 mL – per L. Room temperature storage. 
SDS-PAGE 
Coomassie blue gel 
destaining solution 
Glacial acetic acid 100  mL, methanol 100  mL – per L. 
Room temperature storage. 
SDS-PAGE 
PBST PBS, 0.05% (v/v) Tween-80. Stored at 4
o
C Western Blotting 
Transfer Buffer Tris base 2.9 1g, Glycine 1.465 g, 18.2 MΩ/cm H2O 400 
mL, Methanol 100  mL. Room temperature storage. 
Western Blotting 
Start Buffer Na2HPO4 2.84 g, NaCl 29.2 g Imidazole 0.68 g – per L, 
pH 7.4. Room temperature storage. 
IMAC 
Elution Buffer Na2HPO4 2.84 g, NaCl 29.2 g Imidazole 34 g – per L, pH 
7.4. Room temperature storage. 
IMAC 
 
Table 2.6: Reagents and Buffers for Protein Analysis. 
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Reagent Composition Use 
Phosphate Buffered 
Saline (PBS) 
NaCl 8 g, KCl 0.2 g, KH2PO4 0.2 g, Na2HPO4.12 H2O 
1.44 g 
Proteomics 
Lysis Solution Urea 4.8 g, CHAPS 0.4 g – per 10 mL. Aliquoted into  
1  mL quantities and stored at -20
 o
C. 2  µL of IPG 
buffer (pH 2-10 or 4-7) added to every 100  µL before 
use 
Proteomics 
Rehydration Solution Urea 4.8 g, CHAPS 0.4 g, 1% v/v bromophenol blue 20 
µL – per 10 mL. Aliquoted into 0.7 mL quantities and 
stored at -20
o
C. 14 µL of IPG buffer (pH 3-10 or 4-7) 
and 1.4 mg DTT added to each tube before use 
Proteomics. 2D-E 
Equilibration stock 
solution 
1.5 M Tris-HCl pH 8.8 10 mL, Urea 72 g, Glycerol 69 
mL, SDS 2g, 1% (v/v) bromophenol blue 200 µL – per 
200 mL. Stored in 20 mL aliquots at -2
o
C 
Proteomics. 2D-E 
Equilibration buffer 
with DTT 
Equilibration stock solution 20 mL, DTT 0.2 g – per 20 
mL 
Proteomics. 2D-E 
Equilibration buffer 
with IAA 
Equilibration stock solution 20 mL, IAA 0.9 g – per 20 
mL 
Proteomics. 2D-E 
14% (w/v) Resolving 
Gel 
18.2MΩ/cm  H2O 58 mL, 1.5 M Tris-HCl pH 8.8 37.5 
mL, 10% (w/v) SDS stock 1.5 mL, 40% (v/v) solution 
of 37.5:1 acrylamide:bisacrylamide 52.2 mL, 10% 
(w/v) APS 750 µL, TEMED 75 µL 
Proteomics. 2D-E 
Agarose sealing 
solution 
Running Buffer (1x) 19 mL, Agarose 0.1g, 1% (w/v) 
bromophenol blue 40 µL. 
Proteomics. 2D-E 
2D gel fixing solution Methanol 500 mL, Glacial acetic acid 120 mL per L Proteomics. 2D-E 
Colloidal Coomassie 
blue stock 
Ammonium sulphate 100 g, Phosphoric acid 20 mL, 
Coomassie blue G-250 1 g – per L. Dissolve 
Coomassie blue G-250 in 20 mL of 18.2MΩ/cm  H2O 
and add to ammonium sulphate previously  
dissolved in phosphoric acid and 18.2MΩ/cm  H2O. 
Made up to 1 L. Stored at room temperature. 
Proteomics. 2D-E 
Colloidal Coomassie 
blue staining solution 
Well mixed Colloidal Coomassie blue stock solution 4 
parts, Methanol 1 part. 
Proteomics. 2D-E 
Trypsin stock   
(1 µg/µL). Promega 
and NEB.
 
Trypsin lyophilized powder 20 µg/ mL (100 µg), 
50mM Glacial acetic acid (100 µL). Long term storage 
at -80
o
C, shot term storage at -20
o
C 
Proteomics. Protein 
digestion. 
Trypsin solution   
(20 µg/mL). 
1 µg/µL
 
Trypsin stock (2 µL),  
50  mM NH4HCO3 (98 µL) 
Proteomics. Protein 
digestion. 
LC-MS buffer A LC-MS grade Water 95 mL, LC-MS grade Acetonitile 
5 mL, Formic acid 0.1 mL - per 100 mL 
Proteomics. LC-MS 
analysis 
LC-MS buffer B LC-MS grade Water 5 mL, LC-MS grade Acetonitile 
95 mL, Formic acid 0.1 mL 
Proteomics. LC-MS 
analysis 
LC-MS Buffer C 
 
50% (v/v) acetonitrile in LC-MS grade water Proteomics. LC-MS 
analysis 
BSA Standards 10  mg/mL stored at 20
o
C and diluted for use Estimation of 
protein 
concentration 
Bradford Reagent Brilliant blue G in phosphoric acid and methanol 
(Sigma), stored at 4
o
C 
For Bradford’s 
assay 
 
Table 2.7: Reagents and Buffers for Proteomics studies 
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Enzyme/Peptide Co-constituent Use Supplier 
KOD Hot Start 
DNA Polymerase – 
1.0 U/µl
 
10 x PCR Buffer for KOD Hot Start 
DNA Polymerase (recipe not 
available), 25 mM MgSO4,   
dNTP Mix (2 mM each) 
PCR Novagen 
T4 DNA ligase 
(133 U/µL)
 
50 mM Tris-HCl pH 7.5, 10 mM 
MgCl2, 10 mM DTT, 1 mM ATP, 25  
µg/mL acetylated BSA 
PCR New England 
Biolabs 
RibonucleaseA 10 µL of 10 mg/mL
 
RNase to 1 mL of TE buffer 
 Sigma 
Lysozyme (Hen 
egg white,  
10 mg/mL)
 
Used unbuffered  New England 
Biolabs 
Nde I 1 x Buffer 4 (20 mM Tris-acetate, 10 
mM Magnesium acetate, 50 mM 
Potassium acetate, 1 mM DTT,  
pH 7.9) 
Restriction New England 
Biolabs 
Xho I 1 x Buffer 2 (10 mM Tris-HCl, 10 mM 
MgCl2, 50 mM NaCl,  
1 mM DTT, pH 7.9) 
Restriction New England 
Biolabs 
BamH I 1 x Buffer E (6 mM Tris-HCl, 6 mM 
MgCl2, 100 mM NaCl, 1 mM DTT,  
pH 7.5) 
Restriction Promega 
Sal I 1 x Buffer D (6 mM Tris-HCl, 6 mM 
MgCl2, 150 mM NaCl, 1 mM DTT,  
pH 7.9) 
Restriction Promega 
α-chymotrypsin 
from bovine 
pancrease 
20 mg/mL, diluted in a solution of 
0.001 M HCl / 0.002 M  CaCl2; once 
diluted stored at -20
o
C and used up 
within 1week 
Protease 
coupled 
enzyme 
assay 
Sigma 
Cyclophilin from 
calf thymus 
1 mg/mL, diluted in a solution of  20 
mM HEPES / 140 mM NaCl / 10% 
(v/v) glycerol; stored at -20
o
C 
Protease 
coupled 
enzyme 
assay 
Sigma 
Peptide (Pep1) Suc-Ala-Phe-Pro-Phe-pNa, M.W. 
700.75 Da; diluted in 66% (v/v) 
DMSO 
Protease 
coupled 
enzyme 
assay 
Sigma 
Peptide (Pep2) Suc-Ala-Lys-Pro-Phe-pNa, M.W. 
681.75 Da; diluted in 66% (v/v) 
DMSO 
Protease 
coupled 
enzyme 
assay 
Bachem 
Peptide (Pep3) Suc-Ala-Ala-Pro-Phe-pNa, M.W. 
624.7 Da; diluted in 66% (v/v) DMSO 
Protease 
coupled 
enzyme 
assay 
Bachem 
 
Table 2.8 Enzymes and Peptides used in this study 
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Kit Use Source 
Prolex Steptococcal 
Grouping Latex Kit 
Lancefield Streptococcal 
grouping 
 
PRO-LAB 
DIAGNOSTICS 
BCIP/NBT Substrate Kit 
(substrate for alkaline 
phosphatase) 
 
Western Blotting ZYMED Laboratories 
DNeasy Blood and Tissue 
Kit®  
Extraction and purification of 
genomic DNA 
Qiagen 
PCR purification kit 
 
Purification of dsDNA from a 
PCR. 
Qiagen 
Miniprep kit (NZytech) Extraction of pDNA from E. 
coli 
Prozomix 
NZYGelpure Kit DNA gel purification 
 
Prozomix 
Hyaluronan Test Kit 
(Version 1.01) 
 
Quantitation of hyaluronic 
acid capsule 
Nzomics Biocatalysis 
 
Table 2.9 Kits used in this study 
 
 
 
 
 
 
 
2.3 Bioinformatics Tools 
 
The programmes and websites used for bioinformatics analysis are discussed below. 
 
 
2.3.1 Prediction of S. equi 4047 PrtM full gene, coding sequence, and protein 
sequence 
  
The coding sequence for the gene of interest (the putative maturase lipoprotein - PrtM  - 
Hamilton et al., 2006) from S. equi 4047 was obtained via the Nucleotide database of 
the National Center for Biotechnology Information (NCBI) - 
http://www.ncbi.nlm.nih.gov/nuccore. The FASTA format of the sequence 
(http://www.ncbi.nlm.nih.gov/nuccore/NC_012471.1?report=fasta&from=676781&to=677782)  
shows a 1 kb region from base 676781 to 677782. 
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The protein sequence (accession number YP_002746044) of the gene was obtained via 
Protein database of NCBI (http://www.ncbi.nlm.nih.gov/protein/). The ‘Translate tool’ 
in Expasy was also used to translate the gene sequence into amino acid sequence 
(http://www.expasy.org/tools/dna.ht mL). 
 
2.3.2 Signal Peptide prediction 
The presence of signal peptides was predicted by using the SignalP 3.0 server 
(http://www.cbs.dtu.dk/services/SignalP/). 
 
 
 
2.3.3 Gene Search and Conserved Domain/Sequence Similarity Search 
A gene search via NCBI (http://www.ncbi.nlm.nih.gov/gene) was used to identify genes 
of interest and their protein sequences identified via NCBI 
(http://www.ncbi.nlm.nih.gov/protein) as well.  After obtaining a protein sequence, 
protein sequences related by sequence similarity were determined by viewing related 
sequences under the related information link on the same page. The related sequences 
from different organisms obtained are automatically generated via Basic Local 
Alignment Search Tool (BLAST) of NCBI. Conserved domain search was carried out 
via NCBI conserved domain (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) 
search tool. 
 
2.3.4 Multiple sequence alignment and domain prediction 
The following softwares/websites were used to align similar sequences and to evaluate 
sequence homology with the sequence of S. equi 4047 PrtM.  
 The ClustalW (www.ebi.ac.uk/Tools/clustalw , Larkin et al., 2007.)  
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 M-Coffee  http://tcoffee.crg.cat/apps/tcoffee/do:mcoffee, Wallace et al., 2006; 
and Moretti et al., 2007),  
 T-coffee  version 9.01 http://tcoffee.crg.cat/apps/tcoffee/do:regular, Notredame 
et al., 2000 and Di Tommaso et al., 2011), and  
 uniprot (http://www.uniprot.org/, The UniProt Consortium, 2013).  
 
After aligning the sequences they were copied into Word files for formatting (including 
colour coding the domains). The conserved and semi conserved residues of the 
sequence were determined, and finally the N-terminal, Central and C-terminal domains 
were predicted. 
 
2.3.5 Reverse Translation of Protein Sequences 
The Sequence Manipulation Suite (SMS) sequence analysis tool 
(http://www.bioinformatics.org/sms2/rev_trans.ht mL) was used for the reverse 
translation of protein sequences. 
 
2.3.6  Primer Design 
Primers were designed via Eurofins MWG Operon’s Oligo Design and Calculations 
tools (http://www.eurofinsdna.com/products-services/oligonucleotides0/design-
calculation-tools.ht mL).  
 
The webcutter website (http://rna.lundberg.gu.se/cutter2/) was used to look for internal 
restriction sites. 
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2.3.7 Determination of Protein MW, pI and molar extinction coefficient. 
The expert protein analysis system (Expasy) identification and characterisation tool 
(http://web.expasy.org/protparam/) was used to determine the molecular weight and pI 
of the proteins of interest.  
 
2.3.8 Determination of protein three dimensional (3D) structures: 
PrtM central domain protein sequence (underlined yellow in Figure 4.9a) was inputted 
into the PSIPRED Protein Sequence Analysis Workbench 
(http://bioinf.cs.ucl.ac.uk/psipred/). The PSIPRED v3.3, pGenTHREADER and BioSert 
v2.0 softwares, which are part of the PSIPRED protein sequence analysis workbench, 
were used for this analysis. PSIPRED v3.3 was selected to predict protein secondary 
structure. pGenTHREADER was selected for profile based fold recognition. BioSerf 
v2.0 was selected for automated homology modelling. A valid MODELLER key 
(obtained via http://salilab.org/modeller/registration.html) was entered via the BioSerf 
tab. Finally, the predict button was selected after which the protein 3D structure 
information generated by the PSIPRED protein sequence analysis workbench was 
emailed to a preapproved email address. 
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2.4 General Microbiology 
 
2.4.1 Growth of bacteria on agar plates 
An agar plate was surface dried by placing it open and face down at 65°C for 10-15 
min. An inoculum was streaked onto the dried agar plate, which was subsequently 
incubated under the appropriate conditions.  
 
S. equi strains used in this study were grown on Todd Hewitt agar (Table 2.3) plates 
(supplemented with the appropriate antibiotics if required) overnight (or as long as 
specified for individual experiments) at 37
o
C in a candle jar. E. coli strains were grown 
in LB agar (Table 2.3) at 37
o
C, supplemented with appropriate antibiotics as required. 
All agar cultures were stored at 4
o
C. 
 
2.4.2 Growth of Bacteria in Broth  
Overnight starter broth culture was prepared by inoculating a single colony of bacteria, 
or a 1:100 dilution of  glycerol stock (thawed on ice), into a specified volume of the 
appropriate media (with antibiotics if required) followed by incubation at specified 
temperature and time, as stated for individual experiments. 
 
S. equi broth cultures were grown in Todd Hewitt broth (Table 2.3) without agitation at 
37
o
C. Colonies derived from each glycerol stock were stained (Gram staining section 
2.4.3) to confirm the nature and purity of the culture.   
 
It had previously been reported (Hamilton et al, 2006) that at optical density of 
approximately 0.3 (OD600 nm) this density of bacteria corresponds to approximately 2  x 
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10
8
 CFU/mL of S. equi 4047. Unless otherwise stated, biomass of S. equi 4047 was 
harvested at this optical density. 
 
E coli strains were grown in LB broth (Table 2.3) at the appropriate temperature and 
time, supplemented with appropriate antibiotics as required.  
 
2.4.3 Gram Staining and Microscopy  
An inoculum of the organism was heat fixed onto a clean glass slide. The heat fixed 
film was flooded with methyl violet for 30-40 sec. The stained slide was rinsed off with 
tap water and flooded with Gram’s iodine for 30 - 40 sec. The slide was rinsed again 
with tap water and decolourised with acetone for 2 – 3 sec. After this, the smear was 
rinsed under running tap water, excess water poured off and counterstained with 
safranin for 15- 20 sec. The slide was rinsed with tap water and blotted dry with lint-
free tissue. The slide was completely dried and examined using the oil immersion 
objective of a microscope. Gram-positive bacteria stained deep purple and Gram-
negative bacteria stained pale pink. 
 
2.4.4 Lancefield Streptococcal grouping of S. equi 4047 WT and ΔPrtM 
Prolex Steptococcal Grouping Latex Kit (Table 2.9) was used to carry out Lancefield 
grouping of the S. equi 4047 WT and ΔPrtM strains for identity confirmation. Ready to 
use polyvalent antigens extracted from Streptococcus of Lancefield groub B (provided 
in kit) were used as a positive control and Staphylococcus aureus colonies were used as 
a negative control. 
 
According to the manufacturer’s instructions, to one drop of Extraction Reagent 1 in an 
Eppendorf tube was added a few bacterial colonies from an agar plate and one drop of 
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Extraction reagent 2 and mixed together for 5-10 sec. Five drops of extraction reagent 3 
were added to the tube and the contents mixed. One drop of blue latex suspension 
(group B) was dispensed onto separate circles on the test card provided in kit. One drop 
of bacterial extract from each tube was pipetted besides each drop of blue latex 
suspension and mixed. The card was rocked gently for one minute and observed for 
agglutination under normal lighting.  
 
2.4.5  β-haemolysis test. 
An inoculum from S. equi 4047 WT and ΔPrtM overnight starter cultures (each 20 mL 
THB inoculated with 100 μl glycerol stock of WT or ΔPrtM and incubated at 37°C 
overnight) was inoculated onto 5% (v/v) horse blood agar plates (Table 2.3) and THA 
plates. The plates were incubated in candle jars at 37ºC overnight. The 5% (v/v) horse 
blood agar plates were observed for clear zones of β-haemolysis. 
 
2.4.6 Growth Curve 
A starter culture (section 2.4.2) in 20 mL THB (in 25 mL universals, without antibiotics 
for S. equi 4047 WT and ΔPrtM, but with 5 µg/mL chloramphenicol for complemented 
mutants) was incubated at 37
o
C overnight. Next day, a 1 in 20 dilution of the overnight 
starter culture in THB (with antibiotics if required) was done. 200 µL of the diluted 
overnight starter culture was dispensed into each well of a 96-well plate and OD570 nm 
read hourly over a 24 h period, via an automated ultra microplate reader (EL 808, 
appendix B7). Growth curve results were obtained from a minimum of three 
independent assays. 
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2.4.7 Sodium Chloride Stress test 
1
st
 passage cultures of S. equi 4047 WT or ΔPrtM were grown to an OD570 nm of 
approximately 0.5 and 1.2 mL of culture was spurn down for 10 min at 4000 x g at 
room temperature. The supernatant was discarded and the pellets in each tube were re-
suspended in 1.2 mL of THB, sterile 18.2MΩ/cm H2O, or a given concentration of 
NaCl (0.9%, 14.7% or 29.4% [w/v]). After incubation at 37
o
C overnight for 24 h and 48 
h, serial dilutions (1 in 2, 1 in 10, 1 in 100 and 1 in 1000 ) of tubes containing sterile 
18.2MΩ/cm H2O, and NaCl) were plated onto THA plates to evaluate survival by 
colony count.  For the serial dilutions, the tubes containing sterile 18.2MΩ/cm H2O 
were diluted with only 18.2MΩ/cm H2O; the tubes containing NaCl were diluted with 
the corresponding range of concentrations of NaCl solution. The tube containing only 
THB was also plated onto THA plate as control; to evaluate viability of the organism 
after centrifugation. THA plates were incubated in candle jars at 37
o
C overnight and 
colony counts of experimental plates recorded (a modification of the methods of 
Reffuveille et al. (2012a) and Reffiveille et al. (2012b). NaCl stress test results were 
obtained from a minimum of three independent assays. 
 
2.4.8   Disc Diffusion Antibiotics Sensitivity Test  
200 µL of overnight starter culture of S. equi 4047 WT or ΔPrtM was spread onto THA 
plate. Each plate was seeded with discs each containing one of the following antibiotics: 
ampicillin 10 μg, penicillin-G 6 μg, gentamicin 500 μg, streptomycin 500 μg, 
norfloxacin 5 μg and vancomycin 30 μg (a modification of the methods of Reffuveille 
et al. (2012a) and Reffiveille et al. (2012b). 200 µL of overnight starter culture of S. 
equi 4047 WT or ΔPrtM was also spread onto a plain THA plate. This was repeated for 
each strain in triplicate. 
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2.4.9 Broth Dilution Antibiotics Sensitivity Test  
20 mL THB (in 25 mL universal, with varying dilutions of antibiotics) was inoculated 
with 200 µL of overnight starter culture (of S. equi 4047 WT, ΔPrtM, or complemented 
mutants) and incubated overnight at 37
o
C. Next day, broth cultures were checked for 
turbidity, after which 200 µL was spread onto agar plates (with varying dilutions of 
antibiotics) and incubated overnight at 37
o
C in a candle jar. 
 
2.4.10 Rapid Detection of Hyaluronic acid capsule by Density Bouyancy 
Centrifugation 
A modification of the method of DeAngelis and Weigel (1994) was applied. Overnight 
starter cultures (each of S. equi 4047 WT or ΔPrtM in THB) were diluted 1 in 20 in 20  
mL THB (1 universal per strain) and incubated at 37
o
C to early log phase (OD600 nm 
0.2). Another set of overnight starter cultures (each of S. equi 4047 WT or ΔPrtM in 
THB containing 34 µg/mL hyaluronidase) were  diluted 1 in 20 in 20  mL THB 
containing 50 µg/mL hyaluronidase (1 universal per strain) and incubated at 37
o
C to 
early log phase (OD600 nm 0.2).   
 
4 mL of each early log phase culture in a screw cap 15 mL centrifuge tube was carefully 
and slowly underlaid (using a 9’ Pasteur pipette) with 2 mL of 65% or 50 % (v/v) 
Percoll (buffered with 25mM sodium phosphate, pH 7.0). The 65% or 50 % (v/v) 
Percoll layer was carefully and slowly underlaid (using a 9’ Pasteur pipette) with 2 mL 
of 100% Percoll pad. The tubes were centrifuged at 1000 x g for 10 min. The locations 
of encapsulated cells at the top (yellow THB / 65% or 50% [v/v] Percoll) interface; and 
the acapsular or hyaluronidase treated cells at the lower (65% or 50% (v/v) Percoll / 
100% (v/v) Percoll) interface were observed (Figure 2.0). Three replicas of this 
experiment were carried out. 
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Figure 2.0: Rapid Bouyant Density Separation. 
 
 
 
2.4.11 Colonial morphological assessment of hyaluronic acid capsule 
An inoculum from an overnight starter culture of S. equi 4047 WT or ΔPrtM was plated 
onto THA (plus antibiotics for complemented mutants) plate which was incubated at 
37
o
C for 24 – 48 h in a candle jar [a modification of the method of Prasad et al. (2010)]. 
The morphology of the colonies was noted. 
 
2.4.12 Congo red/Safranin staining for assessment of hyaluronic acid capsule 
An overnight starter culture of S. equi 4047 WT or ΔPrtM was diluted 1:20 and grown 
to OD600 nm of 0.2. A smear (on glass slide) from a culture inoculum was air dried. The 
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smear was stained with safranin stain (a basic dye) for 2 min and the stain tipped off. 
This was followed by staining of the smears with Congo red (a negative dye) for 2 min. 
The smear was then washed slightly with water, air dried and examined under the oil 
immersion objective of a microscope. Safranin stained the cell surface red, congo red 
stained the background red, while capsules remained colourless. 
 
2.4.13 Alcian Blue staining for assessment of hyaluronic acid capsule 
An overnight starter culture of S. equi 4047 WT or ΔPrtM was diluted 1:20 and grown 
to OD600 nm of 0.2. A smear (on glass slide) from a culture inoculum was air dried. The 
smear was stained for 1 min with a freshly prepared 1:9 dilution of alcian blue stain 
stock solution (1 g Alcian blue 8GX in 100 mL of 95% ethanol). After 1 min, the stain 
was washed off with water and counterstained with Ziehl-Neelsen carbol fuchsin, 
washed immediately with water and air dried. The slide was examined under the oil 
immersion objective of a microscope. Hyaluronic acid stained blue, while the cell 
stained pink-red. This was a modification of the method of McKinney (1953). 
 
2.4.14 Crystal violet staining for assessment of hyaluronic acid capsule 
The capsular staining method of Hiss (1905) modified by Anthony (1931) was modified 
and employed. An overnight starter culture of S. equi 4047 WT or ΔPrtM was diluted 
1:20 and grown to OD600 nm of 0.2. A smear (on glass slide) from an inoculum was air 
dried and then flooded with a solution of 1% (w/v) crystal violet for 2 min. The crystal 
violet was rinsed gently with a solution of 20% (w/v) copper sulfate. The slide was air 
dried and examined under the oil immersion objective of a microscope. Cells stained 
purple, while capsules stained faint blue or remained as a white halo. 
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2.4.15 Quantitative Hyaluronic acid capsule test 
An overnight starter culture of S. equi 4047 WT or ΔPrtM was diluted 1:20 in THB and 
incubated at 37
o
C to OD600 nm of 0.4.  A volume of 0.5 mL culture (OD600 nm of 0.4) was 
centrifuged and pellet resuspended in 500 μL of sterile 18.2 MΩ/cm H2O. Serial 
dilutions of the bacterial suspension were plated onto THA to confirm equivalent cfu 
per 1 mL. Chloroform was added to 400 μL of the bacterial suspension in a 2 mL screw 
cap tube and shaken for 5 min in a Stuart Rotator (appendix B28). The mixture was 
centrifuged at 13,000 x g for 10 min. Hyaluronic acid in the aqueous phase was 
determined using a Hyaluronic Acid Test Kit (Version 1.01, Nzomics Biocatalysis). 2 
mL of 18.2 MΩ/cm H2O, 0.2 mL solution 1 (buffer), and 0.2 mL of test solution 
(extracted aqueous phase sample or control - hyaluronic acid from Sigma) were pipetted 
into a 3 mL quartz cuvette. A second cuvette (blank) contained 0.2 mL of 18.2 MΩ/cm  
H2O instead of test solution. Each cuvette was covered and the solutions mixed and left 
to equilibrate for 3 min in a spectrophotometer set at 235 nm (room temperature). The 
starting absorbance (A1) was recorded and each cuvette swirled to homogenise the 
suspension. 0.2 mL of solution 2 (hyaluronate lyase enzyme) was added into each 
cuvette and mixed. The absorbance was read spectrophotometrically continuously for 4 
min until it plateaued. The plateaued absorbance (A2) was recorded and the 
concentrations of hyaluronan in each sample calculated from the formula below: 
 
[(A2 - A1) Sample – (A2 - A1)Blank] x 0.2314 = mg/mL of hyaluronan. 
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2.5 General Biomolecular Methods 
 
2.5.1 Plasmids 
The plasmids used in this study are listed in Table 2.10 
 
Plasmid Characteristics Application Source 
pET-28a Kan
 r
, T7, lac, lacI
 q 
Expression vector Novagen 
(appendix A17) 
pVA838 9.2 kb, Em
 r
, Cm
 r
. SalI 
SphI, BamHI, NruI and 
XbaI cleavage
 
sites 
E. coli -
Streptococcus 
shuttle vector 
Macrina et al., 
1982. 
(appendix A18) 
pVA838/PrtM123 pVA838 to which the 
N-terminal, the Central 
and the C-terminal 
domain genes of PrtM 
had been cloned; Cm
r
. 
Production of 
complemented 
mutant 
ΔPrtM123/pVA838 
This study 
pVA838/PrtM12 pVA838 to which only 
the N-terminal and  the 
Central domain genes 
of PrtM had been 
cloned; Cm
r
. 
Production of 
complemented 
mutant 
ΔPrtM12/pVA838 
This study 
pET28a/PrtM pET28a to which S. 
equi 4047 PrtM full 
gene had been ligated. 
Kan
r
 
Transformation into 
E. coli BL21 for 
expression of Full 
length protein 
This study 
pET28a/central-
PrtM 
pET28a to which S. 
equi 4047 PrtM central 
domain gene had been 
ligated. Kan
r
 
Transformation into 
E. coli BL21 for 
expression of central 
domain protein 
This study 
Table 2.10 Plasmids used in this research. 
 
 
2.5.2 Extraction of Genomic DNA 
1 mL of overnight broth culture was centrifuged (13,000 x g at room temperature) in 
Eppendorf tubes for 2 min. Supernatant was discarded and cell pellets centrifuged again 
for 40 sec to remove excess supernatant. Gram staining and Lancefield grouping were 
done to confirm the identity of isolates in biomass.  All cell pellets of about the same 
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size were used immediately or stored in the freezer (-20ºC) pending DNA extraction. 
Genomic DNA was extracted from each pellet using Qiagen DNeasy DNA Extraction 
Kit (Table 2.9), according to the manufacturer’s instructions. 
 
 
2.5.3 Oligonucleotide Primers 
Oligonucleotide primers were synthesized by Eurofins MWG Operon 
(http://www.eurofinsdna.com/products-services/). The oligonucleotide primers used in 
this study are listed in Table 2.11 
 
Oligonucleotide 
name 
Sequence        (Primer 
Length) 
5’ → 3’ 
Restriction 
Site 
Annealing 
temperatures 
  1
o
     and    2
o
 
GC 
content 
Use 
SequiPrtMf TTC CCA TTA TCC AGC ATG 
AG (20) 
n/a 55.3 
oC and 50.3oC 45% PCR/ID of 
WT and Δ 
SequiPrtMr ACA  ATT CAA AGC CCC 
ACT CA (20) 
n/a 55.3 
oC and 50.3oC 45% PCR/ID of 
WT and Δ 
SEQPrtmf gatcgatccatATGTGTCAGTCTA
CAAATGACAATACAAGTG 
(42) 
NdeI 69.4 
oC and 64.4oC 38.1% PCR/cloning 
of full PrtM 
gene 
SEQPrtmr gatcgatcctcgagATATTTTTCTG
ACTTAGATTTAGAAGATTGA
C (46) 
XhoI 70.3
 oC and 64.4oC 37% PCR/cloning 
of full PrtM 
gene 
Prtmidcolif tgccatagcatATGACTACTCAGG
TCACTACTCTAGACAATG 
(42) 
NdeI 71.4
 oC and 64.5oC 42.9% PCR/cloning 
of PrtM 
central 
domain 
Prtmidcolir tgccatagctcgagttaGGCTTTTTTG
GTTACCTTAACA (39) 
XhoI 69.5
 oC and 64.5oC 41% PCR/cloning 
of PrtM 
central 
domain 
Prtmequif tgccatagggatccGGTGGAATGGT
TGTTTTAGATGATG (39) 
BamH I 71.6
 oC 46.2% PCR/  
complement
ed mutant 
production 
Prtm123equir tgccataggtcgacCTATTTTTCTGG
ACTTAGATTTAGAAGATTGA
C (46) 
Sal I 70.3
 oC and 65.3oC 37% PCR/  
complement
ed mutant 
production 
Prtm12equir tgccataggtcgacctaGGCTTTTTTG
GTTACCTTAACA (39) 
Sal I 70.5 and 65.5
oC 43.6% PCR/  
complement
ed mutant 
production 
Table 2.11 Oligonucleotide Primers used in this study. Those nucleotides that do not 
anneal to the initial template are shown in lowercase. 1
o
 indicates primary annealing 
temperature. 2
o
 indicates secondary annealing temperature. 
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2.5.4 Polymerase Chain Reaction (PCR) 
PCR was carried out using primers, DNA template and other components (dNTPs, 
KOD Hot Start polymerase, MgSO4 Buffer) from Novagen (Appendix A9). The 
constitution of a typical PCR mix is shown in Table 2.12. 
          
Order Component Volume 
1 Sterile18.2 MΩ/cm H20  35 μL 
2 dNTPs (2 mM) 5 μL 
3 Buffer (10 x) 5 μL 
4 MgSO4 (25 mM) 2 μL 
5 F primer(20 μM) 1 μL of 1in 10 
dilution 
6 R primer (20 μM) 1 μL of 1in 10 
dilution 
7 Template DNA 1 μL 
8 KOD Hot Start polymerase (1 U/μl) 1 μL 
Table 2.12 Typical PCR Mix 
 
 
A PCR mix was prepared in the order shown in Table 2.12, to give a final reaction 
volume of 50 μl in labeled PCR (0.2 mL) tube. Each PCR reaction was run overnight 
under the thermal cycling conditions shown in Table 2.13. 
 
PCR Stage  Temperature (
o
C) Time # of Cycles 
Initial denaturing 95 2 min 1 
Denaturing 95 15 sec  
5 
 
1
o 
Annealing
 
X 30 sec 
Extension 72 1 min/kb 
Denaturing 95 15 sec  
25 
 
2
o 
Annealing
 
Y 30 sec 
Extension 72 1 min/kb 
Final Extension 72 10 min 1 
Hold  10 - 1 
Table 2.13 PCR Stages and Conditions. X indicates primary annealing temperatures 
and Y indicates secondary annealing temperatures for the primers as shown in Table 
2.11 
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When required, colony PCR was carried out by suspending a single bacterial colony in 
100 µL of sterile 18.2 MΩ/cm H20 and boiled for 10 min. 2 µL of this mixture was then 
used as a template for the PCR reaction. 
 
To ascertain successful amplification, after PCR reaction, 5-10 µL aliquot was analysed 
by agarose gel electrophoresis. 
 
2.5.5 Agarose Gel Electrophoresis (AGE) 
A 1% (w/v) agarose gel was typically used and the volume prepared depended on the 
number of samples and/or the size of the electrophoresis tank. For a small tank, for 
example, 0.3 g agarose powder was added to 30 mL of 1 x TAE buffer and boiled to get 
a clear gel solution. The solution was allowed to cool to about 55
o
C before being 
carefully poured into the gel tray (containing well forming comb) in an electrophoresis 
tank. The gel was allowed to cool and set; after which the comb was removed.  
 
For non-ethidium bromide stained gels, 5 μl of SYBR-safe (Appendix A7) was added to 
30 mL of boiled solution at 55
o
C before being poured into gel tray. However, for 
ethidium bromide stained gels, staining was carried out after electrophoresis. Gels were 
stained for 10 min in 10 µg/mL ethidium bromide solution.  
 
2 μl of loading buffer ([0.25% (w/v) bromophenol blue; 30% (v/v) glycerol] or [0.25% 
(w/v) xylene cyanol; 30% (v/v) glycerol] depending on the expected size of DNA) was 
added to 10 μl DNA sample. This mixture was loaded into each well of the cast gel and 
5 μl of Hyperladder 1 (Appendix A8) was loaded into one well as a standard marker. 
Samples were electrophoresed for 30-40 min at 120 mA (200 V). DNA bands were 
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visualised, images acquired and saved using a gel documentation system (Bio-Rad Gel 
Doc 2000with Quantity One software). 
 
PCR products were purified using the PCR clean-up protocol of the NZYGelpure kit 
(Table 2.9), according to manufacturer’s instructions. 
 
2.5.6  Gel Purification of DNA 
DNA bands of interest were excised from agarose gel and purified using NZYGelpure 
Kit (Table 2.9), according to the manufacturer’s instructions. 
 
2.5.7 Quantification of DNA in agarose gel 
DNA in a band in agarose gel was quantified via Quantity One software with the Bio-
Rad Gel Doc 2000 imaging system. 
 
2.5.8 Quantification of DNA in solution 
DNA in solution was quantified using an automated NanoDrop uv/vis 
spectrophotometer (ND-1000, appendix B27) or manually via an ultra violet (UV) 
spectrophotometer. 
 
 For DNA quantitation via the UV spectrophotometer (Appendix B29), the instrument 
was zeroed with water (50-100 µL in a quartz cuvette) after which the diluted DNA 
sample (50-100 µL in a quartz cuvette) was scanned in the UV region between 200-300 
nm. The optimum wavelength for absorbance of DNA was assumed to 260 nm, while 
the optimum wavelength to detect protein contamination was assumed to be 280 nm. 
ssDNA of 33 µg/mL, as well as dsDNA of 50 µg/mL
  
each give an OD260 nm reading of 
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1.0. The concentration and purity of DNA in solution was therefore determined as 
described below: 
 
[dsDNA] µg/µL  =  (A260 nm) x 50 x dilution/1000 
DNA purity ratio = (A260 nm)/(A280 nm) 
Pure DNA solutions would have an (A260 nm)/(A280 nm) between 1.8 - 2.0  
 
2.5.9 Restriction digest 
Restriction endonuclease (New England Biolabs) digests were performed according to 
the manufacturer’s instructions. Typically, each µg of DNA was cut with 5 U of 
enzymes at 37
o
C for >1.5 h, unless otherwise stated. When necessary, heat inactivation 
was carried out at 65
o
C for 10 min.  BSA (at a final concentration of 0.1 mg/mL) and 
the appropriate buffer (at a final concentration of 1 x, Table 2.8) were added to the 
reaction mixture. In order to avoid interference with enzyme specificity, glycerol 
concentration in the final reaction did not exceed 10% (v/v). The products of digestion 
were subjected to agarose gel electrophoresis (section 2.5.5); the DNA fragment 
recovered and purified using NZYGelpure Kit (section 2.5.6). 
 
Internal restriction recognition sites for DNA sequences and vetors were determined by 
the NEBcutter program (2012). A list of restriction endonucleases used to cut 
plasmids/vectors is given in Table 2.14. The restriction endonuclease used in this study 
and their corresponding reaction buffers are shown in Table 2.8. 
 
Plasmid/Vector Restiction endonuclease 
pET-28a NdeI/XhoI or XbaI/XhoI 
pVA838 BamHI/SalI 
Table 2.14 Restriction endonucleases used to cut plasmids/vectors 
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2.5.10 Ligation 
Concentrations of DNA insert were determined on samples (after agarose gel 
electrophoresis) using the analysis tool of the Bio-Rad Gel Doc 2000 Quantity One 
software. For a typical ligation experiment, 100 ng of cut vector required 3-10 times 
more molecules of insert. Other components of the reaction include 400 U of T4 DNA 
Ligase (New England Biolabs), 1 µL 10 x T4 DNA ligase Buffer (New England 
Biolabs). The ligation mixture was made up to a final volume of 10 µL with sterile 18.2 
MΩ/cm H20 and incubated overnight at 16
o
C. 
 
2.5.11 Preparation of chemically competent E. coli cells 
The CaCl2 method of Cohen et al. (1972) was applied for the preparation of chemically 
competent E. coli TOP10 or BL21 cells. A single bacterial colony was inoculated into 5 
mL of LB broth and incubated at 37
o
C overnight. The overnight starter culture (1% v/v) 
was used to inoculate 50 mL of LB broth in a 250 mL conical flask and incubated at 
37
o
C, shaking at 200rpm, to an OD600 nm of 0.35, after which the culture was incubated 
on ice for 30 min. The culture was centrifuged at 2700 x g for 10 min at 4
o
C and the cell 
pellet resuspended, by gentle vortexing, in 15 mL of ice-cold solution of 80 mM MgCl2 
- 20 mMCaCl2. After a further incubation on ice 10 min, the sample was centrifuged at 
2700 x g for 10 min at 4
o
C. The cell pellet was resuspended (by gentle vortexing) in 1 
mL of ice-cold 100 mM CaCl2 and placed on ice for 1h. The cells were either used 
immediately or 50% (v/v) glycerol added to a final concentration of 15% (v/v) and 
stored in 50 µL aliquots at -80
o
C. 
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2.5.12 Heat-Shock transformation of chemically competent E. coli (TOP10  or 
BL21) cells 
DNA (10 µL from a ligation reaction, or 1 µL from a plasmid preparation) was added to 
50 µL of chemically competent E. coli cells, mixed gently with a pipette tip and 
incubated on ice for 20 min. The cells were heat shocked for 90sec at 42
o
C and 
incubated again on ice for 2 min. The cells were recovered aseptically by adding 200 
µL of room temperature NZY
+
 enrichment broth and incubated at 37
o
C for 1 h, shaking 
horizontally (for maximum aeration) at 200 rpm. The recovered cells were plated, 
aseptically onto LB agar plates containing appropriate antibiotics and incubated at 37
o
C 
for approximately 16-24 h. 
 
 
2.5.13 Crude Preparation of pDNA for screening of successful transformation 
(STET DNA). 
5 mL of LB broth containing the appropriate antibiotics was inoculated with a single 
colony of the transformant and the culture incubated overnight at 37
o
C, shaking at 200 
rpm. 3 mL of the overnight bacterial culture was centrifuged in two 1.5 mL 
microcentrifuge tubes at 10,000 x g for 1 min. The pellet was pulsed and residual 
supernatant removed. Pellet was resuspended (by vortexing) in 150 µL STET buffer 
(Table 2.5) and 10 µL of freshly prepared 10 mg/mL hen egg white lysozyme added to 
lyse the cells. Sample was boiled for 40 sec and immediately after removal from the 
boiling water bath, centrifuged at 14,000 x g for 15 min. The viscous pellet was 
removed and discarded. 150 µL of chilled isopropanol was added to the supernatant and 
mixed before incubation at -20
o
C for 1 h, to allow for precipitation of DNA. After 1 h 
incubation at -20
o
C, the sample was immediately centrifuged at 14,000 x g for 5 min 
and the supernatant discarded. After removal of residual supernatant by pulsing, the 
   
57 
 
pellet was washed in 500 µL of ethanol and centrifuged at 14,000 x g for 3 min. The 
supernatant was discarded and the pellet pulsed to remove residual supernatant. The 
sample was desiccated for 10 min (to remove any latent ethanol) and resuspended in 30 
µL of TE buffer containing 100 µg/mL of RNase. 
 
2.5.14 Standard Preparation of pDNA (SPIN DNA) 
An overnight culture containing insert (after section 2.5.12) was inoculated 1:100 into 5 
mL or 100 mL LB broth containing the appropriate antibiotics and incubated overnight 
at 37
o
C, shaking at 200 rpm. The plasmid was purified using the NZYminiprep (5 mL 
culture) or NZYmidiprep (100 mL culture) according to the manufacturer’s instructions. 
The pDNA was eluted into TE buffer, the plasmid concentration determined 
spectrophotometrically and the plasmid integrity determined by agarose gel 
electrophoresis (AGE). 
 
2.5.15  pDNA sequencing 
The standard preparation of pDNA (Section 2.5.13) was employed. However, the 
pDNA was eluted into sterile 18.2 MΩ/cm H2O, the concentration determined using 
nanodrop spectrophotometer (Section 2.5.18) and the sample sent to GATC Biotech for 
sequencing. 
 
2.5.16 Production of electrocompetent cells and electrotransformation of S. equi 
4047 WT and ΔPrtM 
A modification of the methods of Slater et al. (2003), Pajunen et al. (2005) and 
Hamilton et al. (2006) was employed in the preparation of competent S. equi cells. An 
overnight culture of S. equi 4047 ΔPrtM (grown in THB) or S. equi 4047 WT (grown in 
THB containing 30 µg/mL hyaluronidase) was diluted 1:20 in 200 mL of same medium 
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and grown at 37
o
C to OD600 nm between 0.12 -0.13. The cells were harvested by 
centrifugation (S. equi 4047 ΔPrtM at 4000 x g; and S. equi 4047 WT at 8000 x g) at 
4
o
C for 10 min. Pellets were washed three times in 10 mL of ice-cold 0.5 M sucrose by 
centrifuging at same speed, temperature and time. After the last wash, the competent 
cells were resuspended in 1 mL of ice-cold 0.5 M sucrose / 10% (v/v) glycerol and 100 
µL aliquots were used immediately for electrotransformation or stored frozen at -80
o
C. 
All tubes or storage vials used were always ice-cold prior to coming in contact with 
competent cells. 
 
A modification of the methods of Wyckoff and Whitehead (1997) and Hamilton et al. 
(2006) was employed in the electrotransformation of S. equi competent cells.  1-5 µg of 
pDNA or recombinant-pDNA was added to 100 µL of competent cells in a pre-chilled 2 
mm Bio-Rad (U.K.) electroporation cuvettes and left to stand on ice for 10 min. 
Electroporation was carried out in a Gene Pulser electroporator (Appendix 31) with 
pulse settings of 2.5 kV/cm, 200 Ω, and 25 µF. Pulse times ranged from 4 – 5 sec. After 
electroporation, 1 mL of ice cold THB / 0.5 M sucrose / 20 mM MgCl2 / 2 mM CaCl2 
was added to the cells and left to stand on ice for 10 min. Cells were then incubated at 
37
o
C for 2 h, after which they were put back on ice. Within 30 min, serial dilutions (in 
THB) were plated onto THA plates containing 5 µg/mL chloramphenicol, followed by 
incubation in a candle jar at 37
o
C for 24 - 96 h, until colonies were observed. 
 
2.5.17 Bradford’s assay 
Protein determination by the Bradford (1976) method entailed the preparation of 10 
dilutions of BSA in 500 μL aliquots, ranging from 1-10μg/mL. 500 μL of Bradford’s 
solution (Table 2.7) was then added to each standard dilution and mixed. Protein 
concentration in each standard was measured in a glass cuvette at A595 nm against a blank 
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containing 500 μL of 18.2 M/cm H2O mixed with 500 μL of Bradford’s solution. 
After every measurement, the glass cuvette was washed with methanol. All 
measurements were completed within 40 min of addition of Bradford’s solution, 
followed by the drawing of a standard curve (Figure 2.1). Dilutions of the protein to be 
determined were made in 500 μL volumes and measured after the addition of 
Bradford’s solution in the same way as the standards. Diluted sample A595 nm values that 
fell on the standard curve were then used to calculate protein concentration, using the 
equation below. 
 
Protein concentration   mg/mL= (Concentration obtained from the curve) x (dilution of 
sample) / 1000 
 
 
 
Figure 2.1: Standard curve for the quantification of protein by Bradford assay. 
The curve was generated by the addition of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, + 10 g/mL BSA 
in 500 L 18.2 M/cm H2O to 500 L Bradford’s reagent. The A595 nm of the solution 
was determined after 5 min incubation at room temperature. 
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2.5.18 Spectrophotometric determination of protein concentration 
Determination of protein concentration using the UV spectrophotometer (Appendix 
B29) was achieved by taking A280nm readings of diluted protein sample, with the diluent 
serving as the blank with which the instrument had initially been zeroed. The molar 
extinction coefficient of the protein was determined via the Expasy website (section 
2.3.3) so as to enable the calculation of the concentration of protein in the sample using 
the following formula: 
 
Protein concentration (µg/mL) = [(A280) x molecular weight of protein x dilution 
factor] / molar extinction coefficient of protein. 
 
2.5.19 SDS-PAGE  
SDS-PAGE was carried out according to the method of Laemmli (1970) using The 
BioRad Mini Protean III kit. Two clean glass plates of dimensions 10.1 X 7.2 cm and 
10.1 X 8.2 cm (larger glass plate had a spacer ridge of 0.75 mm attached)  were aligned 
in parallel, clamped and mounted onto the surface of a rubber gasket by applying 
vertical downward pressure. The components of the resolving gel were made up in a 
plastic container and pipetted into the space between the two plates, filling it up to about 
2 cm from the top of the smallest plate. In order to prevent inhibition of polymerisation 
by oxygen, and also to produce a straight top, the surface of the gel was layered with 
18.2 MΩ/cm H2O. The gel was left to set for 20 min, after which that water was 
removed from the surface of the set gel and residual unset gel or water removed with 
the aid of blotting paper (without touching the gel surface with the blotting paper). The 
components of the stacking gel were mixed and pipetted on to the surface of the 
resolving gel, filling it up to the top of the small glass plate. Immediately, a 10-tooth 
comb (1.1 X 0.75 cm) was inserted into the gap between the plates and the gel was then 
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allowed to polymerise for 20 min. The combs were then gently removed to reveal the 
wells which were rinsed immediately with 18.2 MΩ/cm H2O. The gels were placed in 
the electrophoresis module with the smaller glass plates facing inwards, towards the 
centre so as to create a reservoir in the central compartment. The module was then 
lowered vertically into the electrophoresis tank and 1 x SDS-PAGE running buffer 
carefully (avoiding creation of bubbles) poured into the reservoir. The buffer in the 
reservoir was allowed to flow into the wells and formed a layer on the top of the gel. 
 
Samples were prepared by adding 5 µL of SDS-PAGE loading buffer to 20 µL of 
sample, mixed and boiled for 3 min. Size standards were similarly prepared, except that 
8 µL of loading buffer was added to 4 µL of size standard. All samples and standards 
were then centrifuged at 14,000 x g for 1 min. With the aid of the Hamilton syringe, 20 
µL of sample and 10 µL of standard were loaded into wells of the cast SDS-
polyacrylamide gels. The pair of gels were electrophoresed at 120 mA, 200 V for 50-60 
min, until the bromophenol blue dye had migrated off the bottom of the gel. 
 
To visualize the protein bands after electrophoresis, gels were carefully removed from 
between the glass plates and stained in Coommasie blue stain for 10 min, destained 
overnight, washed in 18.2 MΩ/cm H2O, photographed using the Bio-Rad gel doc 
system, while hard copies of the image were  produced using a Mitsubishi Video Copy 
Processor with Mutsubishi thermal paper (Appendix  B9). 
 
2.5.20 Western Blotting  
Western blotting can be used to indicate the presence of lipoproteins in either cell 
associated protein extract or secreted protein extract (Hamilton et al., 2006). To 
evaluate immunogenicity, Western blotting was adapted from Hamilton et al. (2000). 
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SDS-PAGE of sample was carried out as described in section 2.5.15, except that the 
standard was the ready to use Bio-Rad Precision Plus Protein All Blue Standard 
(Appendix C8), unless otherwise stated. After SDS-PAGE, protein bands were 
electrophoretically transfered (Western blotting by Transblot apparatus, Appendix C13) 
onto nitrocellulose membranes (0.2 µM, BioRad).  
 
In order to view protein bands after transfer (a method adapted from Luque-Garcia et 
al., 2006), blots were, optionally, reversibly stained with Ponceau-S solution (Appendix 
A1) and washed in several changes of PBS-Tween (Appendix C10). 
 
After transfer, or after washing off Ponceau-S solution,  non-specific binding sites on 
blot were blocked by incubating blot overnight in 20 mL 5% (w/v) skimmed milk  in 
phosphate buffered saline containing 0.05% (w/v) Tween-80 (PBST, Table 2.6). The 
blocking solution was subsequently discarded and blots were incubated for 2-3 h in 
primary (1º) antibody (Table 2.15) diluted in 5% (w/v) skimmed milk in PBST. After 
washing blots in five changes (5-10 min per wash) of PBST, blots were incubated for 2-
3 h in secondary (2º) antibody (Table 2.15) diluted in 5% (w/v) skimmed milk in PBST. 
Blots were washed again in five changes (5-10 min per wash) of PBST and developed 
in BCIP / NBT alkaline phosphatase substrate reagent (Appendix C12), according to the 
manufaturers instructions. Images of developed blots were acquired via the BioRad Gel 
doc system. 
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1º Antibody/Dilution Corresponding 2º antibody/dilutions 
Horse convalescent serum / 1:1000 α-horse / 1:20,000 
Pony 5788 Pre or Post infection sera / 
1:1000  
α-horse / 1:20,000 
Pony 5726 Pre or Post infection sera / 
1:1000 
α-horse / 1:20,000 
αLppC / 1 :1000 α-rabbit /1:30,000 
αPPMA / 1 :1000 α-rabbit /1:30,000 
αHPr / 1 :2000 α-rabbit /1:30,000 
Table 2.15: Antibodies and dilutions for Western blotting (adapted from Sutcliffe et 
al., 2000). 
 
 
2.5.21 Isolation of cell free extract (CFE) using cracking buffer  
 
A 1:50 dilution in 100 mL THB of the overnight starter culture was incubated at 37
o
C to 
mid-late log phase and the 1 mL of the culture in a microcentrifuge tube subsequently 
centrifuged in at 13000 x g for 2 min at room temperature. The pellet was resuspended 
in a solution {containing 40 µL of 18.2 MΩ/cm H2O and 10 uL of SDS-PAGE sample 
cracking buffer (Table 2.6)} and boiled (in a water bath) for 10 min. After boiling, the 
cell debris was spurn down at 13000 x g at room temperature for 2 min. The resulting 
supernatant (cell free protein extract) was collected into clean microcentrifuge tubes. 
CFE was used for SDS-PAGE and / or Western blotting. 
 
 
2.5.22 Growth and harvesting of Cells/Supernatant for protein extraction  
A 1:50 dilution in 100 mL THB of the overnight starter culture was incubated at 37
o
C to 
mid-log phase and the culture subsequently centrifuged at 4000 x g for 15 min at 4ºC. 
The supernatant was processed immediately or stored in -20
o
C for extraction of secreted 
proteins. The cell pellet was centrifuged briefly at 4000 x g for 40 sec at 4ºC and all 
excess supernatant removed. Pellet was resuspend and washed in two changed of 10 mL 
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of cold, sterile PBS at 4000 x g for 15 min at 4
o
C and supernatant decanted. Gram 
staining (section 2.4.3) and Lancefield grouping (section 2.4.4) were done to confirm 
the identity of isolates in biomass. All excess supernatant was discarded and washed 
cell pellet processed immediately or stored at -20
 o
C pending protein extraction for 2D-
E.  
 
2.5.23 Extraction of Cell-Associated Protein Extracts from Cell Pellets for 2D-E 
Cell pellet (from section 2.5.22) was resuspended in 100 μl of reconstituted (ready to 
use) lysis solution (Table 2.7) to a total volume of approximately 200 μl, and lysed by 
sonication on ice at an amplitude of 14 microns, three times, in 10 bursts (10 sec) at 10 
sec intervals. The protein mixture was harvested by centrifugation at 4000 x g at 4ºC for 
45 min and the supernatant saved. 
 
2.5.24 Isolation of Secreted Proteins from Culture Supernatants 
 Culture supernatants (sections 2.5.22) were either freshly prepared or if retrieved from 
the freezer, thawed to room temperature. To enable precipitation of proteins, 1.5 mL of 
100% (w/v) trichloroacetic acid was added to 25 mL of supernatant in a clean tube and 
kept on ice for 10 min. The mixture was centrifuged at 4000 x g at 4ºC for 15 min and 
the supernatant discarded. The protein pellet was washed three times in 500 μl of ice-
cold acetone, by centrifuging each time for 15 min at 4000 x g, 4ºC. The acetone 
supernatant was discarded after each wash. The protein pellet was washed three times 
by dissolving it in 500 μl of ice-cold 18.2 MΩ/cm H2O and centrifuged for 15 min at 
4000 x g, 4ºC.  200 μl of reconstituted (ready to use) lysis solution (Table 2.7) was 
added to each protein pellet and sonicated once at 14 microns in 10 bursts (10 sec) for 
complete suspension. Concentration of protein in sample was determined by Bradford’s 
   
65 
 
assay (section 2.5.17.4). Any sample that was not used immediately was stored at -80ºC 
until required. 
 
2.5.25 Decontamination/Precipitation of Protein Extract 
 To each of the protein suspension (sections 2.5.23 and 2.5.24) in microcentrifuge tube, 
at room temperature, 800 μl (4 X sample volume) of cold (-20ºC) acetone was added. 
Each tube was vortexed briefly and incubated for 1.5 h at -20º and then centrifuged for 
10 min at 13,000 x g on a bench microcentrifuge. The supernatant was decanted and 
pellets washed with 4 volumes of ice-cold 80% (v/v) acetone by centrifuging for 10 min 
at 13,000 x g. The supernatant was decanted, each tube centrifuged briefly and residual 
supernatant removed with a pipette. The pellet was air dried for approximately 5 min at 
room temperature, being careful not to over dry. Cell pellet was resuspended (by 
sonication at 14 microns in 10 bursts, 10 sec, once) in 350 μl ready to use rehydration 
buffer (Table 2.7) for downstream application. Sample was used immediately or stored 
at -80ºC, and thawed to room temperature when required. 
 
2.5.26 Two Dimensional Gel Electrophoresis (2D-E) 
Proteomics analysis (method of Zhang et al., 2007) was carried out to identify and 
characterize proteins from S. equi 4047 WT, ΔPrtM and complemented mutants. 2D-E 
was carried out until at least six replica gels were obtained for the cell associated and 
secreted protein extracts. 
Ready to use protein samples in rehydration buffer (section 2.5.25) were applied onto 
Immobiline DryStrips (18 cm, pH 3-10 or pH 4–7, Amersham Bioscience, appendix 
B16) for 16 h at room temperature. Isoelectric focusing (IEF) was done on a Multiphor 
II Isoelectric Focussing system (Amersham Bioscience) with running steps of 500 V for 
1 min, 500–3500 V for 1.5 h and 3500 V for 7 h at 20°C. The strips were subsequently 
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incubated in equilibration buffer with DTT (Table 2.7) for 15 min at room temperature, 
followed by a second incubation in equilibration buffer with IAA (Table 2.7) for 
another 15 min.  
The second dimension was carried out in either a 2 plate electrophoresis tank [14% w/v 
SDS-polyacrylamide gel using the Protean II XL 2-D cell (Bio-Rad, Appendix B11a) 
with running conditions of 40 mA per gel for 4 h at 10°C] or a 12 plate electrophoresis 
tank [12% w/v SDS-polyacrylamide gel using the Protean Plus Dodeca cell (Bio-Rad, 
Appendix B11b) with running conditions of 5 mA per gel for 1 h, 10 mA for 1 h and 12 
mA for 16 h at 15°C]. Each gel was then fixed in 200  mL of 2D gel fixing solution 
(Table 2.7) for at least 1 h and stained in 200  mL of colloidal Coomassie blue solution 
(Table 2.7) for 16 h. Gels were destained in two changes of 18.2 MΩ/cm H2O for at 
least 30 min per change, and gel images captured using a Bio-Rad GS-710 image 
densitometer (Appendix B21). Differential expression of proteins was analysed using 
PDQuest™ v 8.0 (Bio-Rad) or Progenesis SameSpots softwares. 
 
2.5.27 Analysis of 2D-E Gels Using PDQuest™ v 8.0 Software 
Gels were analysed, protein spots were detected and quantitated as described by Zhang 
et al., (2007). However a higher version of the PDQuest™ v 8.0 (Bio-Rad) software 
was used. The gel background was subtracted, after which the intensity of the image 
pixel within each protein spot was quantified. Normalization of gels was based on the 
summed density in each gel of a matchset. 
 
The spots from all the gels were individually assigned a spot number by the PDQuest 
software. A reference pattern was generated and a master gel image (Figure 3.25) with 
spot numbers was generated for each matchset. Each gel in the matchset was matched to 
the reference gel, the master gel image (Zhang et al., 2007). Selection of differentially 
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expressed proteins was done according to Wil-coxon two-sample test (p < 0.05), such 
that protein spots were more intense (or less intense) on at least six gels in a matchset 
(Houtman et al., 2003).  
 
The master image contained all the spots that were found in all the gels in a matchset; 
and was very useful for correct identification, excision (cutting or spot picking), and 
tagging/labeling of the spots. 
 
2.5.28 Analysis of 2D-E Gels Using Progenesis SameSpots v 4.5 Software 
The analysis of 2D gels in the later part of this research was carried out using a fourth 
generation analysis software, Progenesis SameSpots (Nonlinear Dynamics, 2012). The 
objective of such fourth generation analysis software is to reduce the subjectivity of the 
image analysis (Silva et al., 2010). The alignment step of the workflows utilized in 
previous generations of analysis software entailed tedious manual validation steps 
requiring significant user intervention to ensure correct spot detection and matching 
between gel images (Silva et al., 2010). In the SameSpots work flow, the alignment step 
is performed before spot detection and manual review steps in order to prevent the user 
from introducing biased alignments between spots that are located in similar (but not 
identical) positions (Silva et al., 2010). This also facilitates simultaneous spot detection 
on all gel images in an experiment, so that the resulting spot boundaries are identical on 
all gel images in the experiment (Silva et al., 2010). 
 
Gel images were imported into the programme for the Progenesis SameSpots Software. 
A representative gel image was selected and all the other gel images were aligned to the 
representative reference gel image. Unreliable spots, like those that were too small to be 
picked or those in damaged areas were removed by filtering them and deleting spots 
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that matched set criteria. To enable comparison of protein expression, matchsets were 
generated by defining which gel images represented a particular experimental condition. 
This was achieved by using the between-subject design in the experimental design setup 
screen of the Progenesis SameSpots Software. 
 
Interesting and significantly changing spots were detected, using Anova p-value ≤ 0.05 
and maximum fold change ≥ 2 (Nonlinear Dynamics, 2012). Finally, a picking list was 
generated and the spots to be picked were tagged. 
 
2.5.29 In-gel Protein digestion 
Protein spots in approximately 1 mm x 1 mm gel slices were cut from each Colloidal 
Coomassie blue stained spot on the 2D-E gels or a band from SDS-PAGE gel. Each 1 
mm x 1 mm gel slice was transferred into clean, labeled  0.5 mL siliconized 
microcentrifuge tube and trypsinized immediately or preserved by the addition of 500 μl 
of 18.2 MΩ/cm H2O and stored at 4ºC pending trypsinization. If the gel slice was 
stored, the 18.2 MΩ/cm H2O was discarded just before further processing. 
 
Colloidal Coomassie blue stain was washed out of each gel slice by the addition of 
freshly prepared 100 μl of 100 mM NH4HCO3 and 60 μl of LC-MS grade acetonitrile 
(ACN, LC-MS grade) was added to each siliconized microcentrifuge. The tube was 
shaken (200 rpm) for 30 min at 25ºC and the supernatant discarded. This wash step was 
repeated three times until the blue colour was gone from the gel slice. Each gel slice 
was dehydrated by the addition of 60 μl of ACN (LC-MS grade). The tube was then 
incubated at room temperature for 5 min and the liquid discarded. This process was 
repeated again for complete dehydration, after which the gel slices were dried in a 
centrifugal evaporator (Appendix B12) for 15 min at 25ºC. Each dehydrated gel slice 
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was then incubated in 10 μl of 20 μg/ mL Promega trypsin solution (Table 2.7) in a 
water bath at 25ºC for 1 h. After this incubation, approximately 30 μl of 40 mM 
NH4HCO3 was added to each tube to cover the gel and the digestion was incubated at 
37°C overnight.  
 
The reaction was stopped by the addition of 30 μl of 50% (v/v) ACN + 5% (v/v) formic 
acid solution, and shaken (200 rpm) for 30 min at 25ºC. The supernatant was recovered 
and saved because it contained digested peptides. The remaining proteins in the gel slice 
were recovered by adding 30 μl of 83% (v/v) ACN + 0.2% (v/v) formic acid solution, 
and shaken (200 rpm) for 30 min at 25ºC. The supernatant was saved and pooled with 
the previous extract in a microcentrifuge tube. 
 
One or two pin holes were bored on the lid of each microcentrifuge tube containing the 
pooled extract. The extract was then freeze dried for 24-48 h using the Alpha 1-2 LD 
plus freeze drier (Appendix B23). The freeze-dried extracts were either processed 
immediately for mass spectrometric analysis or stored at -80º for a few days pending 
further processing. 
 
2.5.30 HPLC and Mass Spectrometry 
Ion trap mass spectrometry can be used to identify peptides in the sub-mol range 
(Schweiger-Hufnagel et al., 2001). Its multiple fragmentation stages give data with 
excellent information, thus allowing for highly reliable protein identification even from 
mixtures or poorly separated proteins; thus making ion trap mass spectrometry one of 
the leading mass spectrometric techniques in proteomics (Schweiger-Hufnagel et al., 
2001). 
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7 μl of LC-MS buffer A (Table 2.7) was added to each freeze dried peptide extract 
(from section 2.5.27) and content mixed carefully with a clean pipette tip. 7 μl of each 
solubilized sample was pipetted into one well of a 384-well mocroarray plate (Appendix 
B26). The solubilized peptides were analyzed on spherical high capacity traps 
(HCTultra™, Bruker Daltonics, appendix B25) using electrospray ionization (ESI)  ion 
trap mass spectrometer coupled to the high performance liquid chromatography (HPLC) 
machine (UltiMate 3000™ - Dionex, Appendix B24). The mass spectrometer was 
controlled by the software EsquireControl™ (Bruker Daltonics). The samples’ identities 
were electronically stored using the HyStar 3.2™ (Brucker Daltonics) software (a 
valuable software to help coordinate experiments when a liquid chromatography system 
is coupled with mass spectrometer, Bruker Daltonics, 2010). HyStar 3.2™ (Brucker 
Daltonics) functions by controlling the chromatography system instruments, which 
interface in diverting the solvent flow into the spectrometers or intermediate collectors 
(Bruker Daltonics, 2010). 
 
Mass spectrometry of samples was carried out in ESI positive ion mode. Automated 
MS–MS mode was activated so that the mass spectrometer automatically detected and 
fragmented molecular ions whenever the MS ion signal intensity exceeded the 
previously fixed level (Schweiger-Hufnagel et al., 2001). All across the LC peak, MS 
and MS–MS were performed alternately until the ion intensity was below the set 
intensity threshold again (Schweiger-Hufnagel et al., 2001). A summary of the capillary 
LC-MS/MS peptide separation parameters is shown in Table 2.16  
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LC/MS Parameter Range 
LC system UltiMate 3000™ - Dionex, Appendix B24 
Column polystyrene- divinylbenzene (PS-DVB) Monolithic 
Column 200 μm I.D. x 50 mm (60ºC) 
column PS-DVB Monolithic, 200 μm i.d. x 5 mm 
Loading solvent LC-MS buffer A (Table 2.7) 
Elution solvents LC-MS buffer A (Table 2.7) 
 
LC-MS Buffer B (Table 2.7) 
 
LC-MS Buffer C (50% [v/v] acetonitrile in 18.2 
MΩ/cm  - Appendix F3) 
 
Gradient 0-35%(v/v) ACN in 9 min, parallel LC 
Samples freeze dried peptide extract solubilized in 7 μl of LC-
MS buffer A (section 2.5.18) 
Injection 4 μL sample 
Flow rate 3.003 μL/min 
MS HCTultra™ (Bruker Daltonics, Appendix B25) - 
electrospray ionization (ESI) ion trap mass 
spectrometer. 
ESI-MS/MS Positive ion mode, mass range 50-3000 m/z, cycle 
time 0.12 min 
Max ion trap accumulate time 200.00 ms 
Average scan 4 
Number of precursors 3 
Nebulizer of ionization source 10.0 psi 
Dry gas of ionisation source 5.0 L/min 
Dry temperature of ionization source 300ºC 
Table 2.16 Summary of the capillary LC-MS/MS peptide separation parameters 
   
 
 
2.5.31  MS Data Analysis 
 
The EsquireControl™ (Bruker Daltonics) has inbuilt procedure for MS/MS precursor 
ion selection and fragmentation; and can extract only the relevant information from the 
samples (Schweiger-Hufnagel et al., 2001). The processing of the acquired MS and 
MS/MS data is triggered automatically by a script which includes the following steps: 
 
 The EsquireControl™ (Bruker Daltonics) software performed chromatogram 
integration, mass annotation and charge deconvolution, after which the 
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deconvoluted and the non-deconvoluted data were combined and subsequently 
exported (Schweiger-Hufnagel et al., 2001) 
 
 This data was then exported to a protein database search engine on a local 
MASCOT (Matrix Science, 2009) server and the search result viewed and 
interpreted (Matrix Science, 2009). The MASCOT search employed MS/MS ion 
searches where confidence that a protein, (as opposed to a peptide), had been 
identified correctly came largely from getting multiple matches to peptides from 
the same protein (Matrix Science, 2009). This entailed identifying proteins 
based on raw MS/MS data from one or more peptides. The MASCOT (Matrix 
Science, 2009) search parameters for protein identification are shown in Table 
2.17. The matched peptide and protein sequences were viewed in the ‘Protein 
hits’ results window. 
 
Parameter Identifier 
Type of search MS/MS ion search 
Database NCBInr and/or SwissProt 
Enzyme Trypsin 
Peptide Mass tolerance ±1.2 Da for the parent ion 
Fragment Mass tolerance ±0.5 Da for the fragment ions 
Maximum missed cleavages 2 
Fixed modification Carboxymethyl (C) 
Variable modification Oxidation (M) 
Peptide charges 2+ and 3+ 
Mass values monoisotopic 
Protein mass unrestricted 
Instrument type Default 
Protein ID’s definition by at least 2 peptides, peptide ion  score ≥ 
14. Individual ion scores >60 indicate 
identity or extensive homology (p<0.05). 
 
Table 2.17 Mascot search parameters for protein identification 
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Further evaluation of the proteins identified by Mass spectrometry was carried out using 
the criteria listed below: 
 spot number 
 protein identification - best match hit  
 protein code for best match hit (i.e. the code SEQ_#### or Sez_####) 
 comment as to whether expression is same in both strains, upregulated in wild 
type 4047 (= down regulated in mutant) or upregulated in mutant  (= 
downregulated in wild type). 
 
  
  
  
2.6 Overexpression and Purification of Recombinant Proteins 
  
 
2.6.1 Small Scale Protein expression 
  
To confirm protein expression and levels of expression, 5 mL LB broth (containing the 
appropriate antibiotics) in 25 mL universal was inoculated with a single bacterial colony 
and incubated at 37ºC overnight, shaking at 200 rpm. Next day, the overnight starter 
culture was diluted 1:100 into two 50 mL LB broth (in 250 mL conical flask) containing 
appropriate antibiotics and incubated at 37ºC, shaking at 200 rpm until OD600 nm 
between 0.6 – 1. After incubation, 0.5 mL of 24 mg/mL IPTG was added to each flask. 
Both flasks were incubated overnight (one flask at 20ºC and the other at 30ºC) shaking 
at 200 rpm. Cells were harvested next day by centrifuging each culture at 4ºC for 10 
min at 4000 x g. Pellets were re-suspended in 5 mL START buffer (Table 2.6) and 
sonicated (at an amplitude of 14 microns, for a total of 1 min, with 10 sec interval 
between each 10 sec sonication) in 25 mL universal on ice. Samples were then 
centrifuged at 24,000 x g at 4ºC for 20-30 min, the cell free extract (CFE) was harvested 
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and maintained on ice while the pellet was discarded. SDS-PAGE (section 2.5.15) of 
CFE was done to determine protein expression and levels. 
 
  
 
2.6.2 Large scale protein expression 
 
Two 5 mL LB broth (containing the appropriate antibiotics) cultures (in 25 mL 
universals) were each inoculated with a single bacterial colony and incubated at 37ºC 
overnight, shaking at 200 rpm. Next day, the overnight starter culture was diluted 1:100 
into 100 mL LB broth (in 1 L conical flask) containing appropriate antibiotics and 
incubated at 37ºC, shaking at 200 rpm until  OD600 nm between 0.6 – 1. Subsequently, 10 
mL of 24 mg/mL IPTG was added to the flask which was incubated overnight at 30ºC 
(optimum temperature of protein expression from section 2.6.1) shaking at 200 rpm. 
Next day, cells were harvested from 100 mL culture in four 500 mL plastic bottles 
which were centrifuged at 4ºC for 10min at 4000 xg. Pellets were re-suspended in 5 mL 
Start buffer (Table 2.6) and sonicated (at anamplitude of 14 microns, for a total of 1 
min, with 10 sec interval between each 10 sec sonication) in 25 mL universal on ice. 
Samples were then centrifuged at 24,000 x g at 4ºC for 20-30 min, the CFE was 
harvested and maintained on ice while the pellet was discarded.  
 
 
2.6.3 His-tagged Protein Purification 
Recombinant proteins, under native conditions, containing a stretch if 6 histidine 
residues at the N-terminus (His6 tag) were purified using immobilized metal affinity 
chromatography (IMAC) using a fast flow Ni column with Sepharose chelating resin. 
For high yield purification of recombinant protein, the automated FPLC system gradient 
elution technique was employed.  The column was prepared by adding ~50 mL 
Sepharose chelating fast flow resin to a C series column (Pharmacia Biotech). The 
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column adapters were attached securely after which the column was connected to the 
FPLC system. 1 M NiSO4 solution was passed through the resin until all the resin was a 
uniform colour. The column was subsequently washed by passing through ~ 200 mL of 
start buffer (Table 2.6). Once the column had been equilibrated, CFE (10-20 mL) was 
loaded onto the column, which was then washed with 100 mL of start buffer (Table 2.6) 
at a flow rate of 5 mL/min generated by the FPLC gradient pump. Over the next 50 min, 
the protein was eluted at a flow rate of 5 mL/min using a linear gradient of imidazole 
(elution buffer, Table 2.6) extending from 10 mM to 500 mM. An inline UV 
spectrophotometer connected to the FPLC system was used to determine the presence of 
the target protein by monitoring A280 nm. Samples were collected in 5 mL volumes on a 
fraction collector.  
 
To determine solubilty of protein, two 1 mL aliquot from one tube (believed to contain 
protein fraction) were each mixed with 0.5 g of (NH4)2SO4 and left to stand on ice for 1 
h. Precipitate was resuspended in start buffer (Table 2.6) and 18.2 MΩ/cm H2O. 
 
To confirm purity, a 20 L aliquot from each 5 mL fraction (in tubes thought to contain 
the target protein) was analysed by SDS-PAGE (section section 2.5.15) and the pure 
fractions pooled. 
 
 
2.6.4 Dialysis  
Dialysis of pooled full length recombinant protein fractions (section 2.6.3) was carried 
out using cellulose membrane tubing (M.W. 12,400, size 25 mm x 16 mm, Sigma) 
secured with dialysis tubing closure (gripping length 50 mm, Sigma). The dialysis 
tubing (always handled with gloves and cut into a length to accommodate solution to be 
dialysed) was boiled for about 15 min at 80
o
C in 18.2 MΩ/cm H2O. The boiled dialysis 
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tube was then rinsed in 18.2 MΩ/cm H2O and used immediately or stored for a 
maximum of one week in 18.2 MΩ/cm H2O at 4
o
C. Recombinant protein (section 2.6.3) 
was dialysied at 4
o
C against 25 mM HEPES buffer (pH 7.4) for 1h, then in a second 
change of 25mM HEPES buffer (pH 7.4) for 6 h and finally in a third change of 25 mM 
HEPES buffer (pH 7.4) overnight. The dialysed recombinant protein was aliquoted in 1 
mL volumes into microcentrifuge tubes (with pin holes on the cap). The concentration 
in one 1 mL microcentrifuge tube was determined by Bradford’s assay (section 2.5.17). 
The remaining aliquots were frozen at -20
o
C and freeze dried for 1-2 days. The 
lyophilized recombinant protein was stored at -20
o
C and reconstituted in buffer or 18.2 
MΩ/cm H2O for assay. SDS-PAGE (section 2.5.18) was carried out using 18.2 MΩ/cm 
H2O reconstituted lyophilized recombinant protein, to ascertain the intergrity of the 
dialysed sample. 
 
 
2.6.5 Concentration of IMAC purified proteins 
Pooled recombinant protein (full length or central domain) fractions (section 2.6.3) 
were concentrated at 4
о
C, by centrifugation at 4000 x g in 10 kDa (full length  
recombinant protein) or 5 kDa (central domain recombinant protein) 6 mL cut-off 
concentrator units (Viva Science). After concentrating all the fractions containing the 
recombinant protein to about 200 µL, recombinant protein was futher washed (desalted) 
three times in 5 mL of sterile 18.2 MΩ/cm H2O. Each wash was done by centrifugation 
at 4,000 x g at 4
о
C, until about 200 µL of protein solution was left in the molecular 
weight concentrator tube. Purified and concentrated recombinant protein concentration 
was determined spectrophotometrically (section 2.5.17). 
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2.7 Crystallisation of Recombinant Protein 
 
2.7.1 Manual hanging drop method 
Crystals were grown by the vapour diffusion method. Crystallisation trays were set up 
in 24-multi well plates (Falcon ® Multiwell™ 24 well Becton Dickinson) into which 
0.5 mL of crystallisation buffer (Appendix G1-7) was aliquoted into each well. Around 
the rim of each well was then greased with vacuum grease dispensed from a syringe. 
Silanised Cover slips (molecular dimension) were polished with a silk scarf prior to the 
addition of protein drops. 1 l of protein (section 2.6.3 and 2.6.5) was added to 1 l of 
crystallisation buffer (removed from the well) on a cover slip to form a 2 l drop. The 
cover slip was inverted and sealed above the appropriate well, after which the plates 
were incubated at 22ºC. This method was repeated for all crystallisation buffers 
(Appendix J1-7).  
 
2.7.2 Microbatch - Automated 96-well plate - hanging drop method 
Crystallisation trays (hanging drop method) were also set up using the microbatch 
method at York Structural Biology Laboratory (YSBL). The Hydra96 (Ribbins 
Scientific) dispensed the screens onto each well of the 96-well plate, after which the 
handing drops were set up with Mosquito
R
 crystal screen robot (TTP LabTech). The 
screens set up by this methos were PEG ion, Newcastle screen and Hampton screen 1 
and 2 (Appendix J). 
 
2.7.3 Mounting Crystals and Cryoprotectant Optimization conditions 
The conditions in which crystals grew were then optimised to obtain crystals of good 
quality. This was achieved by varying the concentrations of buffer, salt and precipitant. 
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Once native crystals had grown, the same conditions were then used to set up 
crystallization trays of proteins from the central domain of the enzyme. 
 
Samples were frozen in rayon-fibre loop and subjected to X-ray analysis. The point at 
which ice rings were not seen in the diffraction pattern indicated a suitable additive 
concentration to act as a cryoprotectant. Crystals were harvested in a rayon fibre loop, 
soaked briefly (few sec) in a given concentration of cryoprotectant (which was in the 
original screen) and flash frozen in liquid nitrogen.  
 
2.7.4 Crystal screening 
Each crystal was mounted onto a single-axis goniometer and screened at YSBL by X-
ray (by Dr Edward Taylor) to determine diffraction quality before data collection. 
Crystal data was collected using a 345 mm Mar Research image-plate detector on a 
Rigaku rotating anode RU-200 X-ray generator, with a Cu target operating at 50 kV 
(100 mA) and focusing X-ray optics (MSC). The quality of a crystal was judged by its 
diffraction pattern.  
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2.8 Enzymology 
Enzyme assays were carried out in triplicate. For kinetic experiments, the same aliquot 
of purified recombinant protein (method from section 2.6.3 and 2.6.5) was used. The 
concentration of the recombinant protein (full or central domain, prepared from sections 
2.6.3 and 2.6.5) was determined spectrophotometrically (section 2.5.18). The standard 
protease-coupled PPIase assay employed to assay the activity of recombinant S. equi 
4047 PrtM towards peptide substrates (Pep1, Pep2 and Pep3, Table 2.8) with a 
concensus sequence Suc-Ala-X-Pro-Phe-pNA (X = various amino acids that could 
precede the crucial proline residue and pNa = paranitroaniline) was a modification of 
the methods of Fischer et al. (1984), Kofron et al. (1991), Hani et al. (1999) and Alonzo 
et al. (2011). 
 
 
2.8.1 Protease-coupled Peptidylprolyl Isomerase (PPIase) Assay 
 
The PPIase assay was performed by mixing 10 µL of recombinant protein (40-60 µL 
recombinant protein diluted in 20 mM HEPES / 140 mM NaCl / 10% glycerol), 
cyclophilin (positive control, Table 2.8) or a solution of 20 mM HEPES / 140 mM NaCl 
/ 10% glycerol (negative control) with 480 µL of buffer (20 mM HEPES / 140 mM 
NaCl / 1 mM DTT, pH 7.4 or 8.0) in a microcentrifuge tube and allowing the 
recombinant protein to equilibrate on ice for 5 min. An empty cuvette was placed in the 
spectrophotometer (helios-α, Appendix B3) which was then zeroed at 390 nm. 10 µL of 
ice-cold chymotrypsin (Table 2.8) was pipetted into the empty cuvette in the 
spectrophotometer. The 490 µL mixture (10 µL of recombinant protein, positive control 
or negative control plus 480 µL of buffer) from the microcentrifuge tube was quickly 
added to and mixed with the chymotrypsin in cuvette in the spectrophotometer. Finally 
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and quickly, 500 uL of ice-cold buffer/tetrapeptide [tetrapeptide substrate (Table 2.8) 
diluted up to a final concentration of 25-70 µM in buffer (20 mM HEPES / 140 mM 
NaCl / 1 mM DTT, pH 7.4 or 8.0] solution was added to content in cuvette and mixed 
quickly by pipetting up and down 3 times. The final reaction volume was 1 mL and the 
final concentration of chymotrypsin in the reaction mixture was 0.2 mL/mL. The rate of 
the reaction (cis-trans isomerization) was measured by following the absorbance at 390 
nm (A390 nm), following colour formation (following cleavage of pNa from the trans 
form of the tetrapeptide substrate by protease, chymotrypsin), over time, for a 
maximum of 6 min. Spectrophotometric (helios-α, Appendix B3) readings were 
recorded automatically via the Vision 32 software (version 1.25 from Unicam Ltd) in 
attached computer system. Reported kinetic data are given
 
as the mean value of 
triplicate measurements for every condition. 
 
 
2.8.2 Phenylmethanesulfonyl flouride (PMSF) assay 
 
10 µL purified full length (60 mg/mL) or central domain (40 mg/mL) protein was 
incubated with chymotrypsin (10 µL of 20 mg/mL) in 880 µL assay buffer (20 mM 
HEPES / 140 mM NaCl / 1 mM DTT, pH 7.4) for 20 sec, 2 min and 5 min at 0°C. The 
reaction was stopped by the addition of 100 µL of 10 mM PMSF and subsequent 
incubation for 5 min at 0°C.  10 µL purified full length (60 mg/mL) or central domain 
(40 mg/mL) protein incubated with PMSF-inactivated chymotrypsin (10 µL of 20 
mg/mL), chymotrypsin with PMSF alone, chymotrypsin alone, recombinant protein 
with PMSF alone, and recombinant protein alone served as controls. The reactions were 
analyzed on a 15% (w/v) polyacrylamide gel (Table 2) and by SDS-PAGE (section 
2.5.18). 
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2.8.3 Enzyme Kinetics 
 
In order to determine the Steady-State Kinetic Parameters for PrtM, recombinant 
proteins were assayed at varied substrate concentrations as indicated in section 2.8.1. 
 
kcat (/s
-1
) was calculated by using Beer-Lambert law:  A = Є C d 
d = pathlength = 1 cm  
C = ΔA / Є 
C = ΔA390 nm / Є 
Where:  
- ΔA390 nm = difference in absorbance (between catalyzed and uncatalysed 
reaction) per sec  
- Є = extinction coefficient of para-nitroaniline (8270 / M / cm) 
- C = moles of product (pNA) per sec, per L, per µg enzyme used 
- C / 1000 x106 / (total enzyme added- mg) = Vmax U/µg) 
- U = µmoles of product produced per min 
- Vmax x MW of enzyme in grams = kcat 
 
The reaction volume was 1000 µL, therefore C was divided by 1000 to give moles of 
product per min per 1000 µL. This value was then multiplied by 10
6
 to be converted 
into µmoles of product produced per min per 1000 µL and this was defined as U. U was 
then divided by the total amount of enzyme added to the assay (µg). This gave the value 
for Vmax which is units of enzyme activity per sec per µg. Vmax was then converted 
from µmoles of product produced per sec per µg, to µmoles of product produced per sec 
per µmoles by multiplying with the molecular weight of enzyme in µg to give the value 
for kcat. 
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Absolute kinetic analysis was determined by assaying (2.8.1) 3-4 substrate 
concentrations (determined empirically) in triplicate. To ascertain if these data reflected 
true Michaelis-Menten kinetics, a Line-weaver-Burk plot was constructed and used to 
determine value of KM (calculated by reciprocalising the X intercept in the Line-
weaver-Burk plot).  
 
Specificity constant (/ M / s) was determined by dividing kcat by KM. 
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3 Results of General Characterisation of S. equi 4047 WT and 
ΔPrtM 
 
 
3.1 Introduction 
 
One of the aims of this research was to characterize PrtM by evaluating its 
immunogenicity and conservation in S. equi 4047 WT and ΔPrtM. To achieve this, agar 
slant cultures [of S. equi 4047 WT which was originally isolated in 1990 from a 
submandibular
 
abscess of a New Forest pony; and ΔPrtM (PrtM-deficient mutant strain 
- ΔprtM138-213, with a deletion of nucleotides 138
 
to 213)] maintained in the
 
culture 
collection of the Animal Health Trust, Newmarket, United
 
Kingdom were evaluated. 
 
The identities of the isolates (S. equi 4047 WT and ΔPrtM) were confirmed by carrying 
out initial screening: growth on THA plates (method in section 2.4.1 and result in 
section 3.2) Gram staining (method in section 2.4.3 and result in section 3.2), 
Lancefield grouping (method in section 2.4.4; result in section 3.2), β-haemolysis tests 
(method in section 2.4.5; result in section 3.2), genomic DNA extraction  (sections 2.5.2 
and 2.5.5; result in Figure 3.2-A) and PCR (primers SequiPrtMf and SequiPrtMr shown 
in Table 2.11 and method in section 2.5.4; result in Figure 3.2-B). After these 
experiments, an evaluation of the growth pattern of both S. equi 4047 WT and ΔPrtM 
strains via growth curve experiments (method in section 2.4.6; results in section 3.3) 
were carried out. 
 
The strategic anchorage of lipoproteins to the outer leaflet of the membranes of Gram-
positive bacteria suggests a role in interaction with the environment (Reffuveille et al., 
2012a). Among other important roles, lipoproteins are thought to play important roles in 
bacterial adaptive response to host environmental changes (Reffuveille et al., 2012a). 
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With the intial results of this research in hand, it was therefore proper to evaluate the 
sensitivity of S. equi 4047 WT and ΔPrtM to some antibiotics (method in section 2.4.8; 
results in section 3.6) as well as to varying concentrations of NaCl (method in section 
2.4.7; results in section 3.5); so as to find out how the two strains cope under 
environmental variation. 
 
S. equi hyaluronic acid capsule may be involved in the pathogenesis of the organism 
(Anzai et al., 1999; Harrington et al., 2002; Timoney et al., 2004). This information, 
coupled with the observation that it was more difficult to get the mid-log phase cells of 
the wild-type (S. equi 4047 WT) to pellet (at 4000 x g for 15 min) in 0.5 M sucrose, 
compared to the mutant strain (S. equi 4047 ΔPrtM), led to a series of investigations. 
Mid to late log phase cells were employed for hyaluronic acid screening because 
streptococcal hyaluronidase is known to destroy the hyaluronic acid capsule in later 
stages of growth (DeAngelis and Weigel, 1994). In the investigation of the hyaluronic 
acid capsule content of the wild-type and mutant strains in this study, the mid-log phase 
cells of both strains were stained by different methods (sections 2.4.12, 2.4.13, 2.4.14); 
followed by density gradient centrifugation (section 2.4.10). When qualitative tests 
(results in sections 3.7 and 3.8) showed that the mutant is encapsulated just like the 
wild-type, a quantitative assay (method in section 2.4.15 and results in section 3.9) was 
carried out to ascertain how much hyaluronic acid is produced by each strain.  
 
Cell free extracts (CFE) obtained from cells (using cracking buffer - method in section 
2.5.21) of S. equi 4047 WT and ΔPrtM were analysed by SDS-PAGE (method in 
section 2.5.19) and Western blots (methods in section 2.5.20; results in section 3.10) 
were used to compare the immunogenicity of both strains.  In order to find out the 
differences and similarities between the proteomes of both strains, the proteomics 
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methods (sections 2.5.22 – 2.5.29 ) of Zhang et al. (2007) was carried used (results are 
shown in sections 3.12 – 3.14). However, before two-dimensional gel electrophoresis 
(2D-E), Western blots (method in section 2.5.20) of the cell and supernatant protein 
extracts (from sections 2.5.25) were double checked to confirm protein origin and 
immunogenicity –results are shown in section 3.11. 
 
 
3.2 Results of Colonial morphology, Gram Staining, Lancefield grouping and β-
haemolysis tests  
 
Both S. equi 4047 WT and ΔPrtM (mutant) strains showed good growth of mucoid 
colonies on THB, with the WT showing slightly larger colonies than the mutant. Gram 
stained smear of all cultures and biomass (of S. equi) used for this research yielded 
Gram-positive cocci in chains. Lancefield grouping confirmed the identities of both the 
WT and mutant as being Lancefield group C Streptococci. 
 
Figures 3.1B and 3.1D show the results of investigation of β-haemolysis in S. equi 4047 
WT and ΔPrtM on 5% horse blood agar (right). These are representative of triplicate 
repeats. There was no apparent difference in the zones of β-haemolysis of both strains. 
Apart from β-haemolysis, the colonies of both strains also appeared mucoid on blood 
agar. 
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A       B 
 
 
C       D 
 
 
 
 
Figure 3.1: Result of Investigation of β-haemolysis in S. equi 4047 WT and ΔPrtM  
in 5% (v/v) horse blood agar (B=WT and D=ΔPrtM). THA culture of S. equi 4047 
WT (A) and ΔPrtM (C) show growth/viability of organism. 
 
 
 
 
 
3.3  S. equi 4047 WT and ΔPrtM DNA Banding Patterns before and after PCR  
 
S. equi 4047 WT and ΔPrtM genomic DNA (Figure 3.2 - A) both have higher molecular 
weight than the largest (10,000 bp) Hyperladder™ (Appendix 8) band.  
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A      B  
   
Figure 3.2: S. equi 4047 WT and ΔPrtM DNA Banding Pattern:  Genomic DNA – 
Figure 3.2A.  PCR of the PrtM gene locus shows that S. equi WT 4047 in band b of 
Figure 3.2B is larger than the PrtM gene locus on ΔPrtM in bands C of Figure 3.2B. 
Primers SequiPrtMf and SequiPrtMr shown in Table 2.11 and method in section 2.5.4. 
Post-PCR DNA - B. a = Hyperladder™ Standard (Appendix A8), b = S. equi 4047 WT 
and c = S. equi ΔPrtM. 
 
From the results shown in Figure 3.2 (B), the amplified region of S. equi 4047 WT is 
larger than that of S. equi 4047 ΔPrtM. This result confirms that the mutant S. equi 4047 
PrtM (ΔprtM138-213) used in this study has a deletion of nucleotides 138
 
to 213 as 
reported by Hamilton et al. (2006). 
 
3.4 S. equi 4047 WT and ΔPrtM growth curves  
The growth curves (Figure 3.3) of S. equi 4047 WT and ΔPrtM are shown in Figure 3.3. 
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Figure 3.3 Growth Curve of S. equi 4047 WT and Mutant (ΔPrtM): A= in THB; B= in THB 
with starter culture containing THB+10% FCS. Actual cultures A and B did not contain any 
FCS. SEQe denotes S. equi 
 
 
3.5 Sodium Chloride Stress Test 
 
The averages of triplicate results of NaCl stress test (method in section 2.4.7) are shown 
in Table 3.1 below. 
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S. equi 4047 
Strain 
/Incubation time 
 H2O 
“whole” 
H2O – 
½dilution 
 
 H2O – 
1/4dilution 
 
H2O  1/10 
dilution 
 
 H2O  1/100 
dilution 
 
H2O – 1/1000 
dilution 
WT / 24 h Lawn Lawn Lawn TNTC +++ TNTC  + 75 
 
∆PrtM /24 h TNTC 
+++ 
TNTC ++ TNTC+ TNTC 170 45 
 
WT / 48 h Lawn TNTC ++ TNTC+ TNTC  + 83 12 
 
∆PrtM /48 h TNTC  + 200 50 20 10 3 
 
 
S. equi 4047 
Strain /Incubation 
time 
0.9% (w/v) 
NaCl “whole”  
0.9% (w/v) 
NaCl – ½ 
dilution  
0.9% (w/v) 
NaCl – ¼ 
dilution  
0.9% (w/v) 
NaCl  1/10 
dilution  
0.9% (w/v) 
NaCl  1/100 
dilution  
0.9% (w/v) 
NaCl  1/1000 
dilution 
WT / 24 h Lawn Lawn Lawn TNTC ++ TNTC  + 110 
 
∆PrtM / 24 h Lawn TNTC +++ TNTC ++ TNTC  + 250 74 
WT  / 48 h Lawn TNTC +++ TNTC ++ TNTC  + 212 23 
 
∆PrtM / 48 h TNTC  + 160 60 38 19 9 
 
 
S. equi 4047 
Strain /Incubation 
time 
14.7% (w/v) 
NaCl “whole” 
14.7%  (w/v) 
NaCl – ½ 
dilution  
14.7%  (w/v) 
NaCl – 
¼dilution 
14.7% (w/v) 
NaCl  1/10 
dilution  
14.7%  
(w/v) NaCl  
1/100 
dilution 
14.7%  (w/v) 
NaCl – 1/1000 
dilution 
WT /  24 h TNTC +++ TNTC++ TNTC + 248 25 4 
∆PrtM / 24 h NG NG NG NG NG NG 
WT / 48 h 218 125 80 10 3 1 
∆PrtM / 48 h NG NG NG NG NG NG 
 
S. equi 4047 Strain 
/Incubation time 
29.4% (w/v) 
NaCl  
“whole” 
29.4% (w/v)  
NaCl – 
½dilution 
29.4% (w/v)  
NaCl – 
¼dilution 
29.4%  (w/v) 
NaCl – 
1/10dilution 
29.4%  
(w/v) NaCl  
1/100 
dilution 
29.4% (w/v) 
NaCl  1/1000 
dilution 
WT  / 24 h TNTC  + TNTC ± TNTC + 103 4 1 
∆PrtM / 24 h NG NG NG NG NG NG 
WT  / 48 h 155 65 30 4 NG NG 
∆PrtM / 48h NG NG NG NG NG NG 
 
Table 3.1: NaCl Stress Test Result for S. equi 4047 WT and ∆PrtM. The average count of 
three replicate results is shown. Before plating on THA, that is after 24 h or 48 h incubation as 
described in section 2.4.7, the tubes containing sterile 18.2MΩ/cm H2O (Table 3.1 A) were 
diluted with only 18.2MΩ/cm H2O; the tubes containing NaCl (Tables 3.1 B, C and D) were 
diluted with the corresponding concentrations of NaCl solution. All broth cultures in tubes 
marked “whole” (second column of Table 3.1 A. B, C and D) were plated undiluted, onto THA, 
after 24h or 48h incubation. Serial dilutions were carried out to enable colony count. NG means 
no growth; TNTC means too numerous to count. 
A 
B 
C 
D 
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Due to the observation that only plates in the last column of Table 3.1 (A,B,C and D) 
showed consistency in countable colonies, their values were used to calculate 
percentage of total surviving organisms under NaCl stress over a 48h period. The 
percentage of surviving strains in 18.2MΩ/cm H2O and varying concentrations of NaCl 
after 24 h and 48 h incubation are shown in Figure 3.4. 
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Figure 3.4: Percentage of surviving strain (S. equi 4047 WT and/or ΔPrtM) per 
NaCl stress test condition 
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3.6 Disc Diffusion Antibiotics Sensitivity Test 
The sensitivity of S. equi 4047 WT and ΔPrtM to several antibiotics was assayed 
as described in section 2.4.8. The results are shown in Table 3.2, A and B. A 
comparison of antibiotic sensitivity and resistance levels of the WT and ΔPrtM 
strains of S. equi 4047 is shown in Figure 3.5. 
 
 
     A 
S. equi 
strain 
 
Antibiotic concentration (µg) / Zone of Inhibition (cm)  
WT 4047 - 
Triplicate 
Assays 
PenicillinG 
(6 µg) 
Streptomycin 
(500 µg) 
Vancomycin 
(30 µg) 
Gentamycin 
(500 µg) 
Ampicillin 
(10 µg) 
Norfloxacin 
(5 µg) 
1 3.6 cm 1.9 cm 1.9 cm 2.2 cm 3.5 cm 1.2 cm 
2 3.6 cm 1.9 cm 2.0 cm 2.4 cm 3.4 cm 1.2 cm 
3 3.6 cm 2.2 cm 2.1 cm 2.2 cm 3.6 cm 1.1 cm 
Average 3.6 cm 2.0 cm 2.0 cm 2.27 cm 3.5 cm 1.17 cm 
 
    B 
S. equi 
strain 
 
Antibiotic concentration (µg) / Zone of Inhibition (cm)  
Mutant 
(ΔPrtM) 
Triplicate 
Assays 
PenicillinG 
(6 µg) 
Streptomycin 
(500 µg) 
Vancomycin 
(30 µg) 
Gentamycin 
(500 µg) 
Ampicillin 
(10 µg) 
Norfloxacin 
(5 µg) 
1 4.4 cm 3.2 cm 2.6 cm 3.4 cm 3.8 cm 1.8 cm 
2 4.4 cm 3.0 cm 2.6 cm 3.2 cm 3.6 cm 2.0 cm 
3 4.2 cm 2.6 cm 2.4 cm 3.0 cm 3.9 cm 1.8 cm 
Average 4.33 cm 2.93 cm 2.53 cm 3.2 cm 3.77 cm 1.87 cm 
 
Table 3.2: Antibiotic Sensitivity Pattern of S. equi 4047 WT (A) and ΔPrtM (B) 
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Figure 3.5 Comparison antibiotic sensitivity and resistance levels of the WT and 
ΔPrtM strains of S. equi 4047 – showing error bars with standard error. For all the 
antibiotics tested, areas of growth inhibition were significantly smaller (according to 
student T-test in appendix G) for the WT compared to the mutant. Mean values (on X- 
axis in cm) are shown. 
 
. 
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3.7 Result of Hyaluronic Acid Capsule staining 
 
An assessment of the hyalyronic acid capsule of S. equi 4047 WT and ΔPrtM was 
carried out by staining inoculums of each strain and analysing their colonial 
morphology as decribed in sections 2.4.11, 2.4.12, 2.4.13 and 2.4.14. The results are 
shown in Figure 3.6 below. 
 
A      B 
   
 
C      D 
   
 
E      F 
   
 
Figure 3.6: Images of capsular stained cells. The production of hyaluronic acid 
capsule by both strains is shown here by the results of capsular staining of S. equi 
isolates. A (S. equi 4047 WT) and B (S. equi ΔPrtM) = (safranin staining; method 
insection 2.4.12); C (S. equi 4047 WT) and D (S. equi 4047 ΔPrtM) = (Alcian blue 
staining; method in section 2.4.13); E (S. equi 4047 WT) and F (S. equi ΔPrtM) = 
(Crystal violet staining; method in section 2.4.14).     
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3.8 Hyaluronic acid capsules detected by Density Bouyancy Centrifugation 
 
As a further confirmatory test for the presence of hyaluronic acid capsule in the mutant (S. equi 
ΔPrtM), density buoyancy centrifugation method (described in section 2.4.10) was used 
to evaluate both the wild type (S. equi  WT) and mutant (S. equi ΔPrtM). The results of 
the assay are shown in Table 3.3. 
 
 
S. equi 4047 
strain 
Hyaluronidase  Concentration 
of Percoll 
Cells at Top 
interface 
Cells at Lower 
interface 
WT -  50% + - 
WT + 50% ± + 
WT - 65% + - 
WT + 65% ± + 
ΔPrtM - 50% + - 
ΔPrtM + 50% ± + 
ΔPrtM - 65% + - 
ΔPrtM + 65% ± - 
 
Table 3.3: Density buoyancy of S. equi 4047 WT and ΔPrtM. Hyaluronidase – 
(minus) means no hyaluronidase in culture media; hyaluronidase + (plus) means 
hyaluronidase was added to culture media. ± (plus/minus) means thin layer of a few 
cells at the interface. Method is described in section 2.4.10. 
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3.9 Concentrations of Hyaluronic Acid Produced by S. equi 4047 WT and ΔPrtM 
 
The hyaluronic acid concentration per mL of culture was calculated as described in 
section 2.4.15. The results of triplicate assays are shown in Figure H1 (appendix H), 
while Figures 3.7 summarises the result in bar chart format. 
 
 
 
Figure 3.7: Hyaluronic acid production in S. equi 4047 WT and ΔPrtM. The WT 
strain produced 5 µg/mL and the mutant strain (ΔPrtM) produced 3 µg/mL hyaluronic 
acid in THB culture at an OD600nm of 0.4.  
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3.10 Analysis of Cell Free Extract (CFE) 
 
With knowledge of the growth pattern and general characteristics of the WT and mutant 
strains in hand (sections 3.1 to 3.9), and before Western blotting (method in section 
2.5.20 and results in section 3.11), Coomassie blue R-250 (Table 2.6) was used to stain 
cell associated and secreted protein cell free extracts (method in section 2.5.21) on gel 
ran by SDS-PAGE (method in section 2.5.19). This enabled viewing and confirming the 
presence of extracted protein bands in gel before further assays were carried out. The 
result is shown in Figure 3.9, with protein bands in all four lanes (b, c, d and e). 
 
 
 
 
 
Figure 3.8: Protein Staining with Coomasie R-250. The presence of bands confirm 
the presence of protein in cell and secreted protein extracts (a) Protein Size Standard 
(appendix C8), (b): S. equi 4047 WT, (c) S. equi 4047 ΔPrtM,  (d) S. equi 4047 WT,  (e) 
S. equi 4047 ΔPrtM. 
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3.11  Results of Western Blots 
 
Before cell associated (section 2.5.23) or secreted protein extracts (section 2.5.24) were 
used for 2D-E, Western blotting (method in section 2.5.20) was used to: double check 
and confirm the identities of both strains (S. equi 4047 WT and ΔPrtM); prove the 
presence of lipoproteins of S. equi origin, as well as evaluate immunogenicity of both 
strains.  
 
Before proceeding to other steps of Western blotting, reversible Ponceau S staining 
(section 2.5.20) was carried out and used to analyse blots containing cell associated 
(section 2.5.23) and secreted protein extracts (section 2.5.24) of S. equi 4047 WT and 
ΔPrtM. This revealed and confirmed protein bands (Figure 3.9) from all extracts. 
Having confirmed the presence of protein bands on blots, Western blotting (section 
2.5.20) was done using the following antibodies (Table 2.15): Horse Converlescent 
serum (results in Figure 3.10), αPPMA (result in Figure 3.11), αLppC (result in Figure 
3.12), αHPr (result in Figure 3.13), as well as pre and post infection antisera from 
Ponies (results in Figure 3.14 and 3.15), 
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Figure 3.9:  Reversible Staining with Ponceau S solution. The presence of protein 
bands on blots is confirmed here by the bands seen after reversible staining. (a) Protein 
Size Standard (Appendix C8), (b): Cell Associated Protein Extract of S. equi 4047 WT, 
(c) Cell Associated Protein Extract of  S. equi 4047 ΔPrtM,  (d) Secreted Protein Extract 
of S. equi 4047 WT,  (e) Secreted Protein Extract of S. equi 4047 ΔPrtM 
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Figure 3.10: Western blot, Reactions of Cell-Associated and Secreted Protein 
Extracts from S. equi 4047 WT and S. equi 4047 ΔPrtM with Horse convalescent 
serum: (a) Protein Size Standard (appendix C8), (b): Cell Associated Protein Extract of 
S. equi 4047 WT, (c) Cell Associated Protein Extract of S. equi 4047 ΔPrtM (d) 
Secreted Protein Extract of S. equi 4047 WT, (e) Secreted Protein Extract of S. equi 
4047 ΔPrtM. The Western blot results show that S. equi 4047 WT and ΔPrtM cross 
reacted with horse covalescent serum. 
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Figure 3.11: Reactions of Cell-Associated and Secreted Protein Extracts from S. 
equi 4047 WT  and S. equi 4047 ΔPrtM with αPPMA: (a) Protein Size Standard 
(appendix C8), (b): Cell Associated Protein Extract of S. equi 4047 WT, (c) Cell 
Associated Protein Extract of S. equi 4047 ΔPrtM,  (d) Secreted Protein Extract of  S. 
equi 4047 WT,  (e) Secreted Protein Extract of S. equi 4047 ΔPrtM, The cell associated  
and secreted protein extracts of both S. equi 4047 WT and S. equi 4047 ΔPrtM both 
cross reacted with the αPPMA antisera. 
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Figure 3.12: Reactions of Cell-Associated  and Secreted Protein Extracts from S. 
equi 4047 WT  and S. equi 4047 ΔPrtM with αLPPC antibody: (a) Protein Size 
Standard (appendix C8), (b): Cell Associated Protein Extract of S. equi 4047 WT, (c) 
Cell Associated Protein Extract of S. equi 4047 ΔPrtM, (d) Secreted Protein Extract of  
S. equi 4047 WT,  (e) Secreted Protein Extract of S. equi 4047 ΔPrtM. Cell associated 
protein extracts of the WT and mutant both cross reacted with αLPPC Antibody. 
However, the secreted protein extract of both isolates did not show any cross reaction 
with this antisera. 
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Figure 3.13: Reactions of S. equi 4047 WT and S. equi 4047 ΔPrtM with αHPr 
antibody: A = Cell associated protein extract; B= Secreted protein extract (a) Protein 
Size Standard (appendix C8), (b): S. equi 4047 WT, (c) S. equi 4047 ΔPrtM. The cell 
associated extracts of both S. equi 4047 WT and S. equi 4047 ΔPrtM cross reacted with 
αHPr antibody. However one band is missing from the reaction of secreted protein 
extract (B) of the mutant. 
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Figure 3.14: Reactions of Cell-Associated  and Secreted Protein Extracts from S. 
equi 4047 WT and S. equi 4047 ΔPrtM  with Pony 5788 antisera:  A= Pre-Infection 
serum: (a) Protein Size Standard (appendix C8), (b): Cell Associated Protein Extract of 
S. equi 4047 WT, (c) Cell Associated Protein Extract of S. equi 4047 ΔPrtM,  (d) 
Secreted Protein Extract of S. equi 4047 WT,  (e) Secreted Protein Extract of S. equi 
4047 ΔPrtM. B= Post-Infection serum: (a) Protein Size Standard (appendix C8), (b): 
Cell Associated Protein Extract of S. equi 4047 WT, (c) Cell Associated Protein Extract 
of S. equi 4047 ΔPrtM,  (d) Secreted Protein Extract of S. equi 4047 WT,  (e) Secreted 
Protein Extract of S. equi 4047 ΔPrtM. The reactions of both the cell associated and 
secreted protein extracts of both strains with pre and post infection serum from ponies 
confirmed the isolates as bonafide S. equi with lipoprotein activities. 
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Figure 3.15: Reactions of Cell-Associated  and Secreted Protein Extracts from S. 
equi 4047 WT  and S. equi 4047 ΔPrtM Pony 5726 antisera:  A= Pre-Infection 
serum: (a) Protein Size Standard (appendix C8), (b): Cell Associated Protein Extract of 
S. equi 4047 WT, (c) Cell Associated Protein Extract of S. equi 4047 ΔPrtM,  (d) 
Secreted Protein Extract of S. equi 4047 WT,  (e) Secreted Protein Extract of S. equi 
4047 ΔPrtM. B = Post-Infection serum: (a) Protein Size Standard (appendix C8), (b): 
Cell Associated Protein Extract of S. equi 4047 WT, (c) Cell Associated Protein Extract 
of S. equi 4047 ΔPrtM,  (d) Secreted Protein Extract of S. equi 4047 WT,  (e) Secreted 
Protein Extract of S. equi 4047 ΔPrtM.  
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3.12 2D-E Gel images of S. equi 4047 WT and ΔPrtM Cell Associated and 
Secreted Protein extracts 
 
After confirming by Western blotting that the protein extracts were of bonafide S. equi 
origin, 2D-E (method in section 2.5.26) was carried out with the intension of detecting 
differences in the proteome of S. equi 4047 WT and ΔPrtM. Initially, Immobiline Dry 
Strips at pH 3-10 were used for pilot study. The 2D-E gel images (Figures 3.16) of both 
the cell associated (obtained as described in sections 2.5.22 and 2.5.25) and secreted 
(obtained as described in sections 2.5.24 and 2.5.25) protein extracts of both strains 
revealed that most of the proteins are localized between pH 4-7. Hence the rest of the 
2D-E was carried out in the pH 4-7 range (Figure 3.17). 
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Figure 3.16: Representative 2D-E images of Protein Extract of S. equi 4047 WT 
and ΔPrtM at pH 3-10.  A= Cell Associated Protein Extract of S. equi 4047 WT. B = 
Cell Associated Protein Extract of  S. equi 4047 ΔPrtM. C = Secreted Protein Extract of 
S. equi 4047 WT. D =  Secreted Protein Extract of S. equi 4047 ΔPrtM. 
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Figure 3.17: Representative 2D-E images of Protein Extract of S. equi 4047 WT  
and S. equi 4047 ΔPrtM at pH 4-7:  A= Cell Associated Protein Extract of  S. equi 
4047 WT. B = Cell Associated Protein Extract of  S. equi 4047 ΔPrtM. C = Secreted 
Protein Extract of S. equi 4047 WT. D =  Secreted Protein Extract of S. equi 4047 
ΔPrtM. 
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3.13 Results of Analysis of 2D-E Gels 
 
The spots from all the gels were individually assigned a spot number by the PDQuest 
software. Finally, a master gel image (Figure 3.18, A and B) with spot numbers was 
generated for each matchset according to the manufacturer’s (PDQuest) instructions 
(section 2.5.26.1).  The master image contains all the spots that can be found in all the 
gels in a matchset; and was very useful for correct identification and excision (cutting or 
spot picking) of the spots. 
 
The determination of presence and quantitative changes in protein expression was 
carried out using the PDQuest software (section 2.5.27); after which spots were picked 
and digested (method in section 2.5.29) for further analysis. HPLC/Mass spectrometry 
(method in section 2.5.30) of the digested proteins yielded the identities of proteins, 
after a MASCOT search (section 2.5.31). A list of the identities of all proteins that were 
expressed and identified from S. equi 4047 WT and S. equi 4047 ΔPrtM are shown in 
Appendix D; while Tables 3.4 to 3.12 show the spot numbers with a description of 
levels of expression.  
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Figure 3.18:  Representative master images with spot IDs: A =  S. equi 4047 WT 
Cell Associated Proteins extract. B = S. equi 4047 ΔPrtM Cell Associated Proteins 
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Significant protein spots from cell associated protein extracts of S. equi 4047 WT  and 
S. equi 4047 ΔPrtM are given in Tables 3.4, 3.5, 3.6, 3.7 and 3.8. These include: 
common protein spots with equal levels of expression in both WT and mutant (Table 
3.4), Common protein spots more highly expressed in the WT (Table 3.5), Common 
protein spots more highly expressed in the Mutant (Table 3.6), protein spots present in 
only the WT (Table 3.7) and protein spots present only in mutant (Table 3.8). 
 
 
 
 
 
WT (4047)                          =               Mutant ( PrtM)   
Spot #3101:   
-50S ribosomal protein L21 [Streptococcus pyogenes 
M1 GAS] 
 
 -30S ribosomal protein S11 [Streptococcus 
pyogenes M1 GAS] 
 
 -50S ribosomal protein L14 [Streptococcus 
pyogenes M1 GAS] 
 
- heat-stable phosphocarrier protein, HPr 
[Streptococcus mutans, Ingbritt, Peptide, 86 aa] 
 
- hypothetical protein SAG1694 [Streptococcus 
agalactiae 2603V/R] 
 
 - general stress protein [Streptococcus equi subsp. 
zooepidemicus MGCS10565] 
 
                  Spot # 5101 
 
 
Table 3.4:Common Spots with equal levels of expression in cell associated protein 
extract: expression in WT  = expression in mutant. 
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WT (4047)                            > Mutant ( PrtM)   
Spot #7302:   
-apolipoprotein A-I precursor 
 
 -RecName: Full=Apolipoprotein A-I; Short=Apo-
AI; Short=ApoA-I; Flags: Precursor 
Spot #8302:  
- apolipoprotein A-I precursor 
Spot #4001:  
 -30S ribosomal protein S6 [Streptococcus equi 
subsp. zooepidemicus] 
 
 -30S ribosomal protein S6 [Streptococcus equi 
subsp. zooepidemicus MGCS10565] 
 
 -hypothetical protein STRINF_01108 
 
 [Streptococcus infantarius subsp. infantarius 
ATCC BAA-102] 
Spot #6002:  
 -30S ribosomal protein S6 [Streptococcus equi 
subsp. zooepidemicus] 
 
 -30S ribosomal protein S6 [Streptococcus equi 
subsp. zooepidemicus MGCS10565] 
 
 -hypothetical protein STRINF_01108 
 
 [Streptococcus infantarius subsp. infantarius 
ATCC BAA-102] 
4204:  
- hypothetical protein SEQ_1025 [Streptococcus 
equi subsp. equi 4047] 
6202:  
- hypothetical protein Sez_0895 [Streptococcus 
equi subsp. zooepidemicus MGCS10565] 
Table 3.5: Common Spots with differential level of expression in cell associated 
protein extract: expression in WT greater than expression in Mutant ( PrtM).  
 
 
 
WT (4047)                             < Mutant ( PrtM)   
Spot #5303:  
- thioredoxin peroxidase [Bacillus sp. NRRL B-
14911] 
Spot #6302:  
- YkuQ [Bacillus sp. NRRL B-14911] 
Table 3.6: Common Spots with differential level of expression in cell associated 
protein extract: S. equi 4047 WT  expression less than S. equi 4047 Mutant ( PrtM)  
expression. 
 
 
 
Spot ID# Proteins 
3201 Xaa-His dipeptidase [Streptococcus equi subsp. zooepidemicus] 
 RecName: Full=NADP-dependent alcohol dehydrogenase 
 Alcohol dehydrogenase zinc-binding domain protein [Thermoanaerobacter italicus 
Ab9] 
 dipeptidase PepV [Streptococcus pyogenes M1 GAS] 
2201  cyclophilin type peptidyl-prolyl cis-trans isomerase protein [Streptococcus equi subsp. 
equi 4047] 
  
 co-chaperonin GroES [Streptococcus equi subsp. zooepidemicus MGCS10565] 
  
5302 purine nucleoside phosphorylase [Streptococcus equi subsp. zooepidemicus 
MGCS10565 
6201 dTDP-4-Keto-6-Deoxyglucose-3 5-epimerase R mLC [Streptococcus equi subsp. 
zooepidemicus MGCS10565] 
6001 hypothetical protein CaO19.10414 [Candida albicans SC5314] 
3601 mannose-6-phosphate isomerase Pmi [Streptococcus equi subsp. zooepidemicus 
MGCS10565] 
6501 6-phosphofructokinase [Streptococcus equi subsp. zooepidemicus MGCS10565] 
5504 alcohol dehydrogenase [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 alcohol dehydrogenase [Streptococcus equi subsp. zooepidemicus] 
Table 3.7: Spots present on only S. equi 4047 WT in cell associated protein extract. 
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Spot ID# Proteins 
0001 sugar phosphotransferase component II B [Streptococcus equi subsp. zooepidemicus 
MGCS10565] 
 
9001 transcriptional regulator [Bacillus sp. NRRL B-14911] 
 
8202 hypothetical protein GK3020 [Geobacillus kaustophilus HTA426] 
 
8201 thioredoxin peroxidase [Bacillus sp. NRRL B-14911] 
 
3203 transcription elongation factor GreA [Streptococcus equi subsp. zooepidemicus 
MGCS10565] 
 
9401 ribosome recycling factor [Streptococcus pyogenes M1 GAS] 
 
Table 3.8: Spots present on only S. equi 4047 Mutant ( PrtM in cell associated 
protein extract. NH means no hit; NRH means no relevant hit. 
 
 
Significant protein spots from secreted protein extracts of S. equi 4047 WT  and S. equi 
4047 ΔPrtM are given in Tables 3.9, 3.10, 3.11, and 3.12. These include: common 
protein spots with equal levels of expression in both WT and mutant (Table 3.9), 
Common protein spots more highly expressed in the WT (Table 3.10), protein spots 
present in only the WT (Table 3.11) and protein spots present only in mutant (Table 
3.12). 
 
 
 
WT                                                           = Mutant ( PrtM)   
Spot #9101:  NH 
 
Spot #7202: NH 
Spot #0201:  
-esterase [Streptococcus equi subsp. zooepidemicus 
MGCS10565] 
 
 -lipoprotein [Streptococcus equi subsp. 
zooepidemicus] 
 
 -lipoprotein [Streptococcus equi subsp. equi 4047] 
 
Spot #0401:  
-esterase [Streptococcus equi subsp. 
zooepidemicus MGCS10565] 
 
 -RecName: Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase 
Spot #7402:  
-RecName: Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase 
 
 -fibronectin-binding protein [Streptococcus equi] 
Spot #6503 
-RecName: Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase 
Table 3.9: Common Spots with equal level of expression in secreted protein 
extract: expression in WT = expression in Mutant. Note: NH means no hit;  NRH 
means no relevant hit. 
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WT                                                          > Mutant ( prtM138-213)   
Spot #5001:  
-unnamed protein product [Manduca sexta 
Spot #5103:  
-IgM heavy chain constant region, secretory form [Bos 
taurus] 
Spot #8102: NRH Spot #7201: NRH 
Spot #9403: 
- exported protein [Streptococcus equi subsp. equi 
4047] 
Spot #7502:  
-esterase [Streptococcus equi subsp. zooepidemicus 
MGCS10565] 
Table 3.10: Common Spots with differential level of expression in secreted protein extract: 
Expression in WT greater than expression in Mutant. NH means no hit; NRH means no relevant 
hit. 
 
 
Spot ID # Proteins 
0005 -RecName: Full=NADP-dependent alcohol dehydrogenase 
- hypothetical protein AN7590.2 [Aspergillus nidulans FGSC A4] 
- unnamed protein product [Escherichia coli str. K-12 substr. MG1655] 
- L-xylulose reductase [Neurospora crassa OR74A] 
 -Alcohol dehydrogenase zinc-binding domain protein [Thermoanaerobacter italicus 
Ab9] 
1101 -unnamed protein product [Escherichia coli str. K-12 substr. MG1655] 
8403 -ALB protein [Bos taurus] 
 -serum albumin [Bos indicus] 
- albumin [Felis catus] 
2201  -hypothetical protein Sez_0895 [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 -RecName: Full=Hyaluronoglucosaminidase; Short=Hyaluronidase 
8501  -Mac family protein [Streptococcus equi subsp. equi 4047] 
 -hypothetical protein CaO19.10414 [Candida albicans SC5314] 
 -RecName: Full=NADP-dependent alcohol dehydrogenase 
7301 -DNA/RNA non-specific endonuclease [Streptococcus equi subsp. zooepidemicus] 
 -fibronectin-binding protein [Streptococcus equi] 
 -serine proteinase inhibitor, clade A, member 1 precursor [Bos taurus] 
9202 -fibronectin-binding protein [Streptococcus equi] 
- DNA/RNA non-specific endonuclease [Streptococcus equi subsp. zooepidemicus] 
 -hypothetical protein TTHERM_00225940 [Tetrahymena thermophila] 
- RecName: Full=Hyaluronoglucosaminidase; Short=Hyaluronidase 
2202 -hypothetical protein Sez_0895 [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 -RecName: Full=Hyaluronoglucosaminidase; Short=Hyaluronidase 
-fibronectin-binding protein [Streptococcus equi] 
- hyaluronoglucosaminidase [Streptococcus pyogenes MGAS10394] 
1401 -lipoprotein [Streptococcus equi subsp. zooepidemicus] 
- lipoprotein [Streptococcus equi subsp. equi 4047] 
 -hyaluronidase, phage associated [Streptococcus phage 370.1] 
 -hyaluronoglucosaminidase [Streptococcus pyogenes MGAS10394] 
- hypothetical protein SPy_1154 [Streptococcus pyogenes M1 GAS] 
2401 -extracellular protein [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 
1402 -extracellular protein [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 -hyaluronidase, phage associated [Streptococcus phage 370.1] 
 -hyaluronoglucosaminidase [Streptococcus pyogenes MGAS10394] 
 -unnamed protein product [Escherichia coli str. K-12 substr. MG1655] 
- RecName: Full=NADP-dependent alcohol dehydrogenase 
 -Alcohol dehydrogenase zinc-binding domain protein [Thermoanaerobacter italicus 
Ab9] 
8401 -Mac family protein [Streptococcus equi subsp. equi 4047 
 
2101 -hypothetical protein Sez_1583 [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 -RecName: Full=Hyaluronoglucosaminidase; Short=Hyaluronidase 
1002  -co-chaperonin GroES [Streptococcus equi subsp. zooepidemicus MGCS10565]] 
 -hylauronidase [Streptococcus phage P9 
Table 3.11: Spots present in secreted protein extract of only the WT  
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Spot ID # Protein 
1201 -RecName: Full=NADP-dependent alcohol dehydrogenase 
 -YALI0B08052p [Yarrowia lipolytica] 
 -hypothetical protein CaO19.10414 [Candida albicans SC5314] 
- Alcohol dehydrogenase zinc-binding domain protein [Thermoanaerobacter italicus Ab9] 
- hypothetical protein AN7590.2 [Aspergillus nidulans FGSC A4] 
- unnamed protein product [Escherichia coli str. K-12 substr. MG1655] 
 
1103 -hypothetical protein Sez_1583 [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 -hyaluronidase, phage associated [Streptococcus phage 370.1] 
 -hyaluronoglucosaminidase [Streptococcus pyogenes MGAS10394] 
 
0101 -cold-shock protein, molecular chaperone, RNA-helicase co-factor [Bacillus subtilis subsp. 
subtilis str. 168 
 
0301 -A family sortase SrtA [Streptococcus equi subsp. zooepidemicus MGCS10565] 
 -sortase SrtA [Streptococcus equi subsp. zooepidemicus] 
- RecName: Full=Hyaluronoglucosaminidase; Short=Hyaluronidase 
-  
0304 -cold shock protein [Bacillus sp. NRRL B-14911 
 
1202 -oligopeptide ABC transporter periplasmic oligopeptide-binding protein OppA 
[Streptococcus equi subsp. zooepidemicus -MGCS10565] 
 -YALI0B08052p [Yarrowia lipolytica] 
 -RecName: Full=NADP-dependent alcohol dehydrogenase 
 -Alcohol dehydrogenase zinc-binding domain protein [Thermoanaerobacter italicus Ab9] 
- hypothetical protein AN8113.2 [Aspergillus nidulans FGSC A4] 
-  
2101 -30S ribosomal protein S6 [Streptococcus uberis 0140J] 
 -cold shock protein [Bacillus sp. NRRL B-14911] 
 -30S ribosomal protein S6 [Streptococcus equi subsp. zooepidemicus MGCS10565 
 
2301 -oligopeptide ABC transporter periplasmic oligopeptide-binding protein OppA 
[Streptococcus equi subsp. zooepidemicus MGCS10565 
 
5301 -thioredoxin peroxidase [Bacillus sp. NRRL B-14911 
 
4201 -50S ribosomal protein L10 [Staphylococcus epidermidis ATCC 12228 
 
Table 3.12: Spots present in secreted protein extract of only the Mutant. 
 
 
 
 
3.14            Discussion 
  
 
The results of statistical analysis (student T-test showing no significant difference p 
<0.05 - in Appendix F) of growth curves (Figure 3.3) of S. equi 4047 WT and ΔPrtM 
are in accordance with previous work of Hamilton et al. (2006) who stated that the 
growth of the S. equi 4047 ΔPrtM in nutrient-rich broth was comparable to that of wild-
type (S. equi 4047 WT). Not finding any significant difference between the growth rate 
of S. equi 4047 WT and ΔPrtM suggests that the deletion of the prtM gene from the 
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mutant, and consequently its (ΔPrtM) lack of PPIase activity (the PPIase activity of 
PrtM of S. equi was proven using recombinat PrtM from S. equi in a protease-coupled 
PPIase assay, results shown in chapter 6 of this study) does not affect growth under the 
conditions applied. 
 
The Gram stain reaction and Lancefield grouping confirm the identities of both S. equi 
4047 WT and Mutant (ΔPrtM) as being Gram-positive, Lancefield group C 
Streptococci. 
 
The result of agarose gel electrophoresis of the genomic DNA (Figure3.2-A) indicate 
that the genomic DNA extraction protocol (section 2.5.2) was successful. The 
amplification result (Figure 3.2-B) shows that S. equi 4047 WT is has a higher 
molecular weight than mutant (ΔPrtM). Therefore, the wild type strain used in this study 
carries the PrtM gene (sequence138-213), while the mutant (ΔPrtM) clearly lacks part 
of the PrtM gene (sequence 138 -213) which is in agreement with the report of 
Hamilton et al. (2006). This PCR result also indicates that the growth conditions used in 
this experiment favour maturase expression.  
 
Bacteria can survive under a wide range of environmental conditions, including osmotic 
variation (Visick and Clarke, 1995); however NaCl can cause damage to the folding of 
cell surface proteins (Ignatova and Gierasch, 2007). S. equi 4047 WT and ΔPrtM were 
subjected to growth in varying concentration of NaCl (results in Section 3.5: Table 3.1 
and Figures 3.4). Both strains were able to survive better in 0.9% (w/v) NaCl (Figure 
3.4) which is not surprising considering that this is the concentration of physiological 
saline which may have served to balance osmotic pressure for the bacterial cells. 
Considering both strains together, a 58% survival rate in 0.9% (w/v) NaCl was followed 
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by a 39% survival in water (Figure 3.4). Only 2% of the organism survived in 14.7% 
(w/v) NaCl (Figure 3.4) and out of this Figure, 100% were the wild type strain (Figure 
3.4). The wild-type strain made up 100% of the 1% (Figure 3.4) of surviving cells in 
29.4% (w/v) NaCl. These data suggest that S. equi 4047 is able to adapt to varying and 
high salt concentrations. However, compared to the mutant (ΔPrtM) which was only 
able to survive in H20 and 0.9% (w/v) NaCl, the higher percentage of S. equi 4047 WT 
surviving in all conditions and at all the concentrations tested, indicate that the absence 
of the prtM gene in the mutant (ΔPrtM) greatly affects its ability to adapt to high NaCl 
concentrations. PPIases have been proven to be important for resistance to NaCl (Li et 
al., 2005; Reffuveille et al., 2012b). Having proven in this study (chapter 6) that PrtM 
recombinant protein of S. equi has PPIase activity, it can therefore be inferred that 
PPIase activity of S. equi maturase lipoprotein (PrtM) is involved in the bacterial 
adaptation to NaCl stress. 
 
 
Triplicate repeats of antibiotics sensitivity tests (results in Table 3.2 and Figure 3.5) 
show that areas of growth inhibition were significantly smaller (student T-test in 
Appendix G) for the WT compared to the mutant (ΔPrtM). PPIases activity has been 
associated with cell wall synthesis and remodeling proteins.  The role of the PPIase, 
PrsA, in B. subtilis viability has been associated with gross cell wall structural defects 
due to a loss of Penicillin Binding Protein (PBP) stability and/or activity upon PrsA 
depletion (Hyyrylainen et al., 2010). In L. monocytogenes, the association of PBP 
activity with PrsA2 PPIase activity was established when a prsA2 N+C construct 
(mutant lacking the entire central PPIase domain) was unable to complement increased 
bacterial sensitivity to Penicillin G exhibited by ΔprsA2 mutants (Alonzo et al., 2012). 
Compared to the wild type, the increased sensitivity of the mutant (ΔPrtM) to Penicillin 
G (Table 3.2 and Figure 3.5) indicates that just like B. subtilis PrsA and L. 
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monocytogenes PrsA2, in S. equi 4047 the PrtM PPIase activity is required, by the 
bacteria, for optimal resistance to β-lactam antibiotics. The fact that ΔPrtM exhibited 
higher sensitivity to all the antibiotics tested (Table 3.2 and Figure 3.5) is also indicative 
that S. equi PrtM PPIase activity is associated with cell wall synthesis and protein 
remodelling. 
 
The production of mucoid colonies on THA and also on blood agar (Figure 3.1) by both 
strains, as well as the results of capsular staining (Figure 3.6), indicate that hyaluronic 
acid is produced by both S. equi 4047 WT and ΔPrtM.  The hyaluronic acid synthase 
gene is located in the has operon which codes for the enzymes involved in the 
production of hyaluronic acid precursors (Blank et al., 2008). In S. equi, the hyaluronic 
acid synthase genes are located in the hasA/hasB/hasC and hasC/glmU/pgi operons 
(Blank et al., 2008). 
 
Having ascertained from staining (results in Figure 3.6) that both strains produce 
hyaluronic acid, it was puzzling that it was impossible to concentrate all the cells of the 
wild-type suspended in 0.5 M sucrose, centrifuged at 4000 x g at 4
o
C for up to 30 min, 
whereas the mutant cells were pelleted after 15 min centrifugation under the same 
conditions. The rapid density buoyancy centrifugation assay (result in section 3.8, Table 
3.3), which followed the capsular staining, also confirmed the fact that both strains 
produce hyaluronic acid. It is possible then that the wild type produces more hyaluronic 
acid than the mutant, hence the difficulty in completely pelleting the wild-type cells. 
The next option was therefore to find out how much hyaluronic acid was produced in 
broth culture, by each strain. DeAngelis and Weigel (1994) reported that a strain 
(NSA156) of Streptococcus pyogenes produced 7 µg/ mL of hyaluronic acid and floated 
in 65% (v/v) Percoll. In this study, S. equi 4047 WT produced 5 µg/ mL and S. equi 
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4047 ΔPrtM produced 3 µg/ mL of hyaluronic acid in THB, at cell density OD600nm at 
0.4 (result in section 3.9, Figure 3.7); and both strains floated in 65% and 50% Percoll 
(Section 3.8, Table 3.3). The ratio of hyaluronic acid produced per mL of culture 
(Figure 3.7) is approximately 3:2 (60:40%) for the WT and ΔPrtM respectively. Is it 
possible then that PPIase activity of the PrtM of S. equi 4047 (as reported in chapter 6 
of this study) is involved in speeding up the folding or remodeling of one or more of the 
enzymes involved in hyaluronic acid synthesis, hence S. equi 4047 WT produces more 
hyaluronic acid than the PrtM-deficient mutant strain? Such involvement is an area for 
future study. 
 
Reversible Ponceau S staining of blots after transfer (method in sections 2.5.20 and  
result in Figure 3.9) was carried out in order to confirm the presence of protein bands in 
the cell associated and secreted protein extracts. The Western blot results (Figure 3.10) 
show that S. equi 4047 WT and ΔPrtM cross reacted with horse covalescent serum. 
Both strains also cross reacted with pre and post infection sera of ponies (Figures 3.14 
and 3.15). These reactions are consistent with bonafide S. equi isolates (Hamilton et al., 
2000; Hamilton et al., 2006). The results were therefore valuable determining 
immunogenicity as well as in authenticating the identities of S. equi 4047 WT and 
ΔPrtM strains used for this research. In addition to this, the Western blot results were 
valuable for confirming the most favourable growth conditions for protein extraction for 
2D-E. 
 
Proteins which are involved in the pathogenesis of S. pneumoniae infections
 
are viewed 
as interesting components for future
 
conjugate or multicomponent protein vaccines 
(Overweg et al., 2000a). The importance of a putative proteinase maturation protein
 
A 
(PpmA) in pneumococcal
 
pathogenesis was demonstrated in a mouse pneumonia model 
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and PpmA was shown to elicit species-specific opsonophagocytic
 
antibodies which 
cross-reacted with various pneumococcal
 
strains (Overweg et al., 2000a). Since PpmA 
is the S. pneumoniae homologue of the PrtM (Hamilton et al., 2006; and Overweg et al., 
2000a) it was interesting to find out the reaction of antibodies against PpmA with 
extracts from both S. equi 4047 WT and ΔPrtM. PpmA serum recognized a protein band 
with the correct molecular size (35 kDa) in whole-cell lysates of S. pneumoniae 
(Overweg et al., 2000a). PpmA was therefore proven to be located at the surface of S. 
pneumoniae. In this research, the cell associated and secreted protein protein extract of 
both S. equi 4047 WT and ΔPrtM both cross reacted with the αPPMA antisera (Figure 
3.11). The cross reaction of mutant (ΔPrtM) with αPPMA antisera suggests that PrtM is 
a good vaccine candidate. 
 
Cell associated protein extracts of S. equi 4047 WT and ΔPrtM both cross reacted with 
αLPPC antibody (Figure 3.12) at the appropriate molecular weights, corresponding to 
previous studies by Hamilton et al. (2000) and Hamilton et al. (2006) where αLPPC 
antibody activity was detected in S. equi at approximately 31.9 kDA. However, the 
secreted protein extract of both isolates did not show any cross reaction with αLPPC 
antisera (Figure 3.12). This was not surprising because the S. equi LppC homologue 
was shown to be a lipoprotein located on the cell surface (Hamilton et al., 2000). 
 
 
The reactions of both the cell associated and secreted protein extracts of both strains (S. 
equi 4047 WT and ΔPrtM) with pre and post infection serum from ponies (Figures 3.14 
and 3.15) confirmed the isolates as bonafide S. equi with lipoprotein activities. A good 
vaccine candidate should be able to induce antibodies that cross react with the target 
protein in all strains of the pathogen. The cross reaction of mutant (ΔPrtM) with serum 
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from all tested ponies’ serum, as well as with horse covalescent serum (Figure 3.10), 
therefore indicate that PrtM is a good vaccine candidate. 
 
Bacteria are known to transport saccharides across the cell membrane and 
phosphorylate them before their release into the cytosol (Kundig et al., 1964). 
Anaerobic and facultatively anaerobic bacteria have and use the phosphoenolpyruvate 
(PEP) phosphotransferase system (PTS) as their main carbohydrate transport system 
(Romano et al., 1970; Saier, 1989).  The PTS system is made up of enzyme I and a 
histidine-containing phosphocarrier protein (HPr) – as its two main energy-coupling 
components, and of enzymes II which are sugar-specific permeases (Herzberg et al., 
1992). HPr is a central part of the phosphoenolpyruvate sugar phosphate system by 
which Streptococci transport sugar as energy source (Hamilton, 1987, and Thompson, 
1987 in Dubreuil et al., 1996). HPr has been identified in S. equi (Sutcliffe et al., 2000; 
and Dixon et al, 2001), with HPr-1 (in which its N-terminal methionine been removed) 
being predominant (Sutcliffe et al., 2000). This is a modification (as in HPr-1) that was 
previously associated with surface localization of streptococcal HPr proteins (Hamilton, 
1987, and Thompson, 1987 in Dubreuil et al., 1996).  It is speculated by Dixon et al., 
(2001) that surface-localised and probably released HPr-1 of S. equi may have roles to 
play in its (HPr-1) mitogenic activity which had previously been demonstrated in S. 
pyogenes by Gerlach et al., (1992). Therefore, the reactions (Figures 3.13 A) of cell 
associated protein extracts of both S. equi 4047 WT and ΔPrtM with αHPr antibody is 
in accordance with previous studies. The post 2D-E/HPLC/MS finding of equal levels 
of expression of HPr (Table 3.4) in the cell associated protein extract of S. equi 4047 
WT and ΔPrtM is therefore not surprising. 
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HPr of Gram-positive bacteria can be phosphorylated and dephosphorylated at the 
serine 46 residue by an ATP-dependent HPr kinase, to give HPr-P or HPr-(Ser-P) 
respectively (Asanuma and Hino, 2002). These two forms or HPr have been reported to 
give two distinct bands (HPr-P being in the upper band) on Western blots (Asanuma 
and Hino, 2002). In B. subtilis, HPr kinase activity is seen under conditions of good 
nutrient supply which are indicated by high ATP and fructose-1,6-bisphosphate 
concentrations; unlike phosphorylase activity which is triggered by high concentrations 
of inorganic phosphate, indicating the absence of good carbon sources (Halbedel et al., 
2004). In S. mutans, serine-phosphorylated HPr functions in concert with particular PTS 
permeases thereby prioritizing carbohydrate utilization through modulation of sugar 
transport activity and the transcription of catabolic operons (Zeng and Burne, 2010). 
The reaction of the secreted protein extract of only the WT but not the mutant (ΔPrtM) 
with anti-HPr (Figure 3.13-B), is suggestive that S. equi PrtM PPIase activity (Chapter 
6)  may be involved in the folding or remodeling of HPr kinase. This absence of the 
upper band (Figure 3.13-B) in the secreted protein extract of the PrtM deficient mutant 
also indicates that released HPr-1 of S. equi may have critical roles to play in HPr-1 
mitogenic activity. 
 
Proteomics approaches (methods of Zhang et al. 2007) were used to identify the cell 
associated and secreted proteins of importance in S. equi 4047 WT and ΔPrtM (methods 
in section 2.5). It was predicted that the inability of the mutant (ΔPrtM) to correctly fold 
the maturase substrates leads to differences in proteolytic processing of the substrate 
proteins and ultimately to differences in their migration on 2D-E gels using SDS-
PAGE.  
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An evaluation of the HPLC/MS (methods in section 2.5.30 and 2.5.31)  results of the 
post-2D-E gel trypsinized proteins spots of the cell associated protein extract (Table 
3.5) indicate that SEQ_1025 (a hypothetical protein of S. equi with protein code  
gi|225870399) is common in both S. equi WT 4047 and Mutant ( prtM138-213), is a best 
match hit; however it (the hypothetical protein) is upregulated (more highly expressed) 
in the S. equi 4047 WT. Another protein of interest identified (Table 3.5) was 
SEZ_0895 (hypothetical protein of Streptococcus equi subsp. zooepidemicus 
MGCS10565, code gi|195978022) and is also upregulated (more highly expressed) in 
the S. equi 4047 WT. 
 
It is very interesting to note that from the secreted protein extract, multiple spots 
apparently contain the same proteins. For example both spot numbers WT9202 and 
WT7301 (Table 3.11) contain fibronectin binding protein (FNE) and SEQ0882 
endonuclease. 
 
IdeE (an IgG-endopeptidase and homologue of the leucocyte receptor Mac-1) was 
identified from a screen of clones reactive with convalescent serum from a gene library 
of S. equi CF32 (Timoney et al., 2007). Antiphagocytic activity for equine neutrophils 
was proven to be neutralized by IdeE-specific antiserum (Timoney et al., 2007). IdeE2 
(Mac family protein) is also an endopeptidase but has greater activity towards horse IgG 
(Guss et al., 2009). Interestingly, a MAC family protein (Table 3.11, spot number 8501) 
was identified in the secreted protein extract of only the WT (S. equi 4047 WT) but not 
in the mutant (S. equi 4047 ΔPrtM). 
 
The rotamase lipoprotein SlrA (streptococcal rotamase A a member of  the cyclophilin 
family) and PpmA (proteinase maturation protein A which shares homologies to 
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PPIases of the parvulin family) have been identified in Streptococcus pneumoniae and 
are both involved in the colonization phase of infection and in the evasion of 
phagocytes (Reffuveille, 2012b). In this study, a PPIase of the cyclophilin type (Table 
3.7, spot 2201) was identified in the cell associated protein extract of only the WT (S. 
equi 4047 WT) but not in the mutant (S. equi 4047 ΔPrtM). This suggests the absence 
of this particular surface located PPIase in the mutant (S. equi 4047 ΔPrtM).  
 
Streptococcal fibronectin (Fn)-binding cell surface proteins are assumed to enhance the 
potential
 
of the bacteria to cause disease (Lindmark et al., 2001). Finding FNE and 
IdeE2, in the secreted protein extract of only S. equi 4047 WT and not the PrtM 
deficient-mutant (ΔPrtM) therefore suggests proteolytic degradation of misfolded 
secreted proteins; and very importantly as well, indicates that PrtM may not only be 
linked to the folding of one specific substrate but could be a multisubtrate foldase. This 
suggests PrtM involvement in S. equi antibiotics sensitivity reaction (Table 3.2 and 
Figure 3.5), in the adaptability of the organism to NaCl stress (Table 3.1, Figures 3.4 a), 
level of hyaluronic acid production (Figure 3.7), as well as in with HPr kinase folding 
and/or remodelling. All these buttress findings from this study that PrtM is a 
multisubstrate foldase. 
 
The 2D-E results establish that the protein profile of S. equi 4047 WT has significant 
differences from that of the mutant (ΔPrtM). These results therefore confirm that, the 
absence of the maturase lipoprotein PrtM (as seen in ΔPrtM), results in readily 
detectable changes in S. equi proteome.  
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4.0 Bioinformatics 
 
4.1 S equi 4047 PrtM sequence and encoded protein sequence  
The sequence (and encoded protein sequence) of the S. equi 4047 PrtM gene (Figures 
4.1 and 4.2, respectively) were obtained as described in section 2.3.1.  
 
ATAGGTGGAATGGTTGTTTTAGATGATGTGTTTCAGGGGGGTGACATTGCTAAGCCGATCAAGGAGGTTC 
GGAGAGGACAGCGCACGATTTATCGTGGCCTTCAGGACTTATTTGCAGCAACTCTTGATAATCCTGGATT 
GACAGCCAGCCTGCTGCCGCTTAGTGATGGCTTGCTGATGATTCGTAAAAATCAAGCAGATATTCGTTTG 
TTAGATTAAGTTACGTTTAAGAAATTGTGATATAATATACTGGTTAATGACAAAAAGGAGCACAAAATCA 
CATGAAAAAATCAACTAAATTACTTGCTGGTATCGTAACCCTAGCATCAGCAATGACCCTAGCAGCCTGT 
CAGTCTACAAATGACAATACAAGTGTCATTACGATGAAGGGCGACACTATCAGTGTTAGTGATTTTTACA 
ATGAAACAAAAAATACAGAGATTTCTCAAAGAGCAATGCTAAACCTTGTGGTTAGTCGTGTTTTTGAGGA 
CCAATACGGTAAAAAGGTTTCTAAGAAAAGAACGGAAGAAGCTTACAATAAATCAGCTGAGCAATACGGT 
GCGTCATTCTCTGCAGCCCTTGCGCAGTCTGGCTTGACAACAGATACCTACAAGCGTCAAATTCGCTCAG 
CCATGCTGGTTGAATATGCTGTTAAAGAAGCAGCTAAAAAAGAGCTGACAGATGCTGATTACAAAAAAGC 
CTATGAGTCATACACACCAGAAATGACTACTCAGGTCACTACTCTAGACAATGAAGAAACAGCAAAGGCT 
GTTTTAGGTGAGGTTAAGGCTGAGGGTGCTGACTTTGCTGCTATTGCTAAGGAAAAGACAACAGCAGCAG 
ACAAGAAGGTAGACTATAAGTTTGACTCAGGAGACACTAAGTTACCAGCAGATGTGATCAAGGCCGCCTC 
AGGATTAAAAGAGGGTGATATTTCAGAGGTGGTTTCTGTCTTAGATCCGGCTACTTATCAAAACAAGTTC 
TATATTGTTAAGGTAACCAAAAAAGCCGAAAAGGCTTCTGATTGGAAGAAATATAAGAAACGTCTAAAAG 
AAATTGTCTTGGCTGAAAAGACACAAAACATTGATTTCCAAAATAAGGTCATTGCAAAGGCCTTAGACAA 
GGCAAATGTTAAGATCAAAGACCAAGCATTTGCTAATATCTTGGCACAGTATGCCAATACTGATAAAAAA 
GCAAGCAAGGCGAACACAAGCAAGTCAGATCAGAAATCATCTTCAGACTCAAGCAAGGATAGTCAATCTT 
CTAAATCTAAGTCAGAAAAATAG 
 
Figure 4.1: The S. equi 4047 PrtM-encoding 1283 nucleotide (nt) sequence: 
(>gi|225698891:676500-677782). The 281 nt upstream sequence contains promoter 
sequences (in red), a ribosome binding site (in blue) and a start codon (underlined). For 
details of primer sequences, refer to Table 2.11 in Chapter 2: Binding site of 
Prtm123equir highlighted yellow, binding site of Prtm12equir and Prtmidcolir 
highlighted lemon green. Binding site of Prtmidcolif highlighted purple. Binding site of 
Prtmequif highlighted grey. Binding site of SEQPrtmr underlined red. Binding site of 
SEQPrtmf underlined green. Central domain sequence underlined yellow. 
 
 
 
MKKSTKLLAGIVTLASAMTLAACQSTNDNTSVITMKGDTISVSDFYNETKNTEISQRAMLNLVV
SRVFEDQYGKKVSKKRTEEAYNKSAEQYGASFSAALAQSGLTTDTYKRQIRSAMLVEYAVKEA
AKKELTDADYKKAYESYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAKEKTTAADKK
VDYKFDSGDTKLPADVIKAASGLKEGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYK
KRLKEIVLAEKTQNIDFQNKVIAKALDKANVKIKDQAFANILAQYANTDKKASKANTSKSDQKS
SSDSSKDSQSSKSKSEK 
 
Figure 4.2: S. equi 4047 PrtM protein sequence with signal peptide (underlined). 
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4.2 S. equi 4047 PrtM signal peptide. 
 
The predicted signal peptide of the S. equi 4047 PrtM domain, shown in Figure 4.3, was 
determined as described in section 2.3.2.  
 
 
 
# Measure  Position  Value    Cutoff   signal peptide? 
  max. C    26       0.160 
  max. Y    26       0.378 
  max. S    17       0.973 
  mean S     1-25    0.901 
       D     1-25    0.582   0.450   YES 
Name=Sequence SP='YES' Cleavage site between pos. 25 and 26:  
ACQ-ST D=0.582 D-cutoff=0.450 Networks=SignalP-TM 
 
Figure 4.3: Predicted Signal peptide of S. equi 4047 PrtM via 
http://www.cbs.dtu.dk/services/SignalP/ 
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4.3 S. equi 4047 PrtM Protein sequences, conserved domain and aligned sequences 
 
The PrsA protein of Bacillus subtilis is an essential membrane-bound lipoprotein, 
proven to be a peptidyl-prolyl cis/trans isomerase (Vitikainen et al., 2004). PrsA protein 
of B. subtilis is assumed to assist post-translocational folding of exported proteins and 
to stabilize them in the compartment between the cytoplasmic membrane and cell wall 
(Vitikainen et al., 2004). PrsA has a stretch of 90 amino acids that are 45% identity to 
E. coli parvulin (Vitikainen et al., 2004); E coli PpiC being of the parvulin family 
(Rahfield et al., 1994; Rudd et al., 1995; Kuhlewein et al., 2004). The PrsA protein of 
B. subtilis shares a high degree of sequence similarity across the entire length of its 
sequence with that of PrsA2 of Listeria monocytogenes (Alonzo et al., 2011). 
 
In order to predict the domain architecture of PrtM of S. equi 4047, its protein sequence 
(Figure 4.2) was matched (method in section 2.3.4) to the sequences of the following 
peptidyl-prolyl cis/trans isomerases (PPIases): PrsA2 of L. monocytogenes, PrsA of B. 
subtillis and PPiC of E. coli. PrtM was shown to align with the aforementioned PPIases 
(alignment results are shown in Figures 4.4, 4.5, 4.6 and 4.7). The sequence of the 
centrally packed conserved region of S. equi 4047 PrtM (Figure 4.8) was translated into 
protein sequence and the first reading frame was selected and used, in conjunction with 
a comparison of several  sequence allignment results (Figures 4.4, 4.5, 4.6 and 4.7), in 
determining the sequence of the central domain (Figure 4.8). The central conserved 
domain is marked by a large number of weakly similar, strongly similar or identical 
amino acid residues (Figures 4.4, 4.5, 4.6 and 4.7). 
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                      10        20        30        40        50        60        70        80 
                       |         |         |         |         |         |         |         | 
PRSA_BACSU    CSSGDKEV-IAKTDAGDVTKGELYTNMK-KTAGASVLTQLVQEKVLDKKY--KVSDKEIDNKLKEYKTQLGDQYTALEKQ 
PrsA2_LISMO   CGGGGD---VVKTDSGDVTKDELYDAMK-DKYGSEFVQQLTFEKILGDKY--KVSDEDVDKKFNEYKSQYGDQFSAVLTQ 
PpiC_ESCCO    -------------------------------------------------------------------------------- 
PrtM_STREQ    CQSTNDNTSVITMKGDTISVSDFYNETKNTEISQRAMLNLVVSRVFEDQYGKKVSKKRTEEAYNKSAEQYGASFSAALAQ 
                                                                                               
Prim.cons.    C3SG3D22SV3KTD3GDVTK3ELY33MKN333G33333QLV3EKVL3DKYGKKVSDK33D3K3NEYK3QYGDQFSA3L3Q 
 
                      90       100       110       120       130       140       150       160 
                       |         |         |         |         |         |         |         | 
PRSA_BACSU    YG--KDYLKEQVKYELLTQKAAKDNIK--VTDADIKEYWEGLKGKIRASHILVADKKTAEEVEKKLK-KGEKFEDLAKEY 
PrsA2_LISMO   SGLTEKSFKSQLKYNLLVQKATEANTD--TSDKTLKKYYETWQPDITVSHILVADENKAKEVEQKLK-DGEKFADLAKEY 
PpiC_ESCCO    ----------------MAKTAA-------------------------ALHILVKEEKLALDLLEQIK-NGADFGKLAKKH 
PrtM_STREQ    SGLTTDTYKRQIRSAMLVEYAVKEAAKKELTDADYKKAYESYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAKEK 
                              :.: *.                         .    : ::: *  :  ::* .* .*  :**:  
Prim.cons.    SGLT3D33K3Q3KY3LLVQKAAK3N3KKE3TDAD3KKYYE333P3ITASHILVADEKTAKEV24KLKA4G22FADLAKEY 
 
                     170       180       190       200       210       220       230       240 
                       |         |         |         |         |         |         |         | 
PRSA_BACSU    STDSSAS-KGGDLGWFAKEGQMDETFSKAAFKLKT------GEVSDPVKTQYGYHIIKKTE--E-RGKYDDMKKELKSEV 
PrsA2_LISMO   STDTATKDNGGQLAPFG-PGKMDPAFEKAAYALKNK-----GDISAPVKTQYGYHIIQMDKPAT-KTTFEKDKKAVKASY 
PpiC_ESCCO    SICPSGK-RGGDLGEFR-QGQMVPAFDKVVFSCPV------LEPTGPLHTQFGYHIIKVLY----RN------------- 
PrtM_STREQ    TTAADKK---VDYKFDSGDTKLPADVIKAASGLKEGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYKKRLKEIV 
              :  .  .    :        ::   . *..            .   *   *  ::*::                       
Prim.cons.    STD4S4KD3GGDLG4F424G2MDPAF4KAAF4LK42DISEVGEVSDPVKTQYGYHIIKVTK2AEKR4333K3KK3LK33V 
 
                     250       260       270       280       290       300       310 
                       |         |         |         |         |         |         | 
PRSA_BACSU    LEQKLNDNAAVQEAVQKVMKKADIEVKDKDLKDTFNTSSTSNSTSSSSSNSK---------------------- 
PrsA2_LISMO   LESQLTT-ENMQKTLKKEYKDANVKVEDKDLKDAFKDFDGSSSSDSDSSK------------------------ 
PpiC_ESCCO    -------------------------------------------------------------------------- 
PrtM_STREQ    LAEKTQNIDFQNKVIAKALDKANVKIKDQAFANILAQYANTDKKASKANTSKSDQKSSSDSSKDSQSSKSKSEK 
                                                                                               
Prim.cons.    LE3KL332333QK333K33KKANVKVKDKDLKD3F33333S3S33S3SS3SKSDQKSSSDSSKDSQSSKSKSEK 
 
Figure 4.4: CLUSTALW alignment. Sequence highlighted in yellow = deleted in S. equi Mutant PrtM that was used for this research. Identical aa (*); strongly similar conserved aa 
substitutions (:) or weakly similar aa(.). Signal peptide sequences were excluded. Amino acids are denoted by single letters and letter colouration represents the physicochemical 
properties of the residues (Larkin et al., 2007). Red: small, hydrophobic, aromatic, but not Y). Blue: acidic. Magenta: Basic, excluding H. Green: Hydroxyl, sulfhydryl, amine, including 
G. Grey: others, including unusual amino/imino acids. The numbering of the residues is consistent with the numbering of the primary consensus (prim. cons.) Identical and conserved 
residues are concentrated in the central domain region. The number of amino acid possibilities at a relative position is represented by numbers within the  prim. cons.  
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PrtM_STREQ        1 CQSTNDNTS-VITMKGDTISVSDFYNETKNTEISQRAMLNLVVSRVFEDQYGKKVSKKRTEEAYNKSAEQYGASFSAALAQ   80  
PRSA_BACSU        1 CSSGDK-EVIAKTDAGD-VTKGELYTNMKKT-AGASVLTQLVQEKVLDKKY--KVSDKEIDNKLKEYKTQLGDQYTALEKQ   76  
PrsA2_LISMO       1 CGGGGD--V-VKTDSGD-VTKDELYDAMKDK-YGSEFVQQLTFEKILGDKY--KVSDEDVDKKFNEYKSQYGDQFSAVLTQ   74  
PpiC_ESCCO        1 --------M-AKTAA------------------------------------------------------------------    6  
 
cons              1           . *                                                                       81  
 
 
PrtM_STREQ       81 SGLTTDTYKRQIRSAMLVEYAVKEAAKKELTDADYKKAYESYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAKEKT  161  
PRSA_BACSU       77 YG--KDYLKEQVKYELLTQKAAKDNI--KVTDADIKEYWEGLKGKIRASHILVADKKTAEEVEKKLK-KGEKFEDLAKEYS  152  
PrsA2_LISMO      75 SGLTEKSFKSQLKYNLLVQKATEANT--DTSDKTLKKYYETWQPDITVSHILVADENKAKEVEQKLK-DGEKFADLAKEYS  152  
PpiC_ESCCO        7 -----------------------------------------------ALHILVKEEKLALDLLEQIK-NGADFGKLAKKHS   39  
 
cons             82                                                .    : ::: *  :  ::* .* .*  :**: :  162  
 
 
PrtM_STREQ      162 TAA--D-KKVDYKFDSGDTKLPADVIKAASGLKEGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYKKRLKEIVLA  239  
PRSA_BACSU      153 TDSSAS-KGGDLGWFAKEGQMDETFSKAAFKLKT------GEVSDPVKTQYGYHIIKKT--EERGK-YDDMKKELKSEVLE  223  
PrsA2_LISMO     153 TDTATKDNGGQLAPFG-PGKMDPAFEKAAYALKNK-----GDISAPVKTQYGYHIIQMDKPATKTT-FEKDKKAVKASYLE  226  
PpiC_ESCCO       40 ICPSGK-RGGDLGEFR-QGQMVPAFDKVVFSCPV------LEPTGPLHTQFGYHIIKVL--Y------R------------   92  
 
cons            163   .  . .  :        ::   . *..            .   *   *  ::*::                          243  
 
 
PrtM_STREQ      240 EKTQN-IDFQNKVIAKALDKANVKIKDQAFANILAQYANTDKKASKANTSKSDQKSSSDSSKDSQSSKSKSEK  311  
PRSA_BACSU      224 QKLNDNAAV-QEAVQKVMKKADIEVKDKDLKDTFNTSSTSNSTSSSSSNS----------------------K  273  
PrsA2_LISMO     227 SQLTT-ENM-QKTLKKEYKDANVKVEDKDLKDAFKDFDGSSSSDSDSS------------------------K  273  
PpiC_ESCCO       93 ------------------------------------------------------------------------N   93  
 
cons            244                                                                         :  316  
Figure 4.5: M-Coffee alignment (Bacillus subtillis PrsA, Listeria monocytogenes PrsA2, Escherichia coli PpiC, and S. equi 4047 PrtM). Identical aa (*); 
conserved aa substitutions (: or .). Signal peptide sequences were excluded. Identical and conserved residues are concentrated in the central domain region. The colour 
of individual residue indicates the level of agreement of its alignment with the multiple sequence alignments (Moretti et. al., 2007). Dark red: residues aligned in a 
similar fashion; blue: very low agreement; dark yellow, orange and red: reliably aligned (Moretti et. al., 2007). Cons: conserved residues. 
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PrtM_STREQ        1 CQSTNDNTSVITMKGDTISVSDFYNETKNTEISQRAMLNLVVSRVFEDQYGKKVSKKRTEEAYNKSAEQYGASFSAALAQS   81  
PRSA_BACSU        1 CSSGDKEVIAKTDAGD-VTKGELYTNMKKTAGA-SVLTQLVQEKVLDKKY--KVSDKEIDNKLKEYKTQLGDQYTALEKQY   77  
PrsA2_LISMO       1 CGGGGD--VVKTDSGD-VTKDELYDAMKDKYGS-EFVQQLTFEKILGDKY--KVSDEDVDKKFNEYKSQYGDQFSAVLTQS   75  
PpiC_ESCCO        1 MA--------------------------KT---------------------------------------------------    4  
 
cons              1                             ..                                                      81  
 
 
PrtM_STREQ       82 GLTTDTYKRQIRSAMLVEYAVKEAAKKELTDADYKKAYESYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAKEKTT  162  
PRSA_BACSU       78 G--KDYLKEQVKYELLTQKAAKD--NIKVTDADIKEYWEGLKGKIRASHILVADKKTAEEVEKKLK-KGEKFEDLAKEYST  153  
PrsA2_LISMO      76 GLTEKSFKSQLKYNLLVQKATEA--NTDTSDKTLKKYYETWQPDITVSHILVADENKAKEVEQKLK-DGEKFADLAKEYST  153  
PpiC_ESCCO        5 --------------------------------------------AAALHILVKEEKLALDLLEQIK-NGADFGKLAKKHSI   40  
 
cons             82                                               .    : ::: *  :  ::* .* .*  :**: :   162  
 
 
PrtM_STREQ      163 AAD---KKVDYKFDSGDTKLPADVIKAASGLK-EGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYKKRLKEIVLA  239  
PRSA_BACSU      154 DSSA-SKGGDLGWFAKEGQMDETFSKAAFKLK-TGEVS------DPVKTQYGYHIIKKTE--ERG-KYDDMKKELKSEVLE  223  
PrsA2_LISMO     154 DTATKDNGGQLAPF-GPGKMDPAFEKAAYALKNKGDIS------APVKTQYGYHIIQMDKPATKT-TFEKDKKAVKASYLE  226  
PpiC_ESCCO       41 CPSG-KRGGDLGEF-RQGQMVPAFDKVVFSCP-VLEPT------GPLHTQFGYHIIKVLY---------------------   91  
 
cons            163  .    .  :        ::   . *..       : :       *   *  ::*::                          243  
 
 
PrtM_STREQ      240 EKTQNIDFQNKVIAKALDKANVKIKDQAFANILAQYANTDKKASKANTSKSDQKSSSDSSKDSQSSKSKSEK  311  
PRSA_BACSU      224 QKLNDNAAVQEAVQKVMKKADIEVKDKDLKDTFNTSS----------------------TSNSTSSSSSNSK  273  
PrsA2_LISMO     227 SQLTT-ENMQKTLKKEYKDANVKVEDKDLKDAFKDFD------------------------GSSSSDSDSSK  273  
PpiC_ESCCO       92 ----------------------------------------------------------------------RN   93  
 
cons            244                                                                        :  315  
Figure 4.6: T-Coffee alignment (Bacillus subtillis PrsA, Listeria monocytogenes PrsA2, Escherichia coli PpiC, and S. equi 4047 PrtM). Identical aa (*); 
conserved aa substitutions (: or .). Signal peptide sequences were excluded. Identical and conserved residues are concentrated in the central domain region. The residue 
colour BAD AVG GOOD scheme represents the primary library support for alignment of the residue under consideration on a scale between 0:blue, poorly supported 
and 9:dark red, strongly supported (Di Tommaso et al., 2011). Cons. means conserved residues.   
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1    -CSSGDKEVIAKTDAGDVTKGELYTNMK-KTAGASVLTQLVQEKVLDKKY--KVSDKEID   56  PRSA_BACSU 
1    -CGGGGD--VVKTDSGDVTKDELYDAMK-DKYGSEFVQQLTFEKILGDKY--KVSDEDVD   54  PrsA2_LISMO 
1    ------------------------------------------------------------    0  PpiC_ESCCO 
1    CQSTNDNTSVITMKGDTISVSDFYNETKNTEISQRAMLNLVVSRVFEDQYGKKVSKKRTE   60  PrtM_STREQ 
 
57   NKLKEYKTQLGDQYTALEKQYG--KDYLKEQVKYELLTQKAAKDNIK--VTDADIKEYWE  112  PRSA_BACSU 
55   KKFNEYKSQYGDQFSAVLTQSGLTEKSFKSQLKYNLLVQKATEANTD--TSDKTLKKYYE  112  PrsA2_LISMO 
1    ------------------------------------------------------------    0  PpiC_ESCCO 
61   EAYNKSAEQYGASFSAALAQSGLTTDTYKRQIRSAMLVEYAVKEAAKKELTDADYKKAYE  120  PrtM_STREQ 
            .    : ::: *  :  ::* .* .*  :**: :  .  .    :         
 
113  GLKGKIRASHILVADKKTAEEVEKKLK-KGEKFEDLAKEYSTDSSAS-KGGDLGWFAKEG  170  PRSA_BACSU 
113  TWQPDITVSHILVADENKAKEVEQKLK-DGEKFADLAKEYSTDTATKDNGGQLAPFG-PG  170  PrsA2_LISMO 
1    -MAKTAAALHILVKEEKLALDLLEQIK-NGADFGKLAKKHSICPSGK-RGGDLGEFR-QG   56  PpiC_ESCCO 
121  SYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAKEKTTAADKK---VDYKFDSGDT  177  PrtM_STREQ 
     ::   . *..            .   *   *  ::*:           : .          
 
171  QMDETFSKAAFKLKT------GEVSDPVKTQYGYHIIKKTE---ERGKYDDMKKELKSEV  221  PRSA_BACSU 
171  KMDPAFEKAAYALKNK-----GDISAPVKTQYGYHIIQMDKP-ATKTTFEKDKKAVKASY  224  PrsA2_LISMO 
57   QMVPAFDKVVFSCPV------LEPTGPLHTQFGYHII--------KVLYRN---------   93  PpiC_ESCCO 
178  KLPADVIKAASGLKEGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYKKRLKEIV  237  PrtM_STREQ 
222  LEQKLNDNAAVQEAVQKVMKKADIEVKDKDLKDTFNTSSTSNSTSSSSSNSK--------  273  PRSA_BACSU 
225  LESQLTT-ENMQKTLKKEYKDANVKVEDKDLKDAFKDFDGSSSSDSDSSK----------  273  PrsA2_LISMO 
94   ------------------------------------------------------------   93  PpiC_ESCCO 
238  LAEKTQNIDFQNKVIAKALDKANVKIKDQAFANILAQYANTDKKASKANTSKSDQKSSSD  297  PrtM_STREQ 
 
274  --------------  273  PRSA_BACSU 
274  --------------  273  PrsA2_LISMO 
94   --------------   93  PpiC_ESCCO 
298  SSKDSQSSKSKSEK  311  PrtM_STREQ 
 
Figure 4.7: UniProt alignment (Bacillus subtillis PrsA, Listeria monocytogenes PrsA2, Escherichia coli PpiC, and S. equi 4047 PrtM). Identical aa 
(*); conserved aa substitutions (: or .). Identical and conserved residues are concentrated in the central domain region. Signal peptide sequences were 
excluded.
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                      10        20        30        40        50        60        70        80        90 
                       |         |         |         |         |         |         |         |         | 
PRSA_BACSU    ---MKKIAIAAITATSILALSACSSGDKEV-IAKTDAGDVTKGELYTNMK-KTAGASVLTQLVQEKVLDKKY--KVSDKEIDNKLKEYKT 
PrsA2_LISMO   --MKKKLILGLVMMMALFSLAACGGGGD---VVKTDSGDVTKDELYDAMK-DKYGSEFVQQLTFEKILGDKY--KVSDEDVDKKFNEYKS 
PpiC_ESCCO    ------------------------------------------------------------------------------------------ 
PrtM_STREQ    MKKSTKLLAGIVTLASAMTLAACQSTNDNTSVITMKGDTISVSDFYNETKNTEISQRAMLNLVVSRVFEDQYGKKVSKKRTEEAYNKSAE                                                                                                         
Prim.cons.    MK23KKL33G3VT33S333LAAC3SG3D22SV3KTD3GDVTK3ELY33MKN333G33333QLV3EKVL3DKYGKKVSDK33D3K3NEYK3 
                     100       110       120       130       140       150       160       170       180 
                       |         |         |         |         |         |         |         |         | 
PRSA_BACSU    QLGDQYTALEKQYG--KDYLKEQVKYELLTQKAAKDNIK--VTDADIKEYWEGLKGKIRASHILVADKKTAEEVEKKLK-KGEKFEDLAK 
PrsA2_LISMO   QYGDQFSAVLTQSGLTEKSFKSQLKYNLLVQKATEANTD--TSDKTLKKYYETWQPDITVSHILVADENKAKEVEQKLK-DGEKFADLAK 
PpiC_ESCCO    -------------------------------MAKTA----------A------------ALHILVKEEKLALDLLEQIK-NGADFGKLAK 
PrtM_STREQ    QYGASFSAALAQSGLTTDTYKRQIRSAMLVEYAVKEAAKKELTDADYKKAYESYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAK 
                                              *                          .    : ::: *  :  ::* .* .*  :** 
Prim.cons.    QYGDQFSA3L3QSGLT3D33K3Q3KY3LLVQKA4KAN3KKE3TDAD4KKYYE333P3ITASHILVADEKTAKEV24KLKA4G22FADLAK 
                     190       200       210       220       230       240       250       260       270 
                       |         |         |         |         |         |         |         |         | 
PRSA_BACSU    EYSTDSSAS-KGGDLGWFAKEGQMDETFSKAAFKLKT------GEVSDPVKTQYGYHIIKKTE--E-RGKYDDMKKELKSEVLEQKLNDN 
PrsA2_LISMO   EYSTDTATKDNGGQLAPFG-PGKMDPAFEKAAYALKNK-----GDISAPVKTQYGYHIIQMDKPAT-KTTFEKDKKAVKASYLESQLTT- 
PpiC_ESCCO    KHSICPSGK-RGGDLGEFR-QGQMVPAFDKVVFSCPV------LEPTGPLHTQFGYHIIKVLY----RN--------------------- 
PrtM_STREQ    EKTTAADKK--V-DYKFDSGDTKLPADVIKAASGLKEGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYKKRLKEIVLAEKTQNI 
              : :  .  .    :        ::   . *..            .   *   *  ::*::                               
Prim.cons.    EYSTD4S4KD3GGDLG4F424G2MDPAF4KAAF4LK42DISEVGEVSDPVKTQYGYHIIKVTK2AEKR4333K3KK3LK33VLE3KL332 
                     280       290       300       310       320       330 
                       |         |         |         |         |         | 
PRSA_BACSU    AAVQEAVQKVMKKADIEVKDKDLKDTFNTSSTSNSTSSSSSNSK---------------------- 
PrsA2_LISMO   ENMQKTLKKEYKDANVKVEDKDLKDAFKDFDGSSSSDSDSSK------------------------ 
PpiC_ESCCO    ------------------------------------------------------------------ 
PrtM_STREQ    DFQNKVIAKALDKANVKIKDQAFANILAQYANTDKKASKANTSKSDQKSSSDSSKDSQSSKSKSEK                                                                                                      
Prim.cons.    333QK333K33KKANVKVKDKDLKD3F33333S3S33S3SS3SKSDQKSSSDSSKDSQSSKSKSEK                         
 
Figure 4.8: CLUSTALW amino acid sequence (Bacillus subtillis PrsA, Listeria monocytogenes PrsA2, Escherichia coli PpiC, and S. 
equi 4047 PrtM) alignment – with signal peptide. N-terminal signal peptide (pink), N-terminal domain (green), Central parvulin-type  
(PPIase) domain (red) and C-terminal domain (blue). Identical and conserved residues are concentrated in the central domain region. The 
region deleted in S. equi mutant PrtM that was used for this research is underlined yellow. 
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4.4: Predicted Domain Architecture 
 
By analysing the information generated from Figures 4.4, 4.5, 4.6, 4.7 and 4.8; and by comparing the sequence allignment of PrtM to the 
domains of the other PPIases, the  N-terminal, central and C-terminal domains of PrtM were predicted.  The predicted domain architecture 
of PrtM of S. equi 4047 is shown in Figures 4.9a (protein sequence) and 4.9b (pictorial). 
 
MKKSTKLLAGIVTLASAMTLAACQSTNDNTSVITMKGDTISVSDFYNETKNTEISQRAMLNLVVSRVFEDQYGKKVSKKRTEEAYNKSAEQYGASFSAALA
QSGLTTDTYKRQIRSAMLVEYAVKEAAKKELTDADYKKAYESYTPEMTTQVTTLDNEETAKAVLGEVKAEGADFAAIAKEKTTAADKKVDYKFDSG
DTKLPADVIKAASGLKEGDISEVVSVLDPATYQNKFYIVKVTKKAEKASDWKKYKKRLKEIVLAEKTQNIDFQNKVIAKALDKANVKIKDQAFANILAQY
ANTDKKASKANTSKSDQKSSSDSSKDSQSSKSKSEK 
 
Figure 4.9a: Predicted domain architecture of S. equi 4047 PrtM [N-terminal signal peptide (pink) – 22 amino acids; N-terminal domain (green) - 
125 amino acids; Central parvulin (PPIase) domain (red) – 109 amino acids; and C-terminal domain (blue) – 77 amino acids]. In bold and underlined 
yellow is the sequence that was deleted (inframe internal deletion) in the S. equi 4047 mutant ∆PrtM that was used for this research. 
 
 
 
 
AA:         22       125                   109                 77 
 
Figure 4.9b: Pictorial of Predicted domain architecture of S. equi 4047 PrtM [N-terminal signal peptide (pink) – 22 amino acids; N-terminal 
domain (green) - 125 amino acids; Central parvulin (PPIase) domain (red) – 109 amino acids; and C-terminal domain (blue) – 77 amino acids]. 
SP N-terminus PPIase C-terminus 
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4.5 PrtM recombinant Protein characteristics 
Figure 4.10 shows protein characteristics of the full-length his-tagged S. equi 4047 PrtM 
protein (without signal peptide). Figure 4.11 shows the protein characteristics of the his-
tagged S. equi 4047 PrtM central domain. The molecular weight and pI of the his-tagged 
proteins of interest was determined as described in Section 2.3.7 and results shown in 
Figures 4.10 and 4.11. 
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        10         20         30         40         50         60  
HHHHHHCQST NDNTSVITMK GDTISVSDFY NETKNTEISQ RAMLNLVVSR VFEDQYGKKV  
        70         80         90        100        110        120  
SKKRTEEAYN KSAEQYGASF SAALAQSGLT TDTYKRQIRS AMLVEYAVKE AAKKELTDAD  
       130        140        150        160        170        180  
YKKAYESYTP EMTTQVTTLD NEETAKAVLG EVKAEGADFA AIAKEKTTAA DKKVDYKFDS  
       190        200        210        220        230        240  
GDTKLPADVI KAASGLKEGD ISEVVSVLDP ATYQNKFYIV KVTKKAEKAS DWKKYKKRLK  
       250        260        270        280        290        300  
EIVLAEKTQN IDFQNKVIAK ALDKANVKIK DQAFANILAQ YANTDKKASK ANTSKSDQKS  
       310  
SSDSSKDSQS SKSKSEK  
 
Number of amino acids: 317 
Molecular weight: 35183.4 
Theoretical pI: 9.07 
Amino acid composition: 
CSV format
 
Ala (A)  38  12.0% 
Arg (R)   6   1.9% 
Asn (N)  14   4.4% 
Asp (D)  24   7.6% 
Cys (C)   1   0.3% 
Gln (Q)  14   4.4% 
Glu (E)  22   6.9% 
Gly (G)   9   2.8% 
His (H)   6   1.9% 
Ile (I)  13   4.1% 
Leu (L)  15   4.7% 
Lys (K)  48  15.1% 
Met (M)   4   1.3% 
Phe (F)   8   2.5% 
Pro (P)   3   0.9% 
Ser (S)  31   9.8% 
Thr (T)  25   7.9% 
Trp (W)   1   0.3% 
Tyr (Y)  14   4.4% 
Val (V)  21   6.6% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
Total number of negatively charged residues (Asp + Glu): 46 
Total number of positively charged residues (Arg + Lys): 54 
Atomic composition: 
Carbon      C       1537 
Hydrogen    H       2476 
Nitrogen    N        424 
Oxygen      O        508 
Sulfur      S          5 
Formula: C1537H2476N424O508S5 
Total number of atoms: 4950 
Extinction coefficients: 
Extinction coefficients are in units of  M
-1
 cm
-1
, at 280 nm measured in water. 
Ext. coefficient    26360 
Abs 0.1% (=1 g/l)   0.749, assuming all pairs of Cys residues form cystines 
Ext. coefficient    26360 
Abs 0.1% (=1 g/l)   0.749, assuming all Cys residues are reduced 
 
Figure 4.10 Protein characteristics of full-length his-tagged PrtM (without signal 
peptide). 
 
 
   
136 
 
 
 
10         20         30         40         50         60  
HHHHHHSSGL VPRGSHMTTQ VTTLDNEETA KAVLGEVKAE GADFAAIAKE KTTAADKKVD  
        70         80         90        100        110  
YKFDSGDTKL PADVIKAASG LKEGDISEVV SVLDPATYQN KFYIVKVTKK A  
 
 
Number of amino acids: 111 
Molecular weight: 11943.4 
Theoretical pI: 6.71 
Amino acid composition: 
CSV format
 
Ala (A)  14  12.6% 
Arg (R)   1   0.9% 
Asn (N)   2   1.8% 
Asp (D)   9   8.1% 
Cys (C)   0   0.0% 
Gln (Q)   2   1.8% 
Glu (E)   7   6.3% 
Gly (G)   7   6.3% 
His (H)   7   6.3% 
Ile (I)   4   3.6% 
Leu (L)   6   5.4% 
Lys (K)  14  12.6% 
Met (M)   1   0.9% 
Phe (F)   3   2.7% 
Pro (P)   3   2.7% 
Ser (S)   7   6.3% 
Thr (T)  10   9.0% 
Trp (W)   0   0.0% 
Tyr (Y)   3   2.7% 
Val (V)  11   9.9% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 16 
Total number of positively charged residues (Arg + Lys): 15 
 
Atomic composition: 
Carbon      C        527 
Hydrogen    H        842 
Nitrogen    N        146 
Oxygen      O        168 
Sulfur      S          1 
 
Formula: C527H842N146O168S1 
Total number of atoms: 1684 
 
Extinction coefficients: 
 
This protein does not contain any Trp residues. Experience shows that 
this could result in more than 10% error in the computed extinction coefficient. 
 
Extinction coefficients are in units of  M
-1
 cm
-1
, at 280 nm measured in water. 
 
Ext. coefficient     4470 
Abs 0.1% (=1 g/l)   0.374 
Figure 4.11 Protein characteristics of his-tagged central domain of S. equi 4047 PrtM. 
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4.6 Primers 
 
All primers used for this study were designed as stated in section 2.3.6. These primers are 
listed in Table 2.11 and marked in Figure 4.1. In determining the primers for the S. equi 
4047 PrtM full gene (results in Section 5), the forward primer was designed to upstream 
sequence containing native promoter and ribosome binding sites. The internal forward and 
reverse primers for amplifying the sequence encoding the PrtM central domain were 
designed with restriction sites to allow for cloning as described in Section 5. Forward and 
reverse primers for complemented mutants have restriction sites to enable PrtM to be 
cloned into plasmid pVA838 for complementation (results in Chapter 8). Internal forward 
and reverse primers have restriction sites to clone portions of PrtM into pVA828 for 
complementation. The reverse primers for cloning full PrtM gene into pET28a for 
recombinant gene expression in E. coli were designed with the same reverse primers used 
for cloning full PrtM gene into pVA838, to avoid designing another primer. Reverse 
primers had stop codon (TAG) included. For the expression of PrtM central domain 
recombinant protein in E. coli, internal forward primers were designed with restriction 
sites to enable cloning into pET28a. 
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4.7 Computer model of protein three dimensional (3D) structure: 
 
The 3D structure of PrtM (central domain underlined yellow in Figure 4.9a) was obtained 
as described in Section 2.3.8. 
The PSIPRED Protein Sequence Analysis Workbench (http://bioinf.cs.ucl.ac.uk/psipred/) 
generated the central domain 3D model (Figure 4.12) by selecting the best scoring hits 
using softwares PSI-BLAST, pGenTHREADER and HHPred against the current query 
protein and the protein database. pGenTHREADER software generated alignment scores 
against input sequences from the protein database.  PSIPRED v3.3 generated a predicted 
protein secondary structure (Figure 4.13). All the information generated via  The PSIPRED 
Protein Sequence Analysis Workbench (http://bioinf.cs.ucl.ac.uk/psipred/) can be viewed 
via this link: http://bioinf.cs.ucl.ac.uk/psipred/result/22b4bc7c-3332-11e3-875b-
00163e110593 (for S. equi PrtM central domain). 
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Figure 4.12: S. equi 4047 PrtM central domain 3D model. Helices are highlighted pink 
and sheets highlighted yellow. 
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Figure 4.13: PSIPRED predicted protein secondary structure of S. equi 4047 PrtM 
central domain. 
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4.8  Discussion 
 
PrsA of B. subtilis shares a significant degree of amino acid similarity (45% identity, and 
65% similarity) with L. monocytogenes PrsA2 (Alonzo et al, 2011). Several alignment 
programs were used to get the most biologically correct alignment, by cross-examining the 
resulting alignments. ClustalW alignment yielded: 22.69% identity and 24.48 similarity for 
PrtM_STREQ and PRSA_BACSU; 29.17% identity and 21.73% similarity for 
PrtM_STREQ and PrsA2_LISMO; and 5.11% identity and 9.61% similarity for  
PrtM_STREQ and PpiC_ESCCO (see protein sequences in Figure 4.8) and T-coffee 
alignment, which is a consistency based alingnment (Tommaso et al., 2011), gave a main 
score of 85 (Figure 4.6) which is quite high considering the fact that a value of a 100 
means full agreement between the considered alignment and its associated primary library 
(Tommaso et al., 2011). The PPIase domains of PrtM of S. equi 4047, E. coli PpiC, B. 
subtilis PrsA and  L. monocytogenes PrsA2  share identical putative active site residues 
(Figures  4.4. 4.5, 4.6, 4.7 and 4.8) with the identical and conserved residues being 
concentrated in the central domain region. 
 
Multiple alignments, which are a necessary pre-requisite in phylogeny, remote homologue 
detection and structure prediction (Wallace et al., 2006) were therefore valuable in 
elucidating the domain architechture of PrtM of S. equi 4047. This understanding was 
necessary for accurate design of primers used in Chapters 5 and 8 (see a list of primers 
used for this study in Table 2.11) and for the production of complemented mutants in 
chapter 8 of this study.  
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E. coli PpiC (PpiC_ESCCO in Figures 4.4 – 4.8) is the prototype of the parvulin protein 
family, and defines the minimal catalytic domain of the entire body of parvulin-like 
enzymes (Kuhlewein et al., 2004). Figures 4.7 and 4.8 show that E. coli PPiC, B. subtilis 
PrsA and L. monocytogenes PrsA2 share a good number of conserved and identical amino 
acids with S. equi 4047 PrtM, especially in the central-parvulin domain. The central 
domain contains a lot of conserved amino acids, compared to the catalytic domain of other 
parvulins (Figures 4.8, 4.9a and 4.9b) suggesting that the central domain of the PrtM of S. 
equi 4047 is a parvulin domain. 
 
Generally, parvulins are made up of one, rarely two parvulin boxes and additional N-and 
C-terminal domains (Kuhlewein et al., 2004) with varying lengths and roles in substrate 
binding and/or chaperone-like catalysis of folding (Behrens et al., 2001; Vitikainen et al., 
2004). The predicted modular organization of S. equi 4047 PrtM (Figures 4.9a and 4.9b) is 
similar to that of B. subtilis PrsA and L. monocytogenes PrsA2, with N- and C- terminal 
domains flanking a central domain which is predicted in this study to also be a PPIase 
domain. Protease-coupled PPIase assay results (Chapter 6 of this study) further confirm the 
initial prediction that the central domain of the PrtM of S. equi 4047 has PPIase activity. 
 
Computer generated molecular model information (Figure 4.12 and 4.13) indicates that S. 
equi 4047 PrtM central domain is made up of four α-helices and four β-sheets.  
 
Information generated from the protein parameters search (Section 4.5 - Figures 4.10 and 
4.11) were valuable. For example, the knowledge of protein molecular weights generated 
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(35183.4 Da for his-tagged full-length protein and 11943.4 Da for his-tagged central 
domain protein in Figures 4.10 and 4.11 respectively) were valuable in comparing and 
confirming the sizes of the recombinant proteins (Chapter 5). The extinction coefficient 
(Figures 4.10 and 4.11) were valuable in calculating the concentrations (method in 2.5.18) 
of purified the recombinant proteins (generated in Chapter 5) which were used for enzyme 
assay (Chapter 6) and crystallography (Chapter 7). 
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5.  Results of Production of PrtM (Full Length and Central Domain) 
recombinant Proteins of S. equi 4047 WT 
Full length and central domain recombinant PrtM proteins from wild type (WT) S. equi 
4047 were produced in Escherichia coli as discussed in this Chapter. 
 
5.1 Introduction 
 
The mode of action and the structure of PrtM of S. equi 4047 has never been studied. In 
order to evaluate the function and structure of the PrtM of S. equi 4047, and to ascertain 
whether individual domains within the predicted PrtM architecture (Chapter 4, Figure 4.9a 
and 4.9b) contribute to it’s PPIase activity, the full length and central domain genes of 
PrtM were cloned and transformed into expression host E. coli BL21 (results in Section 
5.2). The best conditions for expressing the full length and central domain recombinant 
proteins were first optimized and confirmed on a small scale (results in Section 5.3), 
followed by large scale overexpression and then purification to homogeneity by IMAC 
(method in Sections 2.6.2 and 2.6.3 and results in Section 5.4) and desalted and 
concentrated by centrifugal filtration (method in Section 2.6.5) prior to 
characteriszation/function/structure analysis (in Sections 5.4, 5.5, 5.6; Chapters 6 and 7).  
 
The purity of recombinant proteins was judged by SDS-PAGE (method in Section 2.5.19, 
result in Figure 5.5 and 5.6) and the identities of the recombinant proteins verified by 
peptide mass fingerprinting (results in Section 5.5).  
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5.2 Results of cloning  
To produce full length and central domain recombinant proteins, the complete PrtM gene 
(Chapter 4, Figure 4.1) as well as the central domain (sequence underlined yellow in 
Figure 4.1, Chapter 4) where amplified by PCR (the sequences of primers SEQPrtmf and 
SEQPrtmr for full length encoding sequence, and Prtmidcolif and Prtmidcolir for the 
central domain encoding sequence are shown in Table 2.11, method of PCR in Section 
2.5.4 ) from S. equi 4047 genomic DNA. 
  
Following purification of PCR product, the PCR fragments (encoding full length and the 
central domain), as well as the pET28-a (diagram in Appendix A17) cloning/expression 
vector were digested (method of digestion in Section 2.5.9) with NdeI/XhoI. Images of 
AGE of double digest products are shown in Figure 5.2. The genes (encoding full length 
and central domain) were individually ligated (ligation method in Section 2.5.10) into 
pET28-a/NdeI/XhoI cloning vector and the ligation products were transformed into E. coli 
TOP10 (see method of TOP10 transformation in Section 2.5.12).  
 
After transformation, plasmids were extracted from E coli TOP 10 (see method of STET 
based extraction in Section 2.5.13). The purified plasmid was sequenced (method in 
section 2.5.15 and result in Appendix E) to confirm proper orientation of DNA insert and 
correct DNA sequence. The inserts (encoding full length and central domain) were 
digested out of the plasmid (images of AGE of digest products are shown in Figure 5.2) to 
confirm successful cloning. After this, recombinant pET28a, which had been re-extracted 
from E coli TOP10 (using spin-column-based extraction, Figure 5.3, method in Section 
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2.5.15), were used to transform the expression host, E coli BL21 (DE3) (method of BL21 
transformation in Section 2.5.12). All E coli (TOP10 or BL21) transformants were 
selectively isolated or grown in LB media containing – 50 μg / mL kanamycin (Table 2.4). 
The pET28a cloning vector (Appendix A17) codes for an oligohistidine tag. Therefore, the 
expressed protein contained an oligohistidine tag at the N-terminus. 
 
 
 
A    B    C 
 
    
 
Figure 5.1: Concentration of digested ligation components, post gel purification. S. 
equi 4047 PrtM Full length A i = 53 ng/µL. S. equi 4047 PrtM Central domain DNA B i 
=37.3 ng/µL. C i = purified pET28a/NdeI/XhoI double digest, 5296 bp = 93.13 ng/uL. S = 
molecular weight DNA size standard (200 – 10,000 bp).  
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 A        S     i     ii     iii    iv    v    vi                B        vi    v    iv    iii    ii     i     S    
        
 
Figure 5.2 Double digestions of plasmids isolated from clones carrying the genes 
encoding PrtM Full Length and Central Domain. Successful cloning is confirmed here 
by the observed inserts. A = for Full length PrtM clone: NdeI/Xhol digested putative 
pET28a/full length PrtM clones.  A v = Full length DNA insert = approximately 1000 bp 
in size. Ai, Aiii and Av = Xba1/Xhol digested plasmid DNA containing inserts; Aii, Aiv 
and Avi = Xba1/Xhol digested plasmid without insert. B = for PrtM Central Domain clone: 
Xba1/Xhol digested putative pET28a/central domain clones (268 bp band in lanes Bv and 
Bvi). S = molecular weight DNA size standard (200 – 10,000 bp).  
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A      B 
 
    
Figure 5.3 Spin-column-based extracted plasmid digestion. A i = XbaI digest of 
pET28a/full length PrtM DNA (bottom = 644 bp and top = 5588 bp fragments); B i and ii 
= XbaI/XhoI digest DNA of pET28a/PrtM central domain (top = 5269, middle = 268 and 
bottom = 118 bp).  These results indicate success of cloning of both (full length and central 
domain) target inserts. S = molecular weight DNA size standard (200 – 10,000 bp).  
 
 
 
5.3 Result of small scale protein expression 
 
After cloning, the expression of recombinant proteins (full-length and central domain) in 
E. coli BL21 was optimized on a small scale as described in Section 2.6.1. Results of small 
scale expression are shown in SDS polyacrylamide gel in Figure 5.6A. The full length 
recombinant protein expressed very well cultured at 20
o
C and at 30
o
C induction 
temperatures (Figure 5.4 Aii and Aiii respectively); with slightly more soluble protein at 
30
o
C. At both temperatures, the band size of about 36 kDa is in agreement with predicted 
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molecular weight (Chapter 4, Figure 4.10). For the central domain recombinant protein, 
CFE for samples Bii, and Biii (Figure 5.4B) were obtained as described in section 2.6.1. 
An initial SDS-polyacrylamide gel (SDS-PAG) using 13% (w/v) acrylamide showed bands 
of expressed recombinant protein in agreement with predicted molecular weight. The 
extracted CFE were then electrophoresed on 15% SDS-PAG (Figure 5.4B). Increasing the 
concentration of the SDS-PAG slowed down the migration of the central domain 
recombinant protein band (approximately 11.5 kDa) in the gel. The central domain 
recombinant protein (Figure 5.4 B) expressed very well at 20
o
C and 30
o
C induction 
temperatures. 
 
  A  i               ii           iii     B  i     ii         iii        iv         v        vi 
     
                              
 
Figure 5.4 SDS-PAGE analysis of PrtM small scale protein expression. A = full length 
recombinant protein on a 13% (w/v) SDS polyacrylamide gel: Ai = LMW marker, Aii and 
Aiii were CFE obtained by method in section 2.6.1 and induced at 20
o
C and 30
o
C 
respectively.  B = central domain recombinant protein on a 15% (w/v) SDS 
polyacrylamide gel: Bi = HMW marker, Bii and Biii were CFE obtained by method in 
section 2.6.1 and induced at 20
o
C and 30
o
C respectively. Biv and Bv were CFE obtained as 
described in section 2.5.21, and induced at 20
o
C and 30
o
C respectively. Bvi=LMW marker. 
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5.4 Result of large scale protein expression and purification 
 
Following the success of small scale expression and optimization of expression conditions 
(results in Section 5.2), large scale expression of recombinant proteins was carried out 
using  E. coli BL21 (DE3) (see method in Section 2.6.2) and CFE of N-terminally histidine 
tagged recombinant proteins purified by gradient elution IMAC with Ni Sepharose high 
performance resin (method in Section 2.6.3). After SDS-PAGE analysis of IMAC 
purification (results shown in Figure 5.5), the pure full length and central domain 
recombinant protein fractions were concentrated and washed using molecular weight 
concentrator (method in Section 2.6.5, and result in Figure 5.6).  
 
Figure 5.7 shows the result of SDS-PAGE analysis of dialysed, freeze dried full length 
recombinant protein (method of dialysis in Section 2.6.4). Due to technical problems and 
the fact that no added advantage was observed, dialysis was discontinued and only 
molecular weight concentrator was used for washing and purification of proteins for 
further analysis. 
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A      B 
  
 
C               D 
     
 
Figure 5.5 SDS-PAGE analysis of post-IMAC purified recombinant proteins. A ii – 
viii & B ii - viii = PrtM full length recombinant protein fractions. C ii to ix & D ii to vi   = 
PrtM central domain recombinant protein fractions. A ix, B i, C x and D i = LMW marker. 
A i, B ix, C i and D vii = HMW marker. 
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 A       B 
    
 
Figure 5.6 SDS-PAGE image of concentrated IMAC-purified recombinant protein: A 
ii, iii and iv = PrtM full length fractions; B ii = PrtM central domain fraction. The final 
concentration was determined spectrophotometrically (method in section 2.5.18). A i and 
B i = LMW marker, A v = HMW marker. The dimer (upper band in A ii, A iii, and A iv) 
gave a Mascot score of 1304, with 26 unique matches out of 64 and 56 % protein sequence 
coverage (Table E3, Appendix E). The monomer (lower band in A ii, A iii, and A iv) gave 
a Mascot score of 1475, with 36 unique matches out of 86 and 59 % protein sequence 
coverage (Table E3, Appendix E). The central domain recombinant protein (Figure 5.8 Bii) 
gave a mascot score of 312, with 6 unique matches out of 32 and 44% protein sequence 
coverage (Table E, Appendix E).   
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      i           ii    iii           iv           v             vi 
 
 
Figure 5.7 SDS-PAGE analysis of reconstituted dialysed full length recombinant 
protein. ii and iii were fractions from dialysed sample; iv and v were fractions which had 
been dialysed, freeze dried and resuspended in 18.2 MΩ/cm H2O. i = LMW marker. vi = 
HMW marker. 
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5.5 Result of in-gel tryptic digest and identification of recombinant proteins by 
HPLC/MS 
 
In order to confirm the identities of the concentrated full length and central domain 
recombinant proteins, bands from Figure 5.6 (A and B) were excised, trypsinized (method 
in Section 2.5.29) and identified by HPLC/MS (method in Section 2.5.30). Mascot 
spectrum analysis (method in Section 2.5.31) reports (links to reports are given below in 
Table 5.0) confirmed that the full length and central domain recombinant protein bands 
(Figure 5.6) were the correct proteins and were of S. equi 4047 origin.  
 
 
 
Recombinant 
protein 
fraction 
Mascot search result 
 
                     Protein code         Protein name 
Full Length - 
upper band - 
dimer 
Protein 
hits    : 
 gi|225870097 
 foldase protein PrsA  
[Strepcoccus equi subsp. equi 4047] 
 
Full Length - 
lower band – 
monomer 
Protein hits    :  gi|225870097 
  foldase protein PrsA  
[Streptococcus equi subsp. equi 4047] 
 
Central 
domain  
 
Protein hits : gi|225870097  
foldase protein PrsA 
 [Streptococcus equi subsp. equi 4047] 
 
Table 5.0: Protein Codes from Mascot spectrum analysis following MS/MS of PrtM 
recombinant  proteins. 
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5.6 Results of Western blots of recombinant proteins 
 
Western blot analysis (method in Section 2.5.20) of the full length and central domain 
recombinant proteins revealed reactions of both fractions with α-PpmA antibody. 
 
 
  A     i            ii    Bi             ii 
    
Figure 5.8 Image of Western blot of PrtM recombinant proteins with high titre α-
PpmA. Ai = Sigma LMW marker, Aii = reaction of full length purified recombinant 
protein fraction; Bi = BioRad protein standard, B ii = reaction of central domain purified 
recombinant protein fraction. Sigma marker (Ai) which was not usually used for Western 
blots, was used because of unavailability of BioRad protein standard at the time. 
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5.7 Discussion 
 
The purity of the recombinant protein was examined by SDS-PAGE and this showed that 
the purified full length recombinant protein (Figure 5.6A) had a molecular weight of about 
36 kDa (monomeric unit) which is in agreement with the predicted molecular weight 
(Section 4, Figure 4.10). The molecular weight of the central domain recombinant protein 
fraction (Figure 5.6B) was about 11.5 kDa and this is also in agreement with the predicted 
molecular weight (Section 4, Figure 4.11). The MS and Mascot search results (Table 5.0) 
and the reactions of both the full length and central domain purified recombinant proteins 
with αPpmA antibody (Figure 5.8), all confirm that cloning and overexpression 
experiments were successful and that both protein fractions are of S. equi 4047 origin. 
With this outcome in hand, both purified recombinant protein fractions were used for 
enzyme assays (Chapter 6) and crystallography (Chapter 7).  
 
Most bacteria have a rigid cell wall which maintains their cell shape and is responsible for 
resistance of internal turgor pressure (van den Ent et al., 2006). The rigidity of the bacterial 
cell wall is due to a fine network of glycan strands which are linked together by short 
peptides forming a peptidoglycan layer - or murein sacculus (Bhavsar and Brown, 2006). 
Penicillin binding proteins (PBPs), which form and cross-link glycan strands through their 
glycosyl transferase and transpeptidase activities, are responsible for the assembly of the 
peptidoglycan layer (Popham and Young, 2003). It has been suggested that some of the 
proteins (like MreB, MreC and MreD - encoded by the mreBCD operon), which affect cell 
morphology might position the peptidoglycan synthesis machinery (Formstone et al., 
2008).  
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van den Ent et al., (2006) showed that MreC is a dimeric protein whose structure may be 
important for its putative scaffolding function in the recruitment of PBPs and in organising 
cell wall synthesis. Consistently, the purified S. equi 4047 PrtM full length recombinant 
protein (Figure 5.6A) contained protein bands equivalent to the dimeric form of about 66 
kDA as well as the monomeric form of about 36 kDa on SDS-PAGE. The formation of 
dimers and oligomers has also been reported for B. subtilis PrsA, which is a PPIase 
implicated in the folding and stability of PBPs (Hyyrylainen, 2010). L. monocytogenes 
PrsA2, a PPIase as well, also forms dimers in solution (Alonzo et al., 2011). From the 
findings of this study, it is therefore very interesting to observe that the PrtM of S. equi 
4047 forms dimers (Figure 5.6A), has been implicated to have a role in the folding of PBPs 
(Section 3.14) and exhibits PPIase activity (Chapter 6).    
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6.0 Results of Enzyme Assays of S. equi PrtM (Full Length and Central 
Domain) Proteins 
 
 
6.1 Introduction 
 
Peptidylprolyl cis-trans isomerases are found in all organisms and are important for the 
folding of newly synthesized proteins (Bang et al., 2000; Gemmill et al., 2005). PPIases 
are believed to be chaperones or folding isomerases which induce conformational changes 
in mature proteins, post-translationally altering their structure and intermolecular 
interactions, thereby affecting their activity (Rutherford and Zuker, 1994). Proline 
isomerization has been proposed as a potential rate-limiting step in in vivo protein folding 
(Brandts et al., 1975; Lazar and Kolter, 1996). 
 
In this study, the enzyme activity of S. equi 4047 PrtM was investigated as a follow up to 
bioinformatics analysis (Figures 4.9a, 4.9b, 4.12 and 4.13), to confirm that it (PrtM) is a 
true PPIase. To do this, the standard protease-coupled assay for PPIase activity (Section 
2.8) was employed. The prolyl bond of the peptide substrates exist in an equillibrium of 
about 5-20% cis- and 80-95% trans-confomers (Hani et al., 1999).
 
Endopeptidases (like 
chymotrypsin, trypsin, or subtilisin)
 
split off the C-terminal pNA residue (chromophore) 
only in the trans population
 
of these proline-containing substrates such that in the presence
 
of sufficient amounts of protease in the reaction mixture, the
 
trans population is cleaved 
off rapidly, whereas the cis population
 
remains intact (Kofron et al., 1991; Kay 1996; and 
Hani et al., 1999). After this first rapid (burst) phase, the slow isomerization
 
reaction that 
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follows (second, slow phase) is accelerated by PPIases and results in the production of 
protease-cleavable
 
trans substrate (Kofron et al., 1991 and Kay 1996). 
 
It had previously been demonstrated that PPIases exhibit a range of substrate specificities 
and that the PPIase assay is generally assessed by isomer-specific proteolysis using 
tetrapeptide derivatives as peptide substrates (Harrison and Stein, 1990; Hani et al., 1999). 
Comparison of S. aureus PrsA with B. subtilis PrsA (both PPIases), indicates differences in 
the substrate preference. In this study three peptides (Pep1 - Suc-Ala-Phe-Pro-Phe-pNA; 
Pep2 - Suc-Ala-Lys-Pro-Phe-pNA; and Pep3 - Suc-Ala-Ala-Pro-Phe-pNA; Table 2.8) were 
used for the PPIase assay. Results (method in section 2.8.1 and results of analysis in 
Appendix I, Figures I1 and I2) revealed that Pep2 (having uncharged, polar and 
hydrophilic lysine before the proline residue) and Pep3 (having uncharged, non-polar 
alanine before the proline residue) were not substrates for PrtM. The enhanced rate of 
cleavage of varying concentrations of Pep1 in the presence of PrtM of S. equi 4047 
(method in section 2.8.1 and results shown in Figures 6.1 – 6.4, and Appendix I3) confirms 
that PrtM of S. equi 4047 is a bonafide PPIase. 
 
After the PPIase assay, the PMSF assay (method in Section 2.8.2, and results in Section 
6.3) was carried out to find out if chymotrypsin (a protease) had any significant effect on 
the recombinant proteins. Although the central domain recombinant protein showed a 
faster rate of reaction with Pep1, than the full length protein (Figures 6.1 to 6.4), because 
of the observed significant cleavage of the central domain recombinant protein by 
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chymotrypsin (Figure 6.5B), the enzyme kinetics (method in Section 2.8.3) of only PrtM 
full length recombinant protein was subsequently calculated (results in Section 6.4). 
 
PPIase activity of S. equi 4047 PrtM was expressed as kcat/KM (M
-1 
s
-1
) – method in Section 
2.8.3 and results in Section 6.4. 
 
 
 
 
6.2 Protease coupled PPIase assay results 
 
Results of the PPIase assay are shown in Figures 6.1 – 6.4.
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Figure 6.1: Protease coupled PPIase assay with 25 µM Pep1. The enhanced rate of cleavage of Pep1 in the presence of 25 µM of 
PrtM of S. equi 4047 is seen here. NEG = negative control, CYP = cyclophilin (positive control), FULL = full length recombinant 
protein. CENT = central domain recombinant protein.  
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Figure 6.2: Protease coupled PPIase assay with 37.5 µM Pep1. The enhanced rate of cleavage of Pep1 in the presence of 37.5 µM 
of PrtM of S. equi 4047 is seen here. NEG = negative control, CYP = cyclophilin (positive control), FULL = full length recombinant 
protein. CENT = central domain recombinant protein. 
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Figure 6.3: Protease coupled PPIase assay with 50 µM Pep1. The enhanced rate of cleavage of Pep1 in the presence of 50 µM of 
PrtM of S. equi 4047 is seen here. NEG = negative control, CYP = cyclophilin (positive control), FULL = full length recombinant 
protein. CENT = central domain recombinant protein. 
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Figure 6.4: Protease coupled PPIase assay with 75 µM Pep1. The enhanced rate of cleavage of Pep1 in the presence of  75 µM of 
PrtM of S. equi 4047 is seen here. NEG = negative control, CYP = cyclophilin (positive control), FULL = full length recombinant 
protein. CENT = central domain recombinant protein. 
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6.3 Phenylmethanesulfonyl flouride (PMSF) assay result 
The PMSF assay (method in Section 2.8.2) result is shown in figure 6.5 below. 
 
 A   i        ii      iii     iv      v     vi     vii    viii    ix     x    
 
 
B     i       ii      iii     iv     v      vi     vii    viii    ix    x 
 
 
Figure 6.5 PMSF assay result: Method in section 2.8.2. A = SDS-PAGE analysis of the reaction 
of full length recombinant protein. B = SDS-PAGE analysis of the reaction of the central domain 
recombinant protein. High molecular weight size standard (i). PMSF inactivated chymotrypsin was 
incubated with the recombinant protein in assay buffer (ii). Before the protease reaction was 
stopped with PMSF, recombinant protein was incubated with chymotrypsin in assay buffer for 20 s 
(iii), 2 min (iv) and 5 min (v). Only chymotrypsin and PMSF in reaction buffer, no recombinant 
protein (vi). Recombinant protein and PMSF only (vii).  Recombinant protein only (viii).  
Chymotrypsin only (ix). 
Da 
 
66000 
 
45000 
36000 
 
29000 
24000 
 
 
20100 
 
 
14200 
6500 
 
 
 
Da 
 
66000 
 
45000 
36000 
 
29000 
24000 
 
20100 
 
 
14200 
6500 
 
 
 
   
166 
 
6.4 Enzyme Kinetics 
 
Triplicates assays for a range (25 µM, 37.5 µM, 50 µM, and 75 µM) of Pep1 were used for 
the PPIase assays (Figures 6.1 to 6.4). However, kcat for the enzyme was calculated (see 
method in Section 2.8.3 and results in Figure 6.6) from average of triplicate PPIase assays 
of the full length recombinant protein with 37.5 µM Pep1 at pH 7.4.  
 
 
 
Figure 6.6 The First Order Rate Constant of PrtM of S. equi 4047: The kcat for S. equi 
4047 PrtM full length recombinant protein = 583.75 /s. KM for S. equi 4047 PrtM full 
length recombinant protein = 100 µM.  kcat/KM for S. equi 4047 PrtM full length 
recombinant protein = 5.84 x 10
6
/M/s.  
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6.5 Discussion 
 
Parvulins (a class of PPIases) of eukaryotic cells, including Human Pin1, specifically 
recognize proline residues that are preceded by phosphorylated serine or threonine residues 
(Yaffe et al., 1997; Hani et al., 1999; Sun et al., 2012).  For other parvulins, their substrate 
recognition is independent of phosphorylation, they therefore have a wider substrate range 
(Lu et al., 2007). S. aureus PrsA prefers a substrate having a negatively charged residue 
before the proline residue (preferred substrate Suc-AEPF-pNA); while B. subtilis PrsA has 
the highest catalytic activity towards Suc-AKPF-pNA peptide (Heikkinen et al., 2009). In 
this study, it has been proven that by the enhanced cleavage of the tetrapeptide (Pep1) by 
both the full length and central domain proteins in the protease coupled assay (Figures 6.1, 
6.2, 6.3, 6.4 and 6.6), S. equi 4047 PrtM is a bonafide PPIase with preference for a 
substrate (Suc-Ala-Phe-Pro-Phe-pNA) with an uncharged, hydrophobic residue 
(phenylalanine) before the proline residue.  
 
Interestingly, B. subtillis PrsA central domain has also been proven to have PPIase activity 
(Vitikainen et al., 2004). In this study, the chymotrypsin, used in the PPIase assay to 
cleave the trans form of Phe-Pro, did not have any significant effect on PrtM full-length 
recombinant protein during the assay (Figure 6.5A). The central parvulin-domain 
recombinant protein was highly sensitive to chymotrypsin (Figure 6.5B), yet the small 
fraction that remained uncleaved by chymotrypsin still showed higher rate of PPIase 
reaction than the full length (Figures 6.1 to 6.4). This implies that the PPIase activity of the 
central parvulin domain of PrtM of S. equi 4047 is very high, much higher than the activity 
of the full length recombinant protein. The enhanced cleavage of the central domain 
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(Figure 6.5B) also implies that the N and C terminal domains are required for the stability 
of the enzyme (PrtM). The N and C terminal domains may help the PrtM enzyme in 
resisting proteolytic cleavage in vivo, therefore may have roles to play in enhancing the 
contribution of PrtM PPIase activity to S. equi 4047 virulence. In future, it will be worth 
finding out the effect of other endopeptidases (like trypsin and subtilisin) on PrtM full 
length and central domain recombinant proteins, and looking at the possibility of carrying 
out similar protease coupled PPIase assay with another endopeptidase. 
 
Cyclophilin (which was used as a positive control) clearly displayed a higher reaction rate 
(Figures 6.1-6.4). This is consistent with findings of Vitikainen et al. (2004) where 
cyclophilin was found to have significantly up to 20-fold higher activity than L. 
monocytogenes PrsA2.  
 
PPIase activity of parvulins can be very low and may be difficult to measure (Rouviere and 
Gross, 1996; Uchida et al, 1999; Schmidpeter et al., 2011; Alonzo et al., 2012). This may 
be due to the observation that streptococcal parvulin homologues do not have a number of 
identical amino acids at essential positions of the functional parvulin domain (Drouault et 
al., 2002). To date PPIase activity has not been detected in S. pneumoniae PpmA, a 
member of the parvulin family (Hermans et al., 2006).  
  
PPIase activity of S. equi 4047 PrtM was expressed as kcat/KM (/M/s). The specificity 
constant kcat/KM for the cis to trans interconversion of the -Phe-Pro- bond Suc-Ala-Phe-
Pro-Phe-pNa is 5.84 x 10
6
 /M/s (Section 6.4). Table 6.1 shows the specificity constant of 
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some PPIases determined by the protease coupled assay. The PPIase of PrtM of S. equi 
4047 is shown at the end. 
Table 6.1: Specificity Constant of PPIases Determined by Protease Coupled Assay 
 
 
PPiase 
Family 
Protein  kcat/KM 
(/M/s) 
 
Substrate  Reference  
Cyclophilin S. pneumoniae 
S1rA 
1.1 x 10
7 Suc-Ala-Ala-Pro-Phe-
pNA 
Hermans et al., 
2006 
Cyclophilin S. pneumoniae 
S1rA 
4.0 x 10
6 
 
Suc-Ala-Phe-Pro-Phe-
pNA 
Hermans et al., 
2006 
FKBP Human FKBP12  3.6 x 10
6 
  
Suc-Ala-Leu-Pro-Phe- 
pNa   
Bossard et al., 
1994  
FKBP Plasmodium 
falciparum  
PfFKBP35 
1.7×10
4 
 
succinyl-Ala-Leu-Pro-
Phe- pNa 
Monaghan and 
Bell, 2005 
Cyclophilin Human 
cyclophilin A  
3.2 x 10
7
 
 Suc-Ala-Ala-Pro-Phe- 
pNa   
Harrison and 
Stein, 1990  
Cyclophilin Human 
cyclophilin A 
1.4 x 10
7 Suc-Ala-Phe-Pro-Phe- 
pNa 
Harrison and 
Stein, 1990 
FKBP Bovive FKBP 0.66 106 Suc-Ala-Leu-Pro-Phe-
pNA 
Kofron et al., 
1991 
Cyclophilin L. pneumophila 
Cyp 18 
4.6 x 10
6 
  
Suc-Ala-Ala-Pro-Phe- 
pNa   
Schmidt et al., 
1996 
 PTPA Rabbit PTPA 1.1 x 106 Suc-Ala-Ala-Pro-Lys-
pNA 
Jordens et al., 
2006 
Parvulin S. aureus PrsA 3.3 x 10
5 Suc-Ala-Glu-Pro-Phe-
pNA 
Heikkinen et 
al., 2009 
Parvulin E. coli Par10 1.35  x 10
7
 Suc-Ala-Leu-Pro-Phe-
pNA 
Uchida et al., 
1999 
Parvulin B. subtilis PrsA 1.4 x 10
6 
 
Suc-Ala-Lys-Pro-Phe- 
pNa 
Vitikainen et 
al, 2004 
Parvulin Saccharomyces 
cerevisiae Ptf1p 
4.2 x 10
6 Suc-Ala-Glu-Pro-Phe- 
pNa 
Hani et al, 
1999 
Parvulin Human Pin1 1.9 x 10
7 Ala-Ala-pSer-Pro-
Arg- pNa 
Yaffe et al., 
1997 
Parvulin E. coli SurA  3.4 x 10
4
 
 Suc-Ala-Leu-Pro-Phe- 
pNa   
Behrens et al., 
2001  
Parvulin S. equi 4047 PrtM 5.84 x 10
6
 Suc-Ala-Phe-Pro-Phe-
pNa 
This study 
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The protease coupled assay is a simple inexpensive assay. However, one disadvantage of 
the protease-coupled assay is that it requires a high concentration of helper proteases to 
obtain
 
the two-phase reaction (Hani et al, 1999). Therefore, this assay can only be used for 
proteins that are relatively resistant to the protease in assay, for the duration of the 
experiment and these parameters should be determined for each PPIase in combination 
with the substrate and the protease (Jordens et al., 2006). 
 
Although the central domain recombinant protein showed significant activity (see Figures 
6.1 – 6.4), its kinetic values were not calculated because of its high sensitivity to the 
protease (chymotrypsin) degradation (Figure 6.5B). The kinetic values for PrtM was 
therefore calculated only from values obtained from PPIase assay with the full length 
recombinant protein which just like the human eukaryotic parvulin homologue -hEPVH 
(Rulten et al., 1999), was more stable to attack by chymotrypsin for the duration of the 
experiment (Figure 6.5A). However, unlike hEPVH, PrtM was considerably resistant to 
chymotrypsin attack at the concentrations used in this study. 
 
 
Another limitation to the protease coupled assay is that only one direction of the reversible 
isomerisation is measured (cis → trans) and only about 10% of the cis content of the 
substrate is monitored, such that the signal-to-noise ratio can cause problems. This 
background can be reduced by dissolving the substrates in 0.48 M LiCl/trifluoroethanol 
(TFE), which shifts the cis content up to 70% (Kofron et al., 1991). Cost and time 
constraints were limiting factors in applying other techniques to determine PPIase activity. 
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However, the protease coupled method employed in this study gave reliable PPIase activity 
results for the full length recombinant protein. 
 
Since the central domain recombinant protein was highly sensitive toward chymotrypsin 
(Section 6.3), its PPIase activity and kinetic constants would be more accurately measured
 
by other techniques, like a protease-free assay. One such assay would be an uncoupled 
protease-free PPIase assay, which uses the standard tetrapeptide substrates of the 
proteolytically coupled test system such that differences in the UV/vis absorption spectra 
of cis and trans conformations of Suc-Ala-Xaa-Pro-Phe-(Y-) anilide (Xaa = Ala, Leu, Phe; 
Y = 4-nitro, 2,4-difluoro) are exploited to monitor the time course of the cis/trans 
isomerization subsequent to a solvent jump from LiCl/trifluoroethanol into aqueous 
solution (Janowski et al.,1997; Bang et al., 2001). 
 
Peptidylprolyl cis-trans isomerases facilitate the refolding of some denatured proteins in 
vitro (Schonbrunner et al., 1991).  PPIase activity of S. equi 4047 PrtM full length and 
central domain recombinant protein could also be measured by studying the refolding 
kinetics of denatured proteins like ribonuclease T1 (RNase T1). The refolding kinetics of 
RNase T1 and some other proline containing proteins has been monitored by electron 
microscopy, fluorescence or protolysis (Schonbrunner et al., 1991; Budiman et al., 2011; 
Golbik et al., 2005; Davis et al., 1989). The use of dynamic proton NMR spectroscopy in 
assaying PPIase activity (Jordens et al., 2006) is another method worth exploring. The 
inhibitory effect of juglone on PrtM of S. equi 4047 is also worth evaluating in future. 
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Distinct functional roles in PPIase activity have been observed for the central, N- and C- 
terminal domains of L. monocytogenes PrsA2 (Alonzo et al., 2012). The PrsA2 N+C 
mutant (lacking the central domain) was unable to catalyze cis → trans isomerization 
(Alonzo et al., 2012). In this study, the full length (PrtM) recombinant protein was proven 
to have PPIase activity; and PrtM central domain has also shown activity. It is hereby 
inferred that a PrtM N+C mutant (lacking the central domain) will be unable to catalyze 
the cis → trans isomerization of Pep1 (Suc-Ala-Phe-Pro-Phe-pNA). However, this is 
subject to confirmation by future work. 
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7.0 Results of Crystallisation of S. equi PrtM (Full Length and Central 
Domain)  
 
7.1 Introduction 
 
Knowing the 3-D structure of the PrtM of S. equi 4047 would be beneficial for the 
development of highly specific drug or peptide analogues which interfere with its activity, 
and thereby provide alternative therapeutic strategies to vaccination. Crystallisation 
screens of the purified PrtM full length and central domain recombinant proteins were 
carried out as described in Sections 2.7.1 – 2.7.4.  Initial crystallization screens were 
carried out using the Clear Strategy Screen (Molecular Dimensions: CSS1 -Appendix J1 
and CSS2-Appendix J2), the Hampton Screen 1 and 2 (Hampton Research: Appendix J3a 
and J3b), the PEG Ion Screen (Hampton Research: Appendix J4), the Newcastle Screen 
(Appendix J6a-J6d) and the Index Screen (Index Screen: Appendix J7a and J7b). 
 
PrtM microcrystals were obtained in 4-6 weeks from Newcastle Screen (condition number 
#93 which was made up of 0.8 M sodium formate, 10% PEG 8000, 10% {w/v} PEG 1000 
and 0.1 M imidazole pH8.0) and from Hampton Screen 2 (condition #24 which was made 
up of 0.05 M caesium chloride, 0.1 M MES pH 6.6 and 30% Jeffamine M.600). These 
screens were optimized (see datails of optimization conditions in Figures 7.0A and 7.1) by 
manual hanging drop method in 24-well XRL plates (Section 2.7.1).  Microcrystals were 
also harvested from Hampton Screen 1&2 (set up in Grenier 96-well plates as described in 
Section 2.7.2) under conditions described in Figure 7.2.  
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Microcystals were hervested (method in Section 2.7.3) in Northumbria University and 
transported in liquid nitrogen to University of York Structural Biology Laboratory (YSBL) 
where x-ray diffraction carried out as described in Section 2.7.4. Results of x-ray 
diffraction analysis of microcrystals by Dr Edward Taylor of YSBL are shown in section 
7.3. 
 
 
7.2 Crystals of S. equi PrtM (Full Length and Central Domain) 
Images of crystals are shown in Figures 7.0, 7.1 and 7.2. 
 
 
         A         B 
            
 
Figure 7.0: S. equi 4047 PrtM full length protein Crystals: A= crystals in optimized 
Newcastle Screen condition #93 (optimized to contain 0.8 M sodium formate, 20% PEG 
8000, 20% {w/v} PEG 1000 and 0.2 M imidazole pH8.0). In addition to poor diffraction 
pattern in Figure 7.4B, crystals (such as in Figure 7.0A) were also seen in mother liquor, 
analysis of these salts crystals was discontinued. B = crystals in Hampton Screen 2 
condition #24 (made up of 0.05 M caesium chloride, 0.1 M MES pH 6.6 and 30% 
Jeffamine M.600) 
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   A       B 
     
 
Figure 7.1: S. equi 4047 PrtM protein Crystals in Hampton Screen 2 condition #24 - 
optimized manually. A = Full length protein crystals. B = central domain protein crystals. 
Condition #24 of Hampton Screen 2 was optimized (to contain 0.01 M caesium chloride, 
0.1 M MES pH6.6 and 20% Jeffamine M.600) for both crystals in Figures 7.1A and 7.1B. 
  
 
 
     A      B 
        
 
Figure 7.2 PrtM protein crystals in Hampton Screen 1&2: A = S. equi 4047 PrtM full 
protein in well E1 of 96-well plate (containing 0.1 M sodium acetate and 0.1 M imidazole 
pH 6.5). B= S. equi 4047 PrtM central domain protein crystals in well B1 of 96-well plate 
(containing 1.4 M sodium acetate and 0.1 M sodium cacodylate pH 6.5). Both trays were 
set up via mosquito. Crystal did not yield good diffraction patterns. 
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7.3 Diffraction Analysis of Microcrystals 
 
A typical example of the image from good diffraction of a crystal is shown in Figure 7.3; 
while Figure 7.4 shows images of patterns obtained from diffraction analysis of crystals in 
this study. 
 
 
 
 
Figure 7.3: Sample x-ray diffraction pattern of a diffracting protein crystal (Courtesy 
Dr Edward Taylor, YSBL). 
 
 
 
Diffraction analysis (method in Section 2.7.4) by Dr E. Taylor of YSBL revealed that some 
of the microcrystals obtained were either salts (microcrystal in Figure 7.0A, diffraction 
pattern in Figure 7.4B) or may have deteriorated during transportation and/or freezing  (for  
example, microcrystal in Figure 7.1A, diffraction pattern in Figure 7.4A).  
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    A           B 
       
 
Figure 7.4 Images of non-diffracting/salt microcrystals: A = non-diffracting 
microcystal image, derived from S. equi 4047 PrtM full length recombinant protein 
microcrystal in Figure 7.0B: microcrystal may have fragmented during freezing or 
transportation, hence non-diffraction pattern. B = crystal from of S. equi 4047 PrtM full 
length recombinant protein microcrystal in Figure 7.0A showing a typical diffraction 
pattern of a salt crystal. 
 
 
 
Due to the fact that crystals were either salts or non-diffracting, it was pointless to send 
them for data collection at the Diamond Light Source synchrotron radiation facility 
(located at the Harwell Science and Innovation Campus in Oxfordshire) where the protein 
(PrtM) structure would have been solved. 
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7.4. Discussion 
Parvulins are ubiquitous globular protein domains of about 100 residues that fold into a   
four-stranded antiparallel β-sheet core made up  of four α-helices βα3βαβ2 (Fanghanel and 
Fischer, 2004). The structure of some parvulins can be found in the Protein Data Bank 
(Research Collaboratory for Structural Bioinformatics, 2012). The prototypical human 
Pin1 (hPin1) has its structure in the Protein Data Bank (Research Collaboratory for 
Structural Bioinformatics, 2012). That of B. subtilis PrsA is also in the Protein Data Bank 
(Research Collaboratory for Structural Bioinformatics, 2012).  Parvulins differ in the 
length and the composition of the S1-H1 loop between the strand β1 and the helix α1 
(Weininger et al., 2010).   
 
The preference, by Human Pin1-type parvulins, for substrates having a negatively charged 
residue (preferably a phosphorylated serine/threonine before the processed proline) is 
believed to be mediated by their loop which has a high number of positively charged 
residues (Ranganathan et al., 1997).    This type of loop is missing in Par14-type parvulins. 
In the SurA PPIase domain for example, the S1-H1 loop is made up of mainly hydrophobic 
residues (Bitto and McKay, 2002).  
 
The structure of the S. aureus PrsA resembles that of hPin1; and just like hPin1, the S. 
aureus PrsA prefers a substrate (preferred substrate is Suc-AEPF-pNA) with a negatively 
charged residue before the proline residue (Heikkinen et al., 2009).  However B. subtilis 
PrsA has the highest catalytic activity towards a substrate (preferred substrate Suc-AKPF-
pNA peptide.) with positively charged residue before the proline residue. E. coli Par10 has 
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a preference for nonpolar residues before and after the proline (Schmidpeter et al., 2011). 
Considering bioinformatics analysis (in which PrtM was predicted to have a central,  N- 
and C- terminal domains just like some other parvulins - Chapter 4),  and the fact that PrtM 
has been proven in this study (Chapter 6) to be a PPIase with a preference for a substrate 
(Suc-Ala-Phe-Pro-Phe-pNA) having an uncharged, bulky hydrophobic residue 
(phenylalanine) before and after the proline residue, it can be predicted that PrtM PPIase 
domain will have a typical parvulin structure (βα3βαβ2) with a four-stranded antiparallel 
β-sheet core and four α-helices. This prediction is further supported by the computer 
generated molecular model information (Figures 4.12 and 4.13) generated in Chapter 4. 
 
The growth of a visually perfect crystal does not always mean that the structure of the 
protein will be solvable by x-ray crystallography, because there is limited correlation 
between a microscopically identified crystal and its diffraction quality (Owen and Garman, 
2005). Difficulties were faced in attempts to solve the structure of the ParC55 breakage-
reunion domain of topoisomerase IV from Streptococcus pneumoniae as most of the 
crystals were twinned, non-diffracting or exhibited a high mosaic spread. Also the crystals, 
which were grown under conditions that favoured diffraction, were difficult to flash-freeze 
without losing their ability to diffract (Sohi et al., 2008). The best crystals obtained in this 
study were non-diffracting. 
 
Since attempts to solve the structure of PrtM of S. equi 4047 by x-ray crystallography were 
unsuccessful in this study, some other techniques may be explored to solve the crystal 
structure of PrtM in future. PrtM has been proven (Chapter 5 of this study) to form dimers 
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in solution. Bordetella pertussis Par27, was the first parvulin protein identified as forming 
dimers in solution (Hodak et al., 2008). In an attempt to solve the structure of B. pertussis 
Par27, its PPIase domains gave rise to diffuse scattering and could not be solved (Clantin 
et al., 2010). Crystal structures were obtained only for its N- and C- terminal domains, 
therefore the structure of Par27 was characterized by applying other techniques (template-
based modelling and small-angle scattering), in addition to X-ray crystallography (Clantin 
et al., 2010).   
 
 
NMR was used in solving the structure of human Par14 (Terada et al., 2001) and B. 
subtilis PrsA (Tossavainen et al., 2006). Solution-state NMR is worth exploring, in future 
attempts to solve the structure PrtM of S. equi 4047. However, solid-state NMR may be a 
better option because this technique offers the chance to solve the structures of proteins 
which are difficult to solve even at atomic resolution (Huber et al., 2012). 
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8.0 Results of Production and characterization of Complemented 
mutants (ΔPrtM123/pVA838 and ΔPrtM12/pVA838). 
 
 
8.1 Introduction 
 
In a pony infection study, Hamilton et al. (2006) discovered that 4 out of 4 ponies infected 
with the S. equi 4047 WT (wild-type) exhibited pathological signs of strangles compared 
with 0 out of 5 ponies infected with ΔPrtM (ΔprtM138-213, mutant with a deletion of 
nucleotides 138
 
to 213). In this study, the information generated so far confirm that PrtM is 
indeed a significant player in the virulence of S. equi 4047. The next task undertaken in 
this research was therefore to demonstrate the effect of complementing the mutant with 
plasmid (pVA838) to which the full (N, central and C terminal domains - 
ΔPrtM123/pVA838) or partial (N and central domains only - ΔPrtM12/pVA838) PrtM 
DNA sequence had been cloned. Demonstrating this effect in vivo is beyond the scope of 
this study. Therefore, complemented mutants (ΔPrtM123/pVA838 and ΔPrtM12/pVA838, 
Table 2.1) were produced, characterised and their proteomes compared (by comparative 
proteomic analysis as discussed in chapter 9) to those of controls (WT 4047/pVA838 and 
ΔPrtM/pVA838). Mukouhara et al. (2011) used the plasmid pVA838 to produce 
complemented mutants in their study of the contribution S. mutans lipoprotein PpiA to 
suppression of macrophage receptor with collagenous structure (MARCO) mediated 
phagocytosis by macrophages. 
 
To produce the complemented mutants in this study, the full length PrtM gene (PrtM123, 
including the 281 nt upstream – Chapter 4, Figure 4.1) as well as the gene segment 
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containing the N-terminus and the central domain (PrtM12, including the 281 nt upstream 
– Chapter 4, Figure 4.1) were cloned into plasmid pVA838 (results in Section 8.2) to make 
recombinant plasmids. This was followed by electrotransformation of the mutant (ΔPrtM) 
with the recombinant plasmids (Section 8.3) to give the complemented mutants 
(ΔPrtM123/pVA838 and ΔPrtM12/pVA838). Subsequently, control strains (S. equi 4047 
WT/pVA838 and ΔPrtM/pVA838) were produced (Section 8.4). 
 
Gram stain reaction (result in Section 8.5) was carried out to confirm the identity of 
complemented mutants and controls. Before carrying out growth curve experiment (results 
in Section 8.7), antibiotics broth dilution assay (method in Section 2.4.9 and results in 
Section 8.6) was done to ascertain the most suitable antibiotics concentration for further 
assays. This was necessitated by the fact that unlike the complemented mutants and 
ΔPrtM123/pVA838 (control), S. equi 4047 WT/pVA838 struggled to grow in THB 
containing >10 µg/mL of chloramphenicol. Including the wild type (S. equi 4047 WT) and 
mutant (ΔPtrtM) in the assay (results in Section 8.6) was to confirm that growth of 
complemented mutants and controls was as a result of newly acquired recombinant 
plasmid.  
 
A preliminary analysis of the protein profile of the complemented mutants and controls 
was achieved via SDS-PAGE analysis of protein extracts (results in Section 8.8). This was 
followed by immunogenic evaluation of proteins by Western blot analysis (results in 
Section 8.9). Comparison of the proteomes of the revertants and controls was carried out 
by 2D-E and HPLC/MS (results in Sections 8.10 - 8.13).  
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8.2 Result of construction of recombinant plasmids pVA838/PrtM123 and 
pVA838/PrtM12  
 
The full length gene (encoding PrtM123 containing the N-, C-terminal and central domains 
and including the 281 nucleotides - upstream sequence containing native promoter and 
ribosome binding site –Chapter 4, Figure 4.1) was amplified (PCR method in Section 2.5.4 
and results in Figure 8.0A) from S. equi 4047 genomic DNA (Section 3, Figure 3.2A) 
using primers Prtmequif and Prtm123equir (Section 2, Table 2.11). The gene section 
encoding PrtM12 (containing only the N-, terminal and central domains and including the 
281 nucleotides - upstream sequence containing native promoter and ribosome binding site 
– Chapter 4, Figure 4.1) was amplified (PCR method in Section 2.5.4, and results in Figure 
8.0B) from S. equi 4047 genomic DNA (Section 3, Figure 3.2A) using primers  Prtmequif 
and Prtm12equir (Section 2, Table 2.11). The PCR products were purified (method in 
Section 2.5.6) and along with pVA838, digested (method in Section 2.5.9 and results in 
Figure 8.1). After double digests, PrtM123 and PrtM12 were separately ligated (method in 
Section 2.5.10) into pVA838 to yield recombinant plasmids pVA838/PrtM123 and 
pVA838/PrtM12, respectively.  
 
E. coli (TOP10, Table 2.2) was transformed (method in Section 2.5.12) with the ligation.  
Transformants were selected on LBA (Table 2.3) plates containing 34 µg/ mL 
chloramphenicol (Table 2.4). Plasmid DNA (method in Section 2.5.13, and result in Figure 
8.2) was extracted from overnight LB/chloramphenicol cultures to check for recombinants. 
Plasmid DNA (method in Section 2.5.14) from midi-plasmid preparations of several of 
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each successful recombinant was then digested (method in Section 2.5.9, results of AGE 
analysis in Figure 8.3) to confirm that the recombinant plasmids contain DNA inserts. 
Having confirmed that recombinant plasmids were successfully produced, the next step 
was electrotransformation (Section 8.3) to produce complemented mutants. 
 
 
 
 A           B   
   i             ii    iii   iv                                        i        ii   iii  iv  
   
 
Figure 8.0: PCR products for production of complemented mutants: A= S. equi 4047 
PrtM upstream sequences + full length PrtM gene (1277 bp lanes Aii-Aiv) and B = S. equi 
4047 PrtM upstream sequences + N-terminal + Central Domain encoding sequences (1004 
bp lanes Bii-Biv). Lane i = molecular weight DNA size standard (200 – 10,000 bp).  
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Figure 8.1 Concentrations of ligation components of agarose gel purified digested 
(BamHI/SalI) fragments (i = pVA838 U1= 10 µg/uL), ΔPrtM123 gene (iii = U3 = 20.6 
µg/uL), ΔPrtM12 DNA sequence (v = U4 =21.1 µg/uL. Lane s = molecular weight DNA 
size standard (200 – 10,000 bp).  
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Figure 8.2 Result of screening of digestions (BamHI/SalI) of plasmid preparations 
from ligation transformants: A= pVA838/PrtM123 (with lanes ii, v, vii, ix, x, xi and xiii 
containing insert) left; and B= pVA838/PrtM12 (only lane v contains insert) right. Lane i = 
molecular weight DNA size standard (200 – 10,000 bp 
 
 
 
 
 
 
 
 
AGE images of midi-preparations of plasmid DNA from overnight cultures of E. coli 
TOP10 containing recombinant plasmids pVA838/PrtM123 and pVA838/PrtM12 are 
shown in Figure 8.3. 
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Figure 8.3 Image of diagnostic (XbaI) digest of plasmid DNA. XbaI cleaves pVA838 as 
well as PrtM123 and PrtM12 DNA. A = pVA838/PrtM123 (6477 bp and 4000 bp in lanes 
ii-v) left; and B = pVA838/PrtM12 (6364 bp and 3,900 bp in lanes ii - v) right. Lane i = 
molecular weight DNA size standard (200 – 10,000 bp).  
 
 
Concentration of midi-preparation plasmid DNA pVA838/PrtM123 (above image left, 
estimated via nanodrop) = 2670.7 ng/µL.  
 
Concentration of midi-preparation plasmid DNA pVA838/PrtM12 (above image, right, 
estimated via nanodrop) = 1390.1 ng/µL.  
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8.3 Results of production of complemented mutants  
 
Complemented mutants ΔPrtM123/pVA838 and ΔPrtM12/pVA838 were produced using 
competent ΔPrtM cells (Section 2.5.16) and recombinant plasmids (pVA838/PrtM123 and 
pVA838/PrtM12 respectively, from Section 8.2). Electrotransformation was carried out as 
described in Chapter 2 (Section 2.5.16). ΔPrtM123/pVA838 yielded 2.99 x 102 
transformants/µg of recombinant plasmid DNA (pVA838/PrtM123) after 24-48 h 
incubation. ΔPrtM12/pVA838 yielded 3.6 x 102/µg transformants/µg of recombinant 
plasmid DNA (pVA838/PrtM12) after 24-48 h incubation. Single colonies of 
transformants were inoculated into THB containing 5 µg/mL of chloramphenicol and 
incubated overnight at 37
o
C. Overnight broth cultures were stored in 1 mL aliquots as 
glycerol stocks (at a final concentration of 25% (v/v) glycerol) at -80
o
C. 
 
 
8.4 Result of Production of controls - S. equi 4047 WT/pVA838 and ΔPrtM /pVA838  
 
S. equi 4047 WT/pVA838, that is the wild type (S. equi 4047 WT) strain containing the 
plasmid (pVA838) without any other insert, was produced as a control that was 
chloramphenicol resistant just like the complemented mutants. ΔPrtM/pVA838, that is the 
mutant (S. equi 4047 ΔPrtM) strain containing the plasmid (pVA838) without any other 
insert, was also produced as a control that was chloramphenicol resistant just like the 
complemented mutants. Competent cells and electrotransformations were carried out 
(method in Section 2.5.16) using plasmid pVA838 (original concentration = 1317.7 
ng/µL). ΔPrtM/pVA838 yielded 3.4 x 102 transformant/µg of plasmid DNA (pVA838) 
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after 24-48 h incubation. S. equi 4047 WT/pVA838
 
yielded 0.24 x 10
2
 transformants/µg of 
plasmid DNA (pVA838) after 72-96 h incubation. Single colonies of transformants were 
inoculated into THB containing 5µg/mL chloramphenicol and incubated overnight at 37
o
C. 
Overnight broth cultures were stored in 1 mL aliquots as glycerol stocks (at a final 
concentration of 25% (v/v) glycerol) at -80
o
C. 
 
 
8.5 Result of Gram stain of complemented mutants. 
 
Gram stain (method in Section 2.4.3) of single colonies of transformants yielded Gram-
positive streptococci for the complemented mutants and controls. 
 
 
8.6 Result of Broth dilution antibiotics sensitivity 
 
Jacks et al. (2003) have reported that the minimum concentration at which 90% of β-
haemolytic streptococci (including S. equi) were inhibited by chloramphenicol was ≤4 
µg/mL. Broth dilution sensitivity to chloramphenicol was carried out as described in 
section 2.4.9. After 24 – 48 h incubation, uncomplemented S. equi 4047 WT and 
uncomplemented mutant (ΔPrtM) were unable to survive (culture media remained clear 
after incubation) in THB cultures containing 5.0 µg/mL, 6.0 µg/mL and 10.0 µg/mL of 
chloramphenicol. However, all the complemented strains (WT 4047/pVA838, 
ΔPrtM/pVA838, ΔPrtM-123/pVA838 and ΔPrtM-12/pVA838) were able to survive 
(survival indicated by turbid cultures after 24 – 48 h incubation) in broth cultures 
containing aforementioned (5.0 µg/mL, 6.0 µg/mL and 10.0 µg/mL) concentrations of 
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chloramphenicol. All strains (complemented and uncomplemented) survived and grew 
well (survival indicated by turbid cultures after 24 – 48 h incubation) in THB to which no 
chloramphenicol was added. These results indicate successful transformation with pVA838 
plasmids into all complemented strains which were resistant to chloramphenicol at the 
concentrations used. These results were also valuable in ascertaining the chloramphenicol 
concentrations in which the complemented mutants could resist and strive. 
 
 
 
8.7 Result of Growth curve  
Growth curve of three independent samples (a, b and c)  of the complemented mutants and 
control was generated (results in Figure 8.4 and Appendix K) as described in Section 2.4.6, 
with the addition of 5 µg/mL chloramphenicol to the THB growth medium.  
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Figure 8.4: Growth curve of complemented mutants and controls: Error bars show no 
significant difference in growth rate up to late exponential phase. 
 
 
 
 
 
 
 
8.8 SDS-PAGE of secreted protein extract and CFE of cell associated protein extract 
Figure 8.5 shows image of SDS-PAGE of protein extracts (method of obtaining CFE and 
secreted protein extract discussed in Sections 2.5.21 and 2.5.24 respectively) of the 
complemented mutants and controls. 
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 A  i   ii iii       iv      v       vi  B  vi    ii      iii      iv      v         i 
   
 
 C i   ii iii       iv      v       vi  D  vi       ii      iii      iv       v      i 
  
 
Figure 8.5: Results of SDS-PAGE of proteins from complemented mutants and 
controls. A&B = 15% (w/v) SDS-PAGE of CFE of cell associated protein extracts: from 
20 mL cultures (A) and ¼ dilutions of CFE from 20 mL cultures (B). C & D = 12% (w/v) 
SDS-PAGE of secreted protein extract: From 20 mL cultures (C) and ¼ dilutions from 20 
mL cultures (D). i = LMW, vi = HMW markers. ii = control S. equi 4047WT /pVA838, iii 
= ΔPrtm123/pVA838, iv = ΔPrtm12/pVA838, v = ΔPrtm/pVA838. 
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8.9 Western Blotting 
Figure 8.7 shows the immunogenic (Western blot method in Section 2.5.20) reactions of 
cell associated and secreted protein extracts of the complemented mutants and controls 
with high titre α-PPMA. 
 
 
 
     i       ii        iii      iv        v       vi     vii     viii      ix 
 
 
Figure 8.6: Western Blot with high titre α-PpmA: Cell associated protein extract (ii = 
control S. equi 4047 WT /pVA838, iii =ΔPrtm123/pVA838, iv = ΔPrtm12/pVA838,  v = 
control ΔPrtm/pVA838), secreted protein extract (vi = control S. equi 4047 WT /pVA838, 
vii =ΔPrtm123/pVA838, viii = ΔPrtm12/pVA838, ix = ΔPrtm/pVA838). i = protein 
standard (BIO-RAD, Appendix A13).  
 
 
 
 
 
 
 
 
Size 
(kDa) 
 
 
 
 
  75 
 
  50 
 
  
 
 
 
 
  25 
 
 
 
 
 
 
 
  10 
   
194 
 
8.10 2D-E of cell associated protein 
 
Representative images of the proteomes of the cell associated protein extracts of the 
complemented mutants and controls obtained after 2D-E (method in Sections 2.5.23, 
2.5.25 and 2.5.26) are shown in Figure 8.7. 
A      B 
   
pH 4              pH 7 pH 4              pH 7 
C      D 
  
Figure 8.7 Representative Images of 2D-E gels of cell associated protein extract: A = 
control, S. equi WT 4047/pVA838; B = control S. equi ΔPrtM/pVA838; C =  S. equi 
ΔPrtM123/pVA838; D =  S. equi ΔPrtM12/pVA838. 
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8.11 2D-E of Secreted Protein extracts 
 
Representative images of the proteomes of the secreted protein extracts of the 
complemented mutants and controls obtained after 2D-E (method in Sections 2.5.24, 
2.5.25 and 2.5.26) are shown in Figure 8.8. 
 
 A      B 
   
  
pH 4           pH 7 pH 4           pH 7 
 
C      D 
                 
Figure 8.8: Representative images of 2D-E gels of secreted protein extract: A = control 
S. equi 4047 WT/pVA838, B = control S. equi 4047 ΔPrtm/pVA838; C = complemented 
mutant - ΔPrtm123/pVA838, D = complemented mutant - ΔPrtm12/pVA838. 
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8.12 Results of Analysis of 2D-gel images by Progenesis SameSpots software  
 
The detection and quantification of spots was done using Progenesis SameSpots software 
(version 4.5, Nonlinear Dynamics, U.K.). Six Coomassie blue stained 2D-E gel images 
from each set were manually and automatically matched and aligned to six of a second set. 
The software (Progenesis SameSpots) automatically chose the most representative image 
from each matchset (Figures 8.9 and 8.10). Spots were prefiltered and manually checked, 
after which statistical analysis of variance criteria was applied (p<0.05 and fold>2.0). 
Spots showing significant and reproducible changes were automatically marked by the 
software (Appendix L).  
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 pH 4                    pH 7 
 
Figure 8.9: Matchset of S. equi 4047 WT/pVA838 versus ΔPrtm123/pVA838 – Cell 
associated protein extract. Shown here is the most representative image from the 
matchset of S. equi 4047 WT/pVA838 versus ΔPrtm123/pVA838 as determined by the 
software (Progenesis SameSpots). Circled spots with numbers indicate differentially 
expressed proteins. Expression levels were determined for each numbered spot as 
described in section 2.5.28. 
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 pH 4                    pH 7 
 
Figure 8.10: Matchset of S. equi 4047 WT/pVA838 versus ΔPrtm123/pVA838 –
Secreted protein extract. Shown here is the most representative image from the matchset 
of S. equi 4047 WT/pVA838 versus ΔPrtm123/pVA838 as determined by the software 
(Progenesis SameSpots). Circled spots with numbers indicate differentially expressed 
proteins. Expression levels were determined for each numbered spot as described in 
section 2.5.28. 
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8.13 Results of LC/MS and Mascot Search 
 
After analyzing the 2D-gels using Progenesis SameSpot software as described in Section 
2.5.28, the significant spots from the gels of each matchset (mass spectrometric results 
tabulated in Tables 8.1 – 8.12) were picked, digested (method in Section 2.5.29) and then 
processed by HPLC/MS (method in Section 2.5.30). Analysis of the results of HPLC/MS 
by Mascot search (method in Section 2.5.31) gave the identities of proteins from some of 
the significant spots (Tables 8.1 – 8.12). 
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Spot ID WT/ 
pVA838 
ΔPrtM123/p
VA838 
Protein ID via Mascot search of LC-MS result 
649 + ±  gi|154721499  translation elongation factor Tu [Bacillus subtilis subsp. spizizenii ATCC 6633] 
 
262 ± +  gi|2209305
59 
 bifunctional acetaldehyde-CoA/alcohol dehydrogenase [Clostridium 
cellulolyticum H10] 
 
913 + - NSH 
883 - + NSH 
Table 8.1: Mascot search results of spots from cell associated protein extract of S. equi 4047 WT/pVA838 vs 
ΔPrtM123/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The 
identities of some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at 
lower levels. NSH means no significant hit. 
 
 
 
 
. 
 
Spot ID WT/ 
pVA838 
ΔPrtM12/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
661 + -  gi|225870097 foldase protein PrsA [Streptococcus equi subsp. equi 4047] 
 
662 + -  gi|225870097 foldase protein PrsA [Streptococcus equi subsp. equi 4047]  
485 + -  gi|225870097 foldase protein PrsA [Streptococcus equi subsp. equi 4047]  
663 + ± NSH 
688 ± + NSH 
Table 8.2: Mascot search results of spots from cell associated protein extract of S. equi 4047 WT/pVA838 vs 
ΔPrtM12/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities 
of some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at lower levels. 
NSH means no significant hit. 
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Spot ID WT/ 
pVA838 
ΔPrtM/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
904 + - NSH 
913 + -  PYRH_OCEIH  Uridylate kinase OS=Oceanobacillus iheyensis (strain DSM 14371 /  
JCM 11309 / KCTC 3954 / HTE831) GN=pyrH PE=3 SV=1 
 
934 + - NSH 
906 + -  SYH_CLOA
B 
 Histidine--tRNA ligase OS=Clostridium acetobutylicum (strain ATCC 824 / 
 DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) GN=hisS PE=3 SV=1 
 
875 + -  RL6_DESAP  50S ribosomal protein L6 OS=Desulforudis audaxviator (strain MP104C)  
GN=rplF PE=3 SV=1 
 
221 + -  LEPA_MO
OTA 
 Elongation factor 4 OS=Moorella thermoacetica (strain ATCC 
39073) GN=lepA PE=3 SV=1 
 
1075 - + NSH 
883 - +  FPG_LACLC  Formamidopyrimidine-DNA glycosylase OS=Lactococcus lactis subsp.  
cremoris GN=mutM PE=1 SV=3 
 
891 - + NSH 
148 + ± NSH 
966 + ±  RPOA_O
ENOB 
 DNA-directed RNA polymerase subunit alpha OS=Oenococcus oeni (strain ATCC 
BAA-331 / PSU-1) GN=rpoA PE=3 SV=1 
 
879 ± + NSH 
Table 8.3: Mascot search results of spots from cell associated protein extract of S. equi 4047 WT/pVA838 vs 
ΔPrtM/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of 
some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at lower level of 
expression. NSH means no significant hit. 
 
 
 
 
 
 
 
 
 
 
   
202 
 
Spot ID ΔPrtM123
/ pVA838 
ΔPrtM12/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
322 + - NSH 
934 - + NSH 
688 - +  gi|307688041 outer membrane protein A [Clostridium cellulovorans 743B]  
262 + ±  FPG_LA
CLC 
 Formamidopyrimidine-DNA glycosylase OS=Lactococcus lactis subsp. 
cremoris GN=mutM PE=1 SV=3 
 
672 + ± NSH 
900 + ±  MGSA_EX
ISA 
 Methylglyoxal synthase OS=Exiguobacterium sp. (strain ATCC BAA-1283 / 
AT1b) GN=mgsA PE=3 SV=1 
 
Table 8.4: Mascot search results of spots from cell associated protein extract of S. equi 4047 ΔPrtM123/pVA838 vs 
ΔPrtM12/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities 
of some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at lower level of 
expression. NSH means no significant hit. 
 
 
 
 
Spot ID ΔPrtM123
/ pVA838 
ΔPrtM/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
556 + - NSH 
874 + -  2::gi|3518768
3 
 iron-containing superoxide dismutase [Bacillus 
cereus] 
 
198 + -  gi|35187683 iron-containing superoxide dismutase [Bacillus cereus]  
933 + ± NSH 
1075 ± + NSH 
1078 ± +  RBSA_BAC
AN 
 Ribose import ATP-binding protein RbsA OS=Bacillus anthracis GN=rbsA 
PE=3 SV=2 
 
899 ± +  GLNH_
BACSU 
 ABC transporter glutamine-binding protein glnH OS=Bacillus subtilis (strain 
168) GN=glnH PE=2 SV=1 
 
Table 8.5: Mascot search results of spots from cell associated protein extract of S. equi 4047 ΔPrtM123/pVA838 vs 
ΔPrtM/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of 
some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at lower level of 
expression. NSH means no significant hit. 
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Spot ID ΔPrtM12/ 
pVA838 
ΔPrtM/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
906 + -  gi|398814302  hypothetical protein PMI05_01395 [Brevibacillus sp. 
BC25] 
 
934 + - NSH 
112 + - NSH 
904 + - NSH 
913 + - NSH 
883 - + NSH 
672 - + NSH 
316 - + NSH 
613 + ± NSH 
1025 + ±  IF2_GE
OKA 
 Translation initiation factor IF-2 OS=Geobacillus kaustophilus (strain 
HTA426) GN=infB PE=3 SV=1 
 
Table 8.6: Mascot search results of spots from cell associated protein extract of S. equi 4047 ΔPrtM12/pVA838 vs 
ΔPrtM/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of 
some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at lower level of 
expression. NSH means no significant hit. 
 
 
 
 
 
Spot ID WT/ 
pVA838 
ΔPrtM123/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
346 + ± NSH 
976 ± + NSH 
747 ± +  gi|154721499 translation elongation factor Tu [Bacillus subtilis subsp. spizizenii ATCC 6633]  
Table 8.7: Mascot search results of spots from secreted protein extract of S. equi 4047 WT/pVA838 vs 
ΔPrtM123/pVA838: Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The 
identities of some of the proteins from significant spots are shown. + means present, - means absent, ± means present but at 
lower level of expression. NSH means no significant hit. 
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Spot ID WT/ 
pVA838 
ΔPrtM12/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
347 + -  gi|1547214
99 
 translation elongation factor Tu [Bacillus subtilis subsp. 
spizizenii ATCC 6633] 
 
1268 + - NSH 
50 + -  gi|60549198 60 kDa chaperonin [Listeria innocua] 
 
Table 8.8: Mascot search of spots from secreted protein extract of S. equi 4047 WT/pVA838 vs ΔPrtM12/pVA838: Results 
of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of some of the proteins from significant 
spots are shown. + means present, - means absent, ± means present but at lower level of expression. NSH means no significant hit. 
 
 
 
Spot ID WT/ 
pVA838 
ΔPrtM/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
355 + -  gi|392461346 elongation factor Tu domain-containing protein, partial  
[Pelosinus fermentans A12] 
 
346 + -  gi|154721499 translation elongation factor Tu [Bacillus subtilis subsp. spizizenii  
ATCC 6633] 
 
322 + -  gi|154721499 translation elongation factor Tu [Bacillus subtilis subsp. spizizenii  
ATCC 6633] 
 
1848 - + NSH 
662 + ± NSH 
656 ± +  gi|307688041  outer membrane protein A [Clostridium cellulovorans 743B]  
976 ± + NSH 
1518 ± + NSH 
1779 ± + 
GUAA_LIS
MO 
 GMP synthase [glutamine-hydrolyzing] OS=Listeria monocytogenes serovar 1/2a 
(strain ATCC BAA-679 / EGD-e) GN=guaA PE=3 SV=1 
 
Table 8.9: Mascot search results of spots from secreted protein extract of S. equi 4047 WT/pVA838 vs ΔPrtM/pVA838: 
Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of some of the proteins from 
significant spots are shown. + means present, - means absent, ± means present but at lower level of expression. NSH means no significant 
hit. 
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Spot ID ΔPrtM123
/ pVA838 
ΔPrtM12/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
415 + - NSH 
1460 + - NSH 
1037 + - NSH 
1891 + - NSH 
904 + ±  gi|307688041  outer membrane protein A [Clostridium cellulovorans 743B]  
1853 + ±  RL24_BACP2  50S ribosomal protein L24 OS=Bacillus pumilus (strain SAFR-032) GN=rplX PE=3 SV=1  
355 ± + NSH 
Table 8.10: Mascot search results of spots from secreted protein extract of S. equi 4047 ΔPrtM123/pVA838 vs ΔPrtM12/pVA838. 
Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of some of the proteins from 
significant spots are shown. + means present, - means absent, ± means present but at lower level of expression. NSH means no significant 
hit. 
 
Spot ID ΔPrtM123
/ pVA838 
ΔPrtM/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
1943 + - NSH 
1932 + - NSH 
1037 + - NSH 
1460 + - NSH 
415 + - NSH 
322 + -  gi|154721499  translation elongation factor Tu [Bacillus subtilis subsp. spizizenii ATCC 6633]  
1848 - + NSH 
1853 + ± NSH 
904 + ±  gi|307688041  outer membrane protein A [Clostridium cellulovorans 743B]  
656 ± + NSH 
1918 ± + NSH 
Table 8.11: Mascot search results of spots from secreted protein extract of S. equi 4047 ΔPrtM123/pVA838 vs ΔPrtM/pVA838: 
Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of some of the proteins from 
significant spots are shown. + means present, - means absent, ± means present but at lower level of expression. NSH means no significant 
hit. 
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Spot ID ΔPrtM12/ 
pVA838 
ΔPrtM/ 
pVA838 
Protein ID via Mascot search of LC-MS result 
355 + -  gi|392461
346 
 elongation factor Tu domain-containing protein, partial [Pelosinus 
fermentans A12] 
 
276 + - NSH 
377 + -  gi|6015080 RecName: Full=Elongation factor Tu; Short=EF-Tu  
1918 - + NSH 
351 + ±.  gi|154721
499 
 translation elongation factor Tu [Bacillus subtilis subsp. 
spizizenii ATCC 6633] 
 
656 ± + NSH 
976 ± +  ADDB_
BACCN 
 ATP-dependent helicase/deoxyribonuclease subunit B OS=Bacillus cereus 
subsp. cytotoxis (strain NVH 391-98) GN=addB PE=3 SV=1 
 
 
Table 8.12: Mascot search results of spots from secreted protein extract of S. equi 4047 ΔPrtM12/pVA838 vs ΔPrtM/pVA838:  
Results of Mascot search following 2D-E, Progenesis SameSpot analysis and HPLC/MS/MS. The identities of some of the 
proteins from significant spots are shown. + means present, - means absent, ± means present but at lower level of expression. 
NSH means no significant hit. 
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8.14  Discussion 
 
Complemented mutants (ΔPrtM123/pVA838 and ΔPrtM12/pVA838) were successfully 
produced as shown in Section 8.1-8.3. However, for meaningful comparison it was 
necessary to introduce the plasmid (pVA838) without any insert into S. equi 4047 WT and 
ΔPrtM. This way, the effect of the plasmid (pVA838) on the proteome of complemented 
mutants was nullified, so that only the effect of the introduction of the inserts (via the 
recombinant plasmids pVA838/PrtM123 and pVA838/PrtM12) was evaluated; and only 
proteins whose stability or localization were dependent on the full (N-terminal, Central and 
C-terminal domains) or partial (N-terminal and central domains) PrtM gene were isolated 
and evaluated from the cell as well as from the secreted proteins.  
 
The observation of very little difference between the proteomes of the WT (WT/pVA838) 
and complemented mutant (ΔPrtM123/pVA838) containing the full PrtM gene as shown in 
Tables 8.1 and 8.7, indicates that the full PrtM gene restored the secreted and cell 
associated protein profiles back to the mutant (ΔPrtM). However, a significant number of 
cell associated proteins (up to four) were present in the WT/pVA838 but absent in the 
complemented mutant (ΔPrtM12/pVA838) containing the partial PrtM gene; notable was 
the presence of the foldase protein PrSA from S. equi 4047 in the WT/pVA838 and its 
absence in ΔPrtM12/pVA838 (Table 8.2). Up to three proteins were detected in the 
secreted protein extract of WT/pVA838 but absent in the complemented mutant 
(ΔPrtM12/pVA838) containing the partial PrtM gene; notable was a 60 kDa chaperonin 
(Table 8.8). Ma et al. (2006) implicated peptidyl-prolyl isomerase (prsA) in the 
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pathogenesis of the Gram-positive Group A Streptococci. prsA has also been found to be 
an essential gene that assists in the secretion, folding, and sequestration of a number of 
secreted proteins in B. subtilis (Vitikainen et al., 2004; and  Tossavainen et al., 2006). In 
this study, PPIase activity was observed in the PrtM full length recombinant protein as well 
as in the PrtM central domain recombinant protein (Chapter 6).  The results of this Chapter 
(8) therefore suggest that the full PrtM gene is essential for optimal PPIase activity in vivo. 
 
The observation from a comparison of the proteomes of WT/pVA838 and 
ΔPrtM123/pVA838 suggest that the cell associated and secreted protein profiles of the 
mutant (S. equi 4047 ΔPrtM) can be largely restored by the introduction of the full PrtM 
gene. Also very importantly, the absence of significant proteins from the proteome of  
ΔPrtM12/pVA838, indicate that the C-terminal domain is very important and that the full 
PrtM gene is required for the stability and proper localization of some important proteins 
like PrsA from S. equi 4047 (in Table 8.2) and 60 kDa chaperonin (Table 8.8). 
 
Although the impact of the deletion of the C terminal domain has been evaluated in this 
study, another area worth exploring in future is the impact a deletion of the N + C terminal 
domains of PrtM would have on S. equi in vitro. Also worth re-evaluating in future are the 
spots that yielded no significant hits on mascot search.  
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9.0 General Discussion and Future work 
 
9.1 General Discussion 
 
Inspite of extensive efforts to prevent outbreaks, S. equi infection remains spread 
worldwide. Strangles continues to be a highly contagious and sometimes deadly equine 
disease and antibiotic use is not consensual since most treatment with antibiotics have  
proven to be ineffective after external signs of disease are noticed (Rodrigues et al., 2012). 
Commercially available vaccines have not been successful against strangles (Harrington et 
al., 2002; Waller and Jolley, 2007; Rodrigues et al., 2012). The need to identify effective 
and safe therapeutic targets for the prevention and treatment of strangles therefore fuelled, 
and has been satisfied, by this research. 
 
 
As discussed in chapter 1 (Section 1.7), although Hamilton et al. (2006) previously 
demonstrated that the putative lipoprotein maturase (PrtM) of S. equi 4047 is a major 
virulence factor, no functional role had been ascribed to it (PrtM). Hence this research set 
out to characterize PrtM and evaluate it as a potential therapeutic target.  
 
It was proven in Chapter 3 (Section 3.5 and 3.14) of this study, that PrtM is involved in S. 
equi 4047 adaptation to NaCl stress. The finding that PrtM exhibits PPIase activity 
(Chapter 6) and the increased sensitivity of the mutant (∆PrtM) to various antibiotics 
(Section 3.6) suggest that the PPIase activity of PrtM is associated with cell wall synthesis 
and protein remodelling. The findings of this study also suggest that PrtM may be involved 
in speeding up the folding or remodelling of one or more of the enzymes involved in 
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hyaluronic acid synthesis (Section 3.8). All these, coupled with the observation that the 
mutant (ΔPrtM) cross reacted with horse convalescent serum, S. equi pre-and post-
infection sera, as well as with αPPMA antisera (Chapter 3) suggest that PrtM is a good 
vaccine candidate. Further support for the fact that PrtM is a good therapeutic target, was 
the reaction of the secreted protein extract of only the WT but not the mutant (ΔPrtM) with 
anti-HPr (Chapter 3, Figure 3.14-B), suggesting that S. equi PrtM may be involved in the 
folding or remodelling of HPr kinase and that released HPr-1 of S. equi may have critical 
roles to play in HPr-1 mitogenic activity. 
 
Proteomics analysis of the WT, mutant - ΔPrtM (Chapter 3) and complemented mutants -
ΔPrtM123/pVA838 and ΔPrtM12/pVA838 (Chapter 8) establish that the protein profile of 
S. equi 4047 WT has some differences from that of the mutant (ΔPrtM). These results 
confirm that, the absence of parts or all of the full PrtM gene result in readily detectable 
changes in the proteome of S. equi 4047. Finding FNE and IdeE2, in the secreted protein 
extract of only S. equi 4047 WT and not the PrtM deficient-mutant (Chapter 3); and 
finding the foldase protein PrSA from S. equi 4047 in the WT/pVA838 but not in 
ΔPrtM12/pVA838 (Chapter 8) suggest proteolytic degradation of misfolded secreted 
proteins and indicates that PrtM may not only be linked to the folding of one specific 
substrate but could be a multisubtrate foldase.  Finding foldase protein PrSA from S. equi 
4047 in the WT/pVA838 (Chapter 8) is consistent with the identification of the same 
protein from the dimeric full length recombinant protein of S. equi 4047 WT (Chapter 5). 
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In B. subtilis, the PrsA lipoprotein (a parvulin foldase) is essential for protein secretion and 
viability (Kontinen and Sarvas, 1993). Interestingly, the predicted modular organization of 
S. equi 4047 PrtM (Figures 4.9a and 4.9b in Chapter 4) is similar to that of B. subtilis PrsA 
and L. monocytogenes PrsA2, with N- and C- terminal domains flanking a central domain 
which is predicted in this study (Chapter 4) to also be a PPIase domain.  
 
Most of the proteins that are translocated across the cytoplasmic membrane of Gram-
positive bacteria are delivered to the membrane–cell wall interface in an essentially 
unfolded form (Sarvas et al., 2004).  To gain functional activity, most proteins must be 
folded into defined three-dimensional structures (Hartl et al., 2011). After translocation, 
proteins rely on various folding factors (including PPIases and chaperones) to reach their 
native state (Foster et al., 2011). Chaperones are able to assist proteins folding into their 
native conformations by inhibiting improper protein-protein interactions and altering the 
activation energy necessary for proper folding (Ellis and van der Vies, 1991).  
 
As mentioned in chapter 1 (Section 1.5), PPIases are folding proteins that catalyze the rate 
limiting cis/trans isomerization of peptidylprolyl (Lazar and Kolter, 1996; Reffuveille et 
al., 2012). Protein folding can be assisted by both molecular chaperones and foldases 
(Zhang et al., 2013). It has been observed that some multidomain PPIases act as both 
PPIases and chaperones (Mok et al., 2006; Zhang et al., 2013). In addition to PPIase 
activity, prokaryotic parvulins also exhibit chaperone-like activities (He et al., 2004). It is 
not surprising therefore, that in addition to PPIase activity that was observed in the full 
length and central domain recombinant proteins of S. equi 4047 WT (Chapter 7), a 60 kDa 
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chaperone was also detected in the S. equi 4047 WT (WT/pVA838 in Chapter 8), 
indicating the co-existence of PPIase and chaperone activities in PrtM. Finding a 60 kDa 
chaperone as well as the foldase protein PrSA from S. equi 4047 in the WT/pVA838 but 
not in ΔPrtM12/pVA838 (Chapter 8 of this study) is also suggestive that the C-terminal 
domain is essential for the PPIase-Chaperonin function of the PrtM of S. equi 4047. It is 
predicted that the central domain of S. equi is made up of parvulin-like four-stranded 
antiparallel β-sheet core and four α-helices βα3βαβ2 (Chapters 4 and 7). Due to the fact that 
PPIases play important roles in a wide range of physiological processes, the design of selective 
and potent inhibitors against PPIases (to potentially treat viral, parasitic, fungal and bacterial 
infections) has been widely researched as is quite promising (Dugave, 2006).  
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9.2 Future work. 
 
As discussed in Section 3.14, the possible involvement of the PPIase activity of the PrtM 
of S. equi 4047 (Chapter 6) in speeding up the folding or remodeling of one or more of the 
enzymes involved in hyaluronic acid synthesis is worth exploring in future because S. equi 
4047 WT produced more hyaluronic acid than the PrtM-deficient mutant strain (Chapter 3, 
Sections 3.9). 
 
The reaction of the secreted protein extract of only the WT but not the mutant (ΔPrtM) 
with anti-HPr (Chapter 3, Sections 3.11 and 3.14), is suggestive that S. equi PrtM PPIase 
activity (Chapter 6)  may be involved in the folding or remodeling of HPr kinase. This 
absence of the upper band (Chapter 3, Section 3.11, Figure 3.14-B) in the secreted protein 
extract of the PrtM deficient mutant also indicates that released HPr-1 of S. equi may have 
critical roles to play in HPr-1 mitogenic activity. Therefore, as extensively discussed in 
Section 3.14, the relationship of PrtM to HPr kinase remodeling and HPr-1 mitogenic 
activity is worth further evaluation. 
 
The enzyme kinetics of the full length recombinant protein of S. equi 4047 was 
successfully calculated in this study (Chapter 6, Section 6.4). The central domain 
recombinant protein was highly sensitive toward chymotrypsin (Chapter 6, Section 6.3). It 
was therefore suggested (Chapter 6, Section 6.5) that other proteases (like trypsin or 
subtilisin) or a protease-free assay could be used to accurately measure the kinetic 
constants of the central domain recombinant protein fraction of S. equi 4047. In addition to 
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this, the benefit of evaluating PPIase activity via other techniques (like studying the 
refolding kinetics of denatured proteins like ribonuclease T1 and dynamic proton NMR 
spectroscopy) was also discussed in Section 6.5.  
 
The inference (in Chapter 6, Section 6.5) that a PrtM N+C mutant (lacking the central 
domain) will be unable to catalyze the cis → trans isomerization of Pep1 (Suc-Ala-Phe-
Pro-Phe-pNa) is subject to confirmation in future work. In addition to this, as discussed in 
Chapter 8 (Section 8.14), it would be valuable to evaluate the proteome of a complemented 
mutant lacking the N+C terminal domains; and also re-evaluate the spots that yielded no 
significant hits on mascot search. 
 
As mentioned (Chapter 7, Section 7.4), the growth of a visually perfect crystal does not 
always mean that the protein’s structure will be solved by x-ray crystallography, due to 
limited correlation between a microscopically beautiful crystal and its diffraction quality 
(Owen and Garman, 2005). Despite success is producing crystals under different 
conditions (Chapter 7, Section 7.2), attempts to solve the structure of PrtM of  S. equi 4047 
by x-ray crystallography were unsuccessful (Chapter 7, Sections 7.3 and 7.4). The 
knowledge of the structure and catalytic mechanism of PrsA-PPIase is necessary for 
successful design of efficient and selective enzyme inhibitors which could be used as 
antibacterial agents against Gram-positive bacteria (Heikkinen et al., 2009). In addition to 
the proven PPIase activity of PrtM (Chapter 6), knowing its (PrtM) crystal structure would 
enhance the selection and design of inhibitors. It is predicted that the central PPIase 
domain of S. equi contains four-stranded antiparallel β-sheet core and four α-helices, 
   
215 
 
βα3βαβ2 (Chapter 4 and Chapter 7). Therefore, the possible use of other techniques (like 
template-based modelling and small-angle scattering in addition to X-ray crystallography 
and solid state NMR) in solving the structure of PrtM in future was suggested and 
discussed in Section 7.4.  
 
 
 
9.3 Conclusion 
 
The involvement of PrtM of S. equi 4047 in adaptation to NaCl stress (Section 3.5 and 
3.14); its involvement in regulating sensitivity to antibiotics and thereby cell wall synthesis 
and protein remodeling (Section 3.6); its possible roles in speeding up the synthesis of 
hyaluronic acid (Section 3.8) and in the folding or remodeling of HPr Kinase (Section 
3.11); its parvulin gene organisation elucidated by bioinformatics analysis (Chapter 4), the 
cross reactions of the mutant (ΔPrtM) with a number of antisera (Section 3.11), the 
observation that PrtM may be a multisubstrate foldase due to the detectable and significant 
differences in the proteomes of the WT, mutant (Chapter 3) and complemented mutants 
(Chapter 8); the dimeric protein formed by the full length recombinant protein fraction of 
S. equi 4047 WT (Chapter 5); and the PPIase-Chaperonine activities of PrtM (Chapters 6 
and 8) all validate PrtM of S. equi 4047 as a viable and novel therapeutic candidate which 
pharmaceutical industries should extensively evaluate for the prevention and treatment of 
strangles. 
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Appendices 
 
Appendix A 
 
A1: Chemicals, Media, Enzymes, and Reagents 
 
Acros 
Adenine 
p-aminobenzoate 
Ammonia solution 
Cysteine 
3, 5-Dinitrosalicylic acid (DNSA) 
Disodium phosphate 
Guanine 
Iodoacetamide 
Monosodium phosphate 
2,7 – naphthalene-disulfonic acid solution 
Nicotimamide 
Sodium hyaluronate 
Uracil 
 
Aldrich 
Pantothenate 
 
Bio-Rad  Laboratories 
Coomasie G250 
Nitrocellulose membrane 
 
British Drugs Hourse (Merck) 
Alcian Blue 8GX 
Biotin 
Folic acid 
 
Fisher BioReagents 
Acrylamide/Bisacrylamide 37.5:1, 40 % solution 
Brilliant blue G 250 
Coomassie Blue R-250 
Lysozyme 
Methanol 
Phenol 
 
Fisher Chemicals 
Acetic acid, glacial 
Acetone 
Acetonitrile 
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Ammonium bicarbonate 
Ammonium sulphate 
Dimethyl sulfoxide 
Ethanol 
Formaldehyde 
Formic acid 
Glutaraldehyde 
Phosphoric acid 
Sodium carbonate 
Sodium tetraborate 
Trichloroacetic acid (TCA) 
Trisodium citrate 
 
Fluka Analytical Chemicals 
Carbol-Fichsin solution according to Ziehl-Heelsen 
 
Melford Laboratories Ltd 
Agarose (High gel strength) 
Dithiothreitol 
Glycine 
Sodium dodecylsulphate 
Tris [Hydroxymethyl] aminomethane (Tris-HCl) 
 
Oxoid 
THA 
THB 
 
Promega 
Trypsin Gold 
 
Riedel-deHaen 
Hydrochloric acid 
Sulfuric acid 
 
Sigma 
Albumin 
Ammonium sulphate 
Angiotensin I 
APS 
Bovine serum albumin, Fraction V (BSA) 
Bromophenol blue 
Carbonic anhydrase 
CHAPS 
Citric acid 
Dipotassium phosphate 
Ethidium bromide 
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Ethylene diamine tetraacetic acid, disodium salt (EDTA) 
Ferrous sulphate 
β-Galactosidase 
Glucose 
Glucuronic acid 
L-glutamic dehydrogenase 
Glyceraldehydes-3-phosphate dehydrogenase 
Glycerol 
Isopropanol (2- propanol) 
α- lactalbumin 
Manganous sulphate 
Magnesium chloride 
β-mercaptoethanol 
Ovalbumin 
Phosporylase b 
Ponceau S solution 
Potassium Chloride 
Potassium phosphate monobasic 
Riboflavin 
Silver nitrate 
Sodium acetate 
Sodium chloride 
Sodium hydroxide 
Sodium sulphite 
Sucrose 
TEMED 
Thiamine 
Trypsinogen 
Urea 
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A2: Protein Size Markers 
SigmaMarker™: 
 
 
Proteins  M.W. (Da) High Low 
Myosin, rabbit muscle 
β-Galactosidase, E. coli  
Phosphorylase b, rabbit muscle  
Fructose-6-phosphate Kinase, rabbit muscle 
Albumin, bovine serum   
Glutamic Dehydrogenase, bovine liver 
Ovalbumin, chicken egg  
Glyceraldehydes-3-phosphate Dehydrogenase, rabbit 
muscle 
Carbonic Anhydrase, bovine erythrocytes 
Trypsinogen, bovine pancreas  
Trypsin Inhibitor, soybean  
α-Lactalbumin, bovine milk  
Aprotinin, bovine lung  
205000 
116000 
97000 
84000  
66000 
55000 
45000  
36000  
 
29000 
24000  
20000  
14200  
6500  
X 
X 
X 
X 
X  
X 
X 
X  
 
 
 
 
 
 
 
 
 
 
X 
 
X 
X 
 
X 
X 
X 
X 
X 
Table A1: Molecular weight distribution in Sigma Markers. 
Lyophilized standards were stored at 2-8º.Lyophilized standards were reconstituted with 100 μl of 18.2 
MΩ/cm H2O to give a final concentration of 2.0-3.5 mg/ mL. The reconstituted standard was aliquoted into 
4μl amounts and stored at 20ºC. Before use, 8μl of SDS-PAGE loading buffer (appendix D6) was mixed with 
the thawed standard and boiled for 3mins. 
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Figure A1: Molecular weight distribution in Sigma Markers (Wide range molecular 
weight, low molecular weight (LMW), and high molecular weight (HMW). Adapted 
from:http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=M3913|SIGMA&N5=S
EARCH_CONCAT_PNO|BRAND_KEY&F=SPEC&lang=en_US> 
(assessed on 20
th
 August, 2009). 
 
 
 
A3  Prolex
TM
 Steptococcal Grouping Latex Kit – PRO-LAB DIAGNOSTICS 
The Prolex
TM
 Steptococcal Grouping Latex Kit was used to serologically carry out 
Lancefield grouping of the S equi strains (wild type and mutant).  
 
 
 
A3.1 Prolex
TM
 Steptococcal Grouping Latex Kit Components 
Blue Latex Suspension Group A  
Blue Latex Suspension Group B  
Blue Latex Suspension Group C  
Blue Latex Suspension Group D  
Blue Latex Suspension Group F  
Blue Latex Suspension Group G  
Extraction Reagent 1  
Extraction Reagent 2  
Extraction Reagent 3  
Polyvalent Positive Control  
Mixing Sticks  
Latex Test Cards  
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A3.2 Streptococcal Grouping Test Protocol: 
 All components were brought to room temperature (22-28
°
C) prior to use. One 
reaction well was labeled for each specimen and one drop of extraction reagent 1 was 
added to each well. Selected 2-4 colonies with a disposable loop and suspended them in 
the extraction reagent 1 until it became turbid. Added one drop of extraction reagent 2 to 
each well and mixed reaction by rocking the plate for 5-10 seconds. Added a few drops of 
extraction reagent 3 to each well and mixed the reaction again for 5 – 10 seconds. 
Dispensed one drop of each blue latex suspension onto separate circles on the tset card. 
With a Pasteur pipette, placed one drop of each extract beside each drop of latex 
suspension. Mixed the blue latex and extract with wooden sticks and rocked the card 
slowly for 60 seconds. Observed for agglutination. 
 
 
A4 Foetal Calf Serum (FCS) 
From EU approved origin 
GIBCO 2012-10 
Ref: 10106 -151 
Lot #: 41F5674F 
Invitrogen Life Technology 
 
Stored aliquots of 10 mL X 10 at -20
 o
C. 
 
 
 
A5 Nzomics-biocatalysis Hyaluronan Test Kit (Version 1.01) 
 
 
 
A6 QIAGEN DNeasy DNA Extraction Kit:  
Blood and Tissue Kit 50D (Catalogue # 69504) 
 
 
 
A6.1 Enzymatic Lysis Buffer from kit (Appendix A6): 20mg/ mL lysozyme 
1 20mM Tris.Cl, pH 8.0 
2 2mM sodium EDTA 
3 1.2% Triton® X-100 
4 20mg/ mL lysozyme; add lysozyme just before use 
 
Components 1, 2 and 3 were mixed prior to lysis. However, lysozyme was added only just 
before extraction was actually carried out. To get 20mg/ mL lysozyme: 
  Weigh 19.3mg lysozyme 
   19.3/20 =0,965 
Therefore, added 965μl of premixed lysis buffer to 19.3mg lysozyme. This give 20mg/ mL 
lysozyme. 
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A.6.2 Buffers (as supplied in kit -appendix A6) 
Buffer AL (216  mL)    216  mL Lysis Buffer  
Buffer ATL (200  mL)    200  mL Tissue Lysis Buffer  
Buffer AW1 (Concentrate, 242 mL)  242  mL Wash Buffer (1) Concentrate  
Buffer AW2 (Concentrate, 324 mL) 324  mL Wash Buffer (2) Concentrate  
Buffer AE (240  mL)    240  mL Elution Buff 
 
 
 
A7: SYBR-safe DNA Gel Stain (Invitrogen) 
10,000 X concentrate in DMSO 
S33102, Lot # 410108 
Invitrogen molecular Probes, Eugene, Oregon, U.S.A, 541 465 8300. 
probes.invitrogen.com 
 
 
 
A8: Hyperladder™ 1 (Bioline) 
Lot # H1-105B 
 
 
Figure A2: Bioline Hyperladder banding pattern 5μl on 1% agarose. 
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A9: PCR Conmponents (Novagen) 
dNTPs    2mM 
KOD Hot Start polymerase  1 u/μ 
MgSO4   25mM 
Buffer    10X 
 
 
 
 
A11 Blood agar base (Merck, #VM402286 515; www.merck.de) 
 
 
 
 
A12 NZYGelpure
TM
 Kit  (Prozomix) 
 http://www.prozomix.com/products/view?product=814&currency=33 
 
  
 
 
A13 Protein Standard: Bio-Rad Precision Plus Protein™ All Blue Standard: for 
Western blotting 
 
 
Figure A3: Bio-Rad Precision Plus Protein™ All Blue Standard Migration distance 
 
 
 
 
A14: BCIP/NBT Substrate Kit (substrate for alkaline phosphatase) – ZYMED 
Laboratories 
 Kit Contents: 
A- concentrated BCIP/buffer solution (10X), 100 mL 
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B- concentrated NBT solution (10X), 100 mL 
 
store at 2-8
o
C. 
 
BCIP is an insoluble substrate for alkaline phosphatase which is good for staining 
blots. Added 1  mL of each reagent to 8 mL of distilled water immediately before 
use. 
 
 
 
A15 IPG Buffer (GE Healthcare) 
Selected and used an IPG buffer with the same pH interval as the immobiline DryStrip to 
be rehydrated. 
 
 
A16 Immobiline™ DryStrip Cover Fluid – GE Lifesciences 
 
 
A17   Map of pET-28a vector (Novagen) 
 
 
FigureA4: Map of pET-28a vector (Novagen) 
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A18 Map pf pVA838 (Macrina et al., 1983) 
 
 
FigureA5: Map of pVA838 (Macrina et al., 1983, p.146) 
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Appendix B 
 
 
B1: Autoclaving 
Autoclave sterilisation was achieved using a benchtop Prestige® Medical 2100 Classic 
autoclave at 121 °C, 32 lb/inch2 pressure for 20 min. 
 
 
 
B2: pH meter 
All adjustments to the pH of solutions and media were achieved using a Jenway Ion Meter 
3340 calibrated with buffers at pH 4.0, 7.0, and 9.2. 
 
 
 
B3: UV-Visible Spectrophotometer (Spectronic Unicam Heλios-α, Thermos Electron 
Corporation). 
 
 
 
B4: Incubators 
Growth of bacteria was performed in static GallenKamp incubators  
 
 
 
B5: Centrifugation 
Centrifugation of volumes below 1.5 mL was achieved using a small Sigma 1-15 bench top 
micro-centrifuge. Volumes above 1.5 mL were centrifuged in a large Sigma 3K18C 
refrigerated bench top centrifuge, using appropriate rotors and inserts. 
 
 
 
B6: Sonication 
Cell lysis was carried out using a MSE Soniprep 150 ultra-sonication machine. 
 
 
 
B7: Microtitre plate reader 
Growth curve assays were measured from samples in 96-well plate at OD570 using EL 808 
Ultra Microplate Reader, Bio-Tek Instrument Inc. 
 
 
 
B8: SDS-PAGE gel kit 
Electrophoresis of proteins was carried out with Bio-Rad Mini-PROTEAN® 3 Cell kit 
powered by an E-C 570-90 E-C apparatus corporation power pack. 
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B9: Gel documentation 
Visualisation of SDS-PAGE gels was done with Bio-Rad Gel Doc 2000 system or a Bio-
Rad GS-710 densitometer system and Quantity One™ software. Hard copies of the gel 
picture were produced using a MitsubishiVideo Copy Processor (Model P91), with 
Mitsubishi thermal paper (K65HM-CE /High density type, 110 mm x 21 m). 
 
 
 
B10: Immobiline DryStrip Kit 
This kit is designed for running the first dimension of 2-D electrophoresis using precast 
Immobiline™ DryStrip gels. 
 
 
 
B11a: Protean II XL 2-D cells and accessories for 2D-E: BioRad 
 
 
B11b: Protean Plus Dodeca Cell and accessories for 2D-E: Biorad 
 
 
 
B12: Centrifugal evaporator 
Extraction of protein digests were dried using CHRIST centrifugal evaporator RVC 2- 
18 
 
 
B13: Progenesis SameSpot™ software (a product of Nonlinear Dynamics) 
 
 
 
B14: Nitrocellulose membrane (Bio-Rad) 
 
 
 
B15: 1D-Electrophoresis Apparatus (Mini-PROTEAN® 3 Cell Assembly) - BioRad 
 
 
 
B16  (Immobiline DryStrip Gels - GE Healthcare) 
 
 
 
B17 Immobiline™ DryStrip Reswelling Trays (GE Healthcare) 
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B18 Multiphor™ II Electrophoresis System and Unit (GE Lifesciences) 
 
 
B19 IEF Electrode Strips (paper): GE Lifesciences 
 
 
 
B21  Bio-Rad GS-710 image densitometer 
 
 
 
B22: Javac Laboratory  High Vacuum pump (D00061 Wombat JL – 2.5 double stage) 
 
 
 
B23: Freeze Drier (Alpha-12 LD plus Christ Freeze Drier) 
 
 
 
B24 HPLC Machine (Ultimate 3000 -  Dionex):  
 
 
 
B25 Mass Spectrometer HCTultra - Bruker Daltonics. A High          Capacity Trap 
(HCT) ultra spectrophotometer for ion trap analysis. 
 
 
 
B26: 384-well microarray plate – Fisher Scientific 
 
 
 
B27 NanoDrop Spectophotometer (ND-1000) 
 Supplied by LabTech International,  
 
 
 
B28 Stuart Rotator (SB2) 
        bibby-scientific  
 
 
 
B29 UV/Visible spectrophotometer  
        Pharmacia Biotech, Ultrospec 2000. 
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B30 Western blotting Semi-Dry Transfer Assembly  
 
Figure B1: Bio-Rad Semi-Dry Trans-Blot Cell Assembly 
 
 
 
B31 Electroporator – Gene Pulser ( Bio-Rad, U.K.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trans-Blot SD Semi Dry Cell: 
1. Safety lid 
2. Cathode assembly with latches 
3. 2 layers soaked filter papers 
4. Gel 
5. Nitrocellulose membrane 
6. 2 layers soaked filter papers 
7. Spring-loaded platinum anode 
platform, mounted on four guide 
posts 
8. power cables 
9. base 
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Appendix C: 2D-E gel images and Spot IDs by PDQuest Software 
 
Appendix C1:  Images of 2D-E gels (pH 4-7) 
 
   
 
   
 
 
   
Figure C1: Images of 2D-E gels of Cell Associated Protein Extract of S. equi 4047 WT at pH 4 
– 7. 
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Figure C2: Gel Image of 2D-E of Cell Associated Protein Extract of S. equi 4047 
ΔPrtM at pH 4-7 
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Figure C3 Gel Image from 2D-E of Secreted Protein Extract of S. equi 4047 WT at 
pH 4 – 7. 
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Figure C4 Gel Image from 2D-E of Secreted Protein Extract of S. equi 4047 ΔPrtM at 
pH 4-7 
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Appendix C2: Spot IDs for 2D-E gel images by PDQuest Software 
 
Spot IDs for 2D-E gel images of S. equi WT 4047 WT and Mutant ( PrtM) Secreted 
Protein Extract. 
 
Figure C5: Master image with spot IDs for 2D-E gel images of S. equi 4047 WT 
Secreted Protein Extract 
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Figure C6: Master image with spot IDs for 2D-E gel images of S. equi 4047 Mutant (
PrtM) Secreted Protein Extract 
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Appendix D: Identities of all proteins after MS/MS 
 
 
Table D1 List of  Protein from  S. equi 4047 WT  and Mutant ( PrtM): Cell 
Associated Protein Extract 
 
Spot # 
Spot 
# Protein name Protein code 
Comment  
on 
expression 
Comment on 
level of hit 
Protein 
code for 
best match 
hit 
WT3101 
PrtM5
101 
 50S ribosomal protein L21 
[Streptococcus pyogenes M1 GAS]  gi|15674860 
same in 
WT and 
mutant   
WT3101 
PrtM5
101 
 30S ribosomal protein S11 
[Streptococcus pyogenes M1 GAS]  gi|15674312 
same in 
WT and 
mutant   
WT3101 
PrtM5
101 
 50S ribosomal protein L14 
[Streptococcus pyogenes M1 GAS]  gi|15674297 
same in 
WT and 
mutant   
WT3101 
PrtM5
101 
 heat-stable phosphocarrier protein, HPr 
[Streptococcus mutans, Ingbritt, 
Peptide, 86 aa]  gi|546175 
same in 
WT and 
mutant   
WT3101 
PrtM5
101 
 hypothetical protein SAG1694 
[Streptococcus agalactiae 2603V/R]  gi|22537834 
same in 
WT and 
mutant   
WT3101 
PrtM5
101 
 general stress protein [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565]  gi|195977498 
same in 
WT and 
mutant 
First choice 
 hit is S. equi 
WT7302 
PrtM8
302  apolipoprotein A-I precursor gi|162678 
up in 
WT/down 
in mutant   
WT7302 
PrtM8
302 
 RecName: Full=Apolipoprotein A-I; 
Short=Apo-AI; Short=ApoA-I; Flags: 
Precursor gi|3915607 
up in 
WT/down 
in mutant   
WT4001 
PrtM6
002 
 30S ribosomal protein S6 
[Streptococcus equi subsp. 
zooepidemicus]  gi|225869197 
up in 
WT/down 
in mutant 
First choice 
 hit is S. equi 
WT4001 
PrtM6
002 
 30S ribosomal protein S6 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195977487 
up in 
WT/down 
in mutant 
lower choice 
 hit is S. equi 
WT4001 
PrtM6
002 
 hypothetical protein STRINF_01108 
[Streptococcus infantarius subsp. 
infantarius ATCC BAA-102]  gi|171779260 
up in 
WT/down 
in mutant   
WT4204 
PrtM6
202 
hypothetical protein SEQ_1025 
[Streptococcus equi subsp. equi 4047] gi|225870399 
up in 
WT/down 
in mutant 
Best match 
hit SEQ_1025 
WT4204 
PrtM6
202 
hypothetical protein Sez_0895 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565] gi|195978022 
up in 
WT/down 
in mutant 
lower choice 
hit is S. equi Sez_0895 
WT5303 
PrtM6
302 
thioredoxin peroxidase [Bacillus sp. 
NRRL B-14911] gi|89100074 
up in 
mutant/dow
n in WT   
WT5303 
PrtM6
302 YkuQ [Bacillus sp. NRRL B-14911] gi|89099375 
up in 
mutant/dow
n in WT   
WT3201  
Xaa-His dipeptidase [Streptococcus 
equi subsp. zooepidemicus]  gi|225868376 only in WT 
First choice 
 hit is S. equi 
WT3201  
 RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 only in WT   
WT3201  
 Alcohol dehydrogenase zinc-binding 
domain protein [Thermoanaerobacter 
italicus Ab9]  gi|255255024 only in WT   
WT3201  
 dipeptidase PepV [Streptococcus 
pyogenes M1 GAS]  gi|15675062 only in WT   
WT3201  
 beta-glucosidase protein [Rhizobium 
etli CFN 42]  gi|86359230 only in WT   
WT3201   hypothetical protein CaO19.10414  gi|68480910 only in WT   
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[Candida albicans SC5314] 
WT2201  
phosphopyruvate hydratase 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195977904 only in WT 
First choice 
 hit is S. equi 
WT2201  
 RecName: Full=Enolase; AltName: 
Full=2-phosphoglycerate dehydratase; 
AltName: Full=2-phospho-D-glycerate 
hydro-lyase  gi|57015278 only in WT   
WT2201   enolase [Streptococcus sobrinus]  gi|28866546 only in WT   
WT2201  
 phosphopyruvate hydratase 
[Streptococcus pneumoniae TIGR4]  gi|15900994 only in WT   
WT2201  
 phosphopyruvate hydratase 
[Streptococcus mutans UA159]  gi|24379669 only in WT   
WT2201  
 hypothetical protein STRINF_01784 
[Streptococcus infantarius subsp. 
infantarius ATCC BAA-102]  gi|171779997 only in WT   
WT2201   enolase [Enterococcus faecalis V583]  gi|29376483 only in WT   
WT2201  
 phosphopyruvate hydratase 
[Streptococcus gordonii str. Challis 
substr. CH1]  gi|157151177 only in WT   
WT2201   enolase [Bacillus coagulans 36D1]  gi|229543256 only in WT   
WT2201  
 cyclophilin type peptidyl-prolyl cis-
trans isomerase protein 
[Streptococcus equi subsp. equi 4047]  gi|225871058 only in WT 
First choice 
 hit is S. equi 
WT2201  
 Phosphopyruvate hydratase 
[Desulfuromonas acetoxidans DSM 
684]  gi|95929414 only in WT   
WT2201  
 enolase [Pediococcus pentosaceus 
ATCC 25745]  gi|116492264 only in WT   
WT2201  
 enolase [Lactobacillus salivarius 
UCC118]  gi|90962138 only in WT   
WT2201  
 co-chaperonin GroES [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565]  gi|195977292 only in WT 
lower choice 
 hit is S. equi 
WT2201  
 enolase [Heliobacterium 
modesticaldum Ice1]  gi|167629687 only in WT   
WT5302  
purine nucleoside phosphorylase 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565 gi|195978281 only in WT 
lower choice 
 hit is S. equi 
WT6201 
 
dTDP-4-Keto-6-Deoxyglucose-3 5-
epimerase R mLC [Streptococcus equi 
subsp. zooepidemicus MGCS10565] gi|195978346 only in WT 
lower choice  
hit is S. equi 
WT6001 
 
hypothetical protein CaO19.10414 
[Candida albicans SC5314] gi|68480910 only in WT   
WT3601 
 
mannose-6-phosphate isomerase Pmi 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195977511 only in WT 
First choice  
hit is S. equi 
WT3601 
 
 RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 only in WT   
WT3601 
 
 Alcohol dehydrogenase zinc-binding 
domain protein [Thermoanaerobacter 
italicus Ab9]  gi|255255024 only in WT   
WT3601 
 
 hypothetical protein AN7590.2 
[Aspergillus nidulans FGSC A4]  gi|67901206 only in WT   
WT3601 
 
 L-xylulose reductase [Neurospora 
crassa OR74A]  gi|85091614 only in WT   
WT6501 
 
6-phosphofructokinase [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565] gi|195978008 only in WT 
First choice  
hit is S. equi 
WT6501 
 
 6-phosphofructokinase [Clostridium 
perfringens str. 13]  gi|18309343 only in WT   
WT6501 
 
 6-phosphofructokinase [Idiomarina 
baltica OS145]  gi|85711053 only in WT   
WT6501 
 
 6-phosphofructokinase [Deinococcus 
geothermalis DSM 11300]  gi|94985737 only in WT   
WT6501 
 
 6-phosphofructokinase [Enterococcus 
faecalis V583] gi|29375624 only in WT   
WT5504  alcohol dehydrogenase [Streptococcus  gi|195977198 only in WT Best match  
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equi subsp. zooepidemicus 
MGCS10565] 
hit 
WT5504 
 
 alcohol dehydrogenase [Streptococcus 
equi subsp. zooepidemicus]  gi|225867661 only in WT 
lower choice 
 hit is S. equi 
 
PrtM0
001 
sugar phosphotransferase component II 
B [Streptococcus equi subsp. 
zooepidemicus MGCS10565] gi|195977278 
only in 
mutant 
lower choice  
hit is S. equi 
 
PrtM9
001 
transcriptional regulator [Bacillus sp. 
NRRL B-14911] gi|89101180 
only in 
mutant   
 
PrtM8
202 
hypothetical protein GK3020 
[Geobacillus kaustophilus HTA426] gi|56421555 
only in 
mutant   
 
PrtM8
201 
thioredoxin peroxidase [Bacillus sp. 
NRRL B-14911] gi|89100074 
only in 
mutant   
 
PrtM3
203 
transcription elongation factor GreA 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565] gi|195978755 
only in 
mutant 
First choice 
 hit is S. equi 
 
PrtM9
401 
ribosome recycling factor 
[Streptococcus pyogenes M1 GAS]  gi|15674582 
only in 
mutant   
       
 
 
 
 
Table D2 List of Proteins from S. equi 4047 WT  and Mutant ( PrtM): Secreted 
Protein Extract 
Spot # Spot # Protein name Protein code 
Comment  
on 
expression 
Comment 
on level of 
hit 
Protein code 
for best 
match hit 
WT0201 PrtM0401 
-esterase [Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195977587 
Same in both 
WT and 
mutant 
First choice 
hit is S. 
equi  
WT0201 PrtM0401 
 -lipoprotein [Streptococcus equi 
subsp. zooepidemicus]  gi|225867979 
Same in both 
WT and 
mutant 
lower 
choice hit is 
S. equi  
WT0201 PrtM0401 
 -lipoprotein [Streptococcus equi 
subsp. equi 4047]  gi|225871106 
Same in both 
WT and 
mutant 
lower 
choice hit is 
S. equi  
WT0201 PrtM0401 
 -hypothetical protein CaO19.10414 
[Candida albicans SC5314]  gi|68480910 
Same in both WT and 
mutant  
WT0201 PrtM0401 
 -RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 
Same in both WT and 
mutant  
WT7402 PrtM6503 
-RecName: 
Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase  gi|3913881 
same in both WT and 
mutant  
WT7402 PrtM6503 
 -fibronectin-binding protein 
[Streptococcus equi  gi|1617432 
same in both 
WT and 
mutant 
lower 
choice hit is 
S. equi  
WT5001 PrtM5103 
unnamed protein product [Manduca 
sexta gi|9725 
up in 
WT/down in 
mutant   
WT5001 PrtM5103 
IgM heavy chain constant region, 
secretory form [Bos taurus]  gi|28592070 
up in 
WT/down in 
mutant 
First choice 
hit is S. 
equi  
WT5001 PrtM5103 
 -IgM heavy chain constant region 
[Bos taurus]  gi|2232299 
up in 
WT/down in 
mutant   
WT9403 PrtM7502 
exported protein [Streptococcus 
equi subsp. equi 4047] gi|225869943 
up in 
WT/down in 
mutant 
First choice 
hit is S. 
equi  
WT9403 PrtM7502 
: -esterase [Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195977587 
up in 
WT/down in 
mutant 
First choice 
hit is S. 
equi  
WT9403 PrtM7502 
 -6-phosphofructokinase [Bacillus 
subtilis subsp. subtilis str. 168]  gi|16079971 
up in 
WT/down in 
mutant   
WT9403 PrtM7502  -ALB protein [Bos taurus]  gi|74267962 
up in 
WT/down in   
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mutant 
WT9403 PrtM7502 
 -6-phosphofructokinase [Bacillus sp. 
SG-1]  gi|149181139 
up in 
WT/down in 
mutant   
WT9403 PrtM7502 
 -6-phosphofructokinase [Bacillus sp. 
NRRL B-14911]  gi|89100372 
up in 
WT/down in 
mutant   
WT3301 Prtm2504 
-peptidyl-prolyl cis-trans isomerase 
cyclophilin-type [Streptococcus equi 
subsp. zooepidemicus MGCS10565]  gi|195978568 
up in 
WT/down in 
mutant 
First choice 
hit is S. 
equi  
WT3301 Prtm2504 
 -REDICTED: similar to keratin 1 
isoform 7 [Macaca mulatta]  gi|109096823 
up in 
WT/down in 
mutant   
WT3301 Prtm2504 
 -serine proteinase inhibitor, clade A, 
member 1 precursor [Bos taurus]  gi|27806941 
up in 
WT/down in 
mutant   
WT3301 Prtm2504 
hypothetical protein CaO19.10414 
[Candida albicans SC5314]  gi|68480910 
up in 
WT/down in 
mutant   
WT3301 Prtm2504 
 -esterase [Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195977587 
up in 
WT/down in 
mutant 
lower 
choice hit is 
S. equi  
WT0005  
-RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 only in WT   
WT0005  
- hypothetical protein AN7590.2 
[Aspergillus nidulans FGSC A4]  gi|67901206 only in WT   
WT0005  
- unnamed protein product 
[Escherichia coli str. K-12 substr. 
MG1655]  gi|466691 only in WT   
WT0005  
- L-xylulose reductase [Neurospora 
crassa OR74A]  gi|85091614 only in WT   
WT0005  
 -Alcohol dehydrogenase zinc-binding 
domain protein [Thermoanaerobacter 
italicus Ab9]  gi|255255024 only in WT   
WT1101  
-unnamed protein product 
[Escherichia coli str. K-12 substr. 
MG1655] gi|466691 only in WT   
WT8403  -ALB protein [Bos taurus]  gi|74267962 only in WT   
WT8403   -serum albumin [Bos indicus]  gi|76445989 only in WT   
WT8403  - albumin [Felis catus]  gi|30962111 only in WT   
WT2201  
-PREDICTED: similar to Keratin, 
type I cytoskeletal 14 (Cytokeratin-
14) (CK-14) (Keratin-14) (K14) [Pan 
troglodytes]  gi|114667176 only in WT   
WT2201  
 -hypothetical protein Sez_0895 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195978022 only in WT 
lower 
choice hit is 
S. equi Sez_0895 
WT2201  
 -RecName: 
Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase  gi|3913881 only in WT   
WT8501  
 -Mac family protein [Streptococcus 
equi subsp. equi 4047]  gi|225870319 only in WT 
First choice 
hit is S. 
equi  
WT8501  
 -hypothetical protein CaO19.10414 
[Candida albicans SC5314]  gi|68480910 only in WT   
WT8501  
 -RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 only in WT   
WT7301  
-DNA/RNA non-specific 
endonuclease [Streptococcus equi 
subsp. zooepidemicus]  gi|225868777 only in WT 
First choice 
hit is S. 
equi  
WT7301  
 -fibronectin-binding protein 
[Streptococcus equi]  gi|1617432 only in WT 
lower 
choice hit is 
S. equi  
WT7301  
 -serine proteinase inhibitor, clade A, 
member 1 precursor [Bos taurus]  gi|27806941 only in WT   
WT9202  
-fibronectin-binding protein 
[Streptococcus equi]  gi|1617432 only in WT 
First choice 
hit is S. 
equi  
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WT9202  
- DNA/RNA non-specific 
endonuclease [Streptococcus equi 
subsp. zooepidemicus]  gi|225868777 only in WT 
lower 
choice hit is 
S. equi  
WT9202  
 -hypothetical protein 
TTHERM_00225940 [Tetrahymena 
thermophila]  gi|146164853 only in WT   
WT9202  
- RecName: 
Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase  gi|3913881 only in WT   
WT2202  
-hypothetical protein Sez_0895 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195978022 only in WT 
Best match 
hit Sez_0895 
WT2202  
 -RecName: 
Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase  gi|3913881 only in WT   
WT2202  
-fibronectin-binding protein 
[Streptococcus equi]  gi|1617432 only in WT 
lower 
choice hit is 
S. equi  
WT2202  
- hyaluronoglucosaminidase 
[Streptococcus pyogenes 
MGAS10394]  gi|50914896 only in WT   
WT1401  
-lipoprotein [Streptococcus equi 
subsp. zooepidemicus]  gi|225867979 only in WT 
First choice 
hit is S. 
equi  
WT1401  
- lipoprotein [Streptococcus equi 
subsp. equi 4047]  gi|225871106 only in WT 
lower 
choice hit is 
S. equi  
WT1401  
 -hyaluronidase, phage associated 
[Streptococcus phage 370.1]  gi|15674762 only in WT   
WT1401  
 -hyaluronoglucosaminidase 
[Streptococcus pyogenes 
MGAS10394]  gi|50914896 only in WT   
WT1401  
- hypothetical protein SPy_1154 
[Streptococcus pyogenes M1 GAS]  gi|15675130 only in WT   
WT2401  
-extracellular protein [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565]  gi|195978139 only in WT 
First choice 
hit is S. 
equi  
WT2401  
- PREDICTED: similar to keratin 1 
isoform 7 [Macaca mulatta]  gi|109096823 only in WT   
WT1402  
-extracellular protein [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565]  gi|195978139 only in WT 
First choice 
hit is S. 
equi  
WT1402  
 -hyaluronidase, phage associated 
[Streptococcus phage 370.1]  gi|15674762 only in WT 
lower 
choice hit is 
S. equi  
WT1402  
 -hyaluronoglucosaminidase 
[Streptococcus pyogenes 
MGAS10394]  gi|50914896 only in WT   
WT1402  
 -unnamed protein product 
[Escherichia coli str. K-12 substr. 
MG1655]  gi|466691 only in WT   
WT1402  
- RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 only in WT   
WT1402  
 -Alcohol dehydrogenase zinc-binding 
domain protein [Thermoanaerobacter 
italicus Ab9]  gi|255255024 only in WT   
WT8401  
-Mac family protein [Streptococcus 
equi subsp. equi 4047 gi|225870319 only in WT 
First choice 
hit is S. 
equi  
WT2101  
-hypothetical protein Sez_1583 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195978685 only in WT 
Best match 
hit is S. 
equi Sez_1583 
WT2101  
 -RecName: 
Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase  gi|3913881 only in WT   
WT1002  
-co-chaperonin GroES [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565]  gi|195977292 only in WT 
First choice 
hit is S. 
equi  
WT1002  
 -PREDICTED: similar to keratin 1 
isoform 7 [Macaca mulatta]  gi|109096823 only in WT   
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WT1002  
 -hylauronidase [Streptococcus phage 
P9  gi|157311178 only in WT   
 PrtM1201 
-RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 
only in 
mutant   
 PrtM1201 
 -YALI0B08052p [Yarrowia 
lipolytica]  gi|50546208 
only in 
mutant   
 PrtM1201 
 -hypothetical protein CaO19.10414 
[Candida albicans SC5314]  gi|68480910 
only in 
mutant   
 PrtM1201 
- Alcohol dehydrogenase zinc-binding 
domain protein [Thermoanaerobacter 
italicus Ab9]  gi|255255024 
only in 
mutant   
 PrtM1201 
- hypothetical protein AN7590.2 
[Aspergillus nidulans FGSC A4]  gi|67901206 
only in 
mutant   
 PrtM1201 
- unnamed protein product 
[Escherichia coli str. K-12 substr. 
MG1655]  gi|466691 
only in 
mutant   
 PrtM1103 
-hypothetical protein Sez_1583 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565]  gi|195978685  
Best match 
hit Sez_1583 
 PrtM1103 
 -hyaluronidase, phage associated 
[Streptococcus phage 370.1]  gi|15674762 
only in 
mutant   
 PrtM1103 
 -hyaluronoglucosaminidase 
[Streptococcus pyogenes 
MGAS10394]  gi|50914896 
only in 
mutant   
 PrtM0101 
-cold-shock protein, molecular 
chaperone, RNA-helicase co-factor 
[Bacillus subtilis subsp. subtilis str. 
168 gi|16079252 
only in 
mutant   
 PrtM0301 
-A family sortase SrtA [Streptococcus 
equi subsp. zooepidemicus 
MGCS10565]  gi|195978143 
only in 
mutant 
First choice 
hit is S. 
equi  
 PrtM0301 
 -sortase SrtA [Streptococcus equi 
subsp. zooepidemicus]  gi|225868523 
only in 
mutant 
lower 
choice hit is 
S. equi  
 PrtM0301 
- RecName: 
Full=Hyaluronoglucosaminidase; 
Short=Hyaluronidase  gi|3913881 
only in 
mutant   
 PrtM0304 
-cold shock protein [Bacillus sp. 
NRRL B-14911 gi|89098567 
only in 
mutant   
 PrtM1202 
-oligopeptide ABC transporter 
periplasmic oligopeptide-binding 
protein OppA [Streptococcus equi 
subsp. zooepidemicus -MGCS10565]  gi|195978795 
only in 
mutant   
 PrtM1202 
 -YALI0B08052p [Yarrowia 
lipolytica]  gi|50546208 
only in 
mutant   
 PrtM1202 
 -RecName: Full=NADP-dependent 
alcohol dehydrogenase  gi|113443 
only in 
mutant   
 PrtM1202 
 -Alcohol dehydrogenase zinc-binding 
domain protein [Thermoanaerobacter 
italicus Ab9]  gi|255255024 
only in 
mutant   
 PrtM1202 
- hypothetical protein AN8113.2 
[Aspergillus nidulans FGSC A4]  gi|67902252 
only in 
mutant   
 PrtM2101 
-30S ribosomal protein S6 
[Streptococcus uberis 0140J]  gi|222153666 
only in 
mutant   
 PrtM2101 
 -cold shock protein [Bacillus sp. 
NRRL B-14911]  gi|89098567 
only in 
mutant   
 PrtM2101 
 -30S ribosomal protein S6 
[Streptococcus equi subsp. 
zooepidemicus MGCS10565  gi|195977487 
only in 
mutant 
lower 
choice hit is 
S. equi  
 PrtM2301 
-oligopeptide ABC transporter 
periplasmic oligopeptide-binding 
protein OppA [Streptococcus equi 
subsp. zooepidemicus MGCS10565 gi|195978795 
only in 
mutant   
 PrtM5301 
-thioredoxin peroxidase [Bacillus sp. 
NRRL B-14911 gi|89100074 
only in 
mutant   
 PrtM4201 
-50S ribosomal protein L10 
[Staphylococcus epidermidis ATCC 
12228 gi|27467221 
only in 
mutant   
       
   
262 
 
Appendix E: DNA Sequence of Plasmid plus PrtM DNA insert without 
the 281 nucleotide upstream sequences: 
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Appendix F: Growth Curve and student T-test of growth curve ODs 
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Student T-test of growth curve ODs 
Time (hrs) 
S. equi 4047 
ΔPrtM 
S. equi 4047 
 WT Time (hrs) 
S. equi 
4047 
ΔPrtM 
S. equi 4047 
WT 
4 0.161 0.18 
 
     14 0.361 0.393 
4 0.167 0.177 
 
     14 0.353 0.4 
4 0.171 0.188 
 
     14 0.35 0.406 
Student T-test= 0.015117 
  
Student T-test= 0.011677 
 
       
       
Time (hrs) 
S. equi 4047 
ΔPrtM 
S. equi 4047  
WT Time (hrs) 
S. equi 
4047 
ΔPrtM 
S. equi 4047 
WT 
6 0.35 0.43 
 
16 0.37 0.39 
6 0.34 0.436 
 
16 0.349 0.394 
6 0.338 0.453 
 
16 0.351 0.401 
Student T-test= 0.005351 
  
Student T-test= 0.026953 
 
       
       
Time (hrs) 
S. equi 4047 
ΔPrtM 
S. equi 4047 
 WT Time (hrs) 
S. equi 
4047 
ΔPrtM 
S. equi 4047 
WT 
8 0.382 0.416 
 
18 0.37 0.387 
8 0.374 0.433 
 
18 0.348 0.39 
8 0.376 0.445 
 
18 0.356 0.398 
Student T-test= 0.017601 
  
Student T-test= 0.028079 
 
       
       
Time (hrs) 
S. equi 4047 
ΔPrtM 
S. equi 4047 
 WT Time (hrs) 
S. equi 
4047 
ΔPrtM 
S. equi 4047 
WT 
10 0.367 0.403 
 
20 0.368 0.381 
10 0.363 0.42 
 
20 0.354 0.391 
10 0.362 0.428 
 
20 0.362 0.395 
Student T-test= 0.013495 
  
Student T-test= 0.032526 
 
       
       
Time (hrs) 
S. equi 4047 
ΔPrtM 
S. equi 4047  
WT Time (hrs) 
S. equi 
4047 
ΔPrtM 
S. equi 4047 
WT 
12 0.364 0.398 
 
22 0.362 0.377 
12 0.356 0.409 
 
22 0.352 0.379 
12 0.358 0.414 
 
22 0.355 0.389 
Student T-test= 0.010125 
  
Student T-test= 0.022381 
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Appendix G: Student T-test of antibiotics sensitivity result 
 
 
Antibiotic     PenicillinG   Streptomycin 
S. equi 4047 strain    WT  ΔPrtM   WT  ΔPrtM  
1st replica -antibiotic concentration in cm 3.6 4.4   1.9 3.2 
2nd replica -antibiotic concentration in cm 3.6 4.4   1.9 3 
3rd replica -antibiotic concentration in cm 3.6 4.2   2.2 2.6 
Student T-test     0.00408170   0.037931147  
  
 
Antibiotic      Vancomycin   Gentamycin 
S. equi 4047 strain     WT  ΔPrtM   WT  ΔPrtM  
1st replica -antibiotic concentration in cm 1.9 2.6   2.2 3.4 
2nd replica -antibiotic concentration in cm 2 2.6   2.4 3.2 
3rd replica -antibiotic concentration in cm 2.1 2.4   2.2 3 
Student T-test     0.023606933   0.009901971  
      
      
           
Antibiotic      Ampicillin   Norfloxacin 
S. equi 4047 strain     WT  ΔPrtM   WT  ΔPrtM  
1st replica -antibiotic concentration in cm 3.5 3.8   1.2 1.8 
2nd replica -antibiotic concentration in cm 3.4 3.6   1.2 2 
3rd replica -antibiotic concentration in cm 3.6 3.9   1.1 1.8 
Student T-test     0.007634036   0.003367042  
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Appendix H:  Hyaluronic acid quantitation result 
The kit manufacturer’s (Nozomis Biocatalysis) formular that was: 
 [(A2-A1)Sample – (A2-A1)Blank] x 0.2314 = mg/ mL of hyaluronan. 
The results of triplicate hyaluronic acid quantitation assays are summarized in figure H1 
(appendix H) 
 
Blank A1 (OD235 nm) A2 (OD235 nm A2-A1 
BLANK1 0.617 0.623 0.006 
BLANK2 0.632 0.638 0.006 
BLANK3 0.598 0.603 0.005 
        Average  of  Blank A2 –A1    = 0.00567 
 
S. equi 4047 
strain A1 (OD 235 nm) A2 (OD 235 nm A2-A1 
WT 0.795 0.808 0.013 
WT 0.755 0.768 0.013 
WT 0.726 0.749 0.023 
Average     of       WT A2-A1    = 0.01633 
WT average  (A2 –A1)  - Blank Average 0.01067 
0.01067    x  0.2314    = 0.002469038 mg/ mL 
       Since 0.5 mL of culture was used, multiplied result by 2 
       5.0 x 10
-3
 mg/ mL = 5 µg/ mL  hyaluronan in WT culture 
 
S. equi 4047 
strain A1 (OD 235 nm) A2 (OD 235 nm A2-A1 
ΔPrtM 0.761 0.769 0.008 
ΔPrtM 0.757 0.768 0.011 
ΔPrtM 0.75 0.768 0.018 
Average   of   ΔPrtM A2 - A1   = 0.01233 
ΔPrtM  Average (A2-A1) -Blank average 0.00667 
   0.00667    x 0.2314     = 0.001543438 mg/ mL 
        Since 0.5 mL of culture was used, multiplied result by 2 
    3.0 x  10
-3
 mg/ mL = 3 µg/ mL  hyaluronan in ΔPrtM culture 
 
Figure H1: Summary of Hyaluronic acid quantitation result 
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Appendix I – Analysis of Protease coupled PPIase assays 
 
 
 
 
Figure I1: Analysis of reactions of Pep2: Full length (FULL) and central domain 
(CENT) recombinant protein fractions. 
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Figure I2: Analysis of reactions of Pep3: Full length (FULL) and central domain 
(CENT) recombinant protein fractions. 
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Figure I3: Analysis of reactions of Pep1: Full length (FULL) and central domain (CENT) 
recombinant protein fractions. 
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Appendix J 
 
Protein crystallisation screens 
Tables J1, J2, J3, J4, J5, J6 and J7 show the solutions used to screen for crystal 
development. Those screens in tables HI and HII are named Clear Strategy Screen (CSS) I 
and II respectively from Molecular Dimensions. The following abbreviations describe 
precipitants: polyethylene glycol (PEG), monomethylether (MME), Jeffamine (O-(2-
Aminopropyl)-O’-(2-methoxy-ethyl) polypropylene glycol 500). 
J1: CSS 1 
Tube Number Salt Precipitant 
1 0.3M Sodium Acetate 25% (w/v) PEG 2Kmme 
2 0.2M Lithium Sulphate 25% (w/v) PEG 2Kmme 
3 0.2M Magnesium Chloride 25% (w/v) PEG 2Kmme 
4 0.2M Potassium Bromide 25% (w/v) PEG 2Kmme 
5 0.2M Potassium Thiocyanate 25% (w/v) PEG 2Kmme 
6 0.8M Sodium Formate 25% (w/v) PEG 2Kmme 
7 0.3M Sodium Acetate 15% (w/v) PEG 4K 
8 0.2M Lithium Sulphate 15% (w/v) PEG 4K 
9 0.2M Magnesium Chloride  15% (w/v) PEG 4K 
10 0.2M Potassium Bromide 15% (w/v) PEG 4K 
11 0.2M Potassium Thiocyanate 15% (w/v) PEG 4K 
12 0.8M Sodium Formate 15% (w/v) PEG 4K 
13 0.3M Sodium Acetate 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
14 0.2M Lithium Sulphate 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
15 0.2M Magnesium Chloride 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
16 0.2M Potassium Bromide 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
17 0.2M Potassium Thiocyanate 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
18 0.8M Sodium Formate 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
19 0.3M Sodium Acetate 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme  
20 0.2M Lithium Sulphate 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme  
21 0.2M Magnesium Chloride 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme  
22 0.2M Potassium Bromide 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme  
23 0.2M Potassium Thiocyanate 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme  
24 0.8M Sodium Formate 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme  
Table JI: CSS I components.  
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J2: CSS II 
Tube Number Salt Precipitant 
1 1.5M Ammonium Sulphate  
2 0.8M Lithium Sulphate  
3 2M Sodium Formate  
4 0.5M Potassium dihydrogen Phosphate  
5 0.2M Calcium Acetate 25% (w/v) PEG 2Kmme 
6 0.2M Calcium Acetate 15% (w/v) PEG 4K 
7 2.7M Ammonium Sulphate  
8 1.8M Lithium Sulphate  
9 4M Sodium Formate  
10 1M Potassium dihydrogen Phosphate  
11 0.2M Calcium Acetate 10% (w/v) PEG 8K, 10% (w/v) PEG 1K 
12 0.2M Calcium Acetate 8% (w/v) PEG 20K, 8% (w/v) PEG 
550mme 
13  40% (v/v) MPD 
14  40% (v/v) 2,3-Butane-diol 
15 5mM Cadmium Chloride 20% (w/v) PEG 4K 
16 0.15M Potassium Thiocyanate 20% (w/v) PEG 550mme 
17 0.15M Potassium Thiocyanate 20% (w/v) PEG 600 
18 0.15M Potassium Thiocyanate 20% (w/v) PEG 1500 
19  35% (v/v) Isopropanol 
20  30% (v/v) Jeffamine 600M pH 6.5 
21 5mM Nickel Chloride 20% (w/v) PEG 4K 
22 0.15M Potassium Thiocyanate 18% (w/v) PEG 3350 
23 0.15M Potassium Thiocyanate 18% (w/v) PEG 5Kmme 
24 0.15M Potassium Thiocyanate 15% (w/v) PEG 6K 
Table JII: CSS II components. 
 
 
J3a: Hampton screen I 
Tube Number Salt Buffer Precipitant 
1 0.02M Calcium Chloride 
dihydrate 
0.1M Sodium Acetate 
trihydrate pH 4.6 
30% (v/v) 2-Methyl-2, 4-
pentanediol 
2   0.4M Potassium Sodium 
Tartrate tetrahydrate 
3   0.4M Ammonium 
dihydrogen Phosphate 
4  0.1M Tris Hydrochloride 
pH 8.5 
2M Ammonium Sulphate 
5 0.2M tri-Sodium Citrate 
dihydrate 
0.1M HEPES- Sodium pH 
7.5 
30% (v/v) 2-Methyl-2, 4-
pentanediol 
6 0.2M Magnesium Chloride 
hexahydrate 
0.1M Tris Hydrochloride 
pH 8.5 
30% (w/v) PEG 4000 
7  0.1M Sodium Cacodylate 
pH 6.5 
1.4M Sodium Acetate 
trihydrate 
8 0.2M tri-Sodium Citrate 
dihydrate 
0.1M Sodium Cacodylate 
pH 6.5 
30% (v/v) iso-Propanol 
9 0.2M Ammonium Acetate 0.1M tri-Sodium Citrate 
dihydrate pH 5.6 
30% (w/v) PEG 4000 
10 0.2M Ammonium Acetate 0.1M Sodium Acetate 
trihydrate pH 4.6 
30% (w/v) PEG 4000 
11  0.1M tri-Sodium Citrate 
dihydrate pH 5.6 
1M Ammonium dihydrogen 
Phosphate 
12 0.2M Magnesium Chloride 
hexahydrate 
0.1M HEPES- Sodium pH 
7.5 
30% (v/v) iso-Propanol 
13 0.2M tri-Sodium Citrate 
dihydrate 
0.1M Tris Hydrochloride 
pH 8.5 
30% (v/v) PEG 400 
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14 0.2M Calcium Chloride 
dihydrate 
0.1M HEPES- Sodium pH 
7.5 
28% (v/v) PEG 400 
15 0.2M Ammonium Sulphate 0.1M Sodium Cacodylate 
pH 6.5 
30% (w/v) PEG 8000 
16  0.1M HEPES- Sodium pH 
7.5 
1.5M Lithium Sulphate 
monohydrate 
17 0.2M Lithium Sulphate 
monohydrate 
0.1M Tris Hydrochloride 
pH 8.5 
30% (w/v) PEG 4000 
18 0.2M Magnesium Acetate 
tetrahydrate 
0.1M Sodium Cacodylate 
pH 6.5 
20% (w/v) PEG 8000 
19 0.2M Ammonium Acetate 0.1M Tris Hydrochloride 
pH 8.5 
30% (v/v) iso-Propanol 
20 0.2M Ammonium Sulphate 0.1M Sodium Acetate 
trihydrate pH 4.6 
25% (w/v) PEG 4000 
21 0.2M Magnesium Acetate 
tetrahydrate 
0.1M Sodium Cacodylate 
pH 6.5 
30% (v/v) 2-Methyl-2, 4-
pentanediol 
22 0.2M Sodium Acetate 
trihydrate 
0.1M Tris Hydrochloride 
pH 8.5 
30% (w/v) PEG 4000 
23 0.2M Magnesium Chloride 
hexahydrate 
0.1M HEPES- Sodium pH 
7.5 
30% (v/v) PEG 400 
24 0.2M Calcium Chloride 
dihydrate 
0.1M Sodium Acetate 
trihydrate pH 4.6 
20% (v/v) iso-Propanol 
25  0.1M Imidazole pH 6.5 1M Sodium Acetate 
trihydrate 
26 0.2M Ammonium Acetate 0.1M tri-Sodium Citrate 
dihydrate pH 5.6 
30% (v/v) 2-Methyl-2, 4-
pentanediol 
27 0.2M tri-Sodium Citrate 
dehydrate 
0.1M HEPES- Sodium pH 
7.5 
20% (v/v) iso-Propanol 
28 0.2M Sodium Acetate 
trihydrate 
0.1M Sodium Cacodylate 
pH 6.5 
30% (w/v) PEG 8000 
29  0.1M HEPES- Sodium pH 
7.5 
0.8M Potassium Sodium 
Tartrate tetrahydrate 
30 0.2M Ammonium Sulphate  30% (w/v) PEG 8000 
31 0.2M Ammonium Sulphate  30% (w/v) PEG 4000 
32   2M Ammonium Sulphate 
33   4M Sodium Formate  
34  0.1M Sodium Acetate 
trihydrate pH 4.6 
2M Sodium Formate 
35  0.1M HEPES- Sodium pH 
7.5 
0.8M Sodium dihydrogen 
Phosphate, 0.8M Potassium 
dihydrogen Phosphate 
36  0.1M Tris Hydrochloride 
pH 8.5 
8% (w/v) PEG 8000 
37  0.1M Sodium Acetate 
trihydrate pH 4.6 
8% (w/v) PEG 4000 
38  0.1M HEPES- Sodium pH 
7.5 
1.4M tri-Sodium Citrate 
dihydrate 
39  0.1M HEPES- Sodium pH 
7.5 
2% (v/v) PEG 400, 2M 
Ammonium Sulphate 
40  0.1M tri-Sodium Citrate 
dihydrate pH 5.6 
20% (v/v) iso-Propanol, 
20% (w/v) PEG 4000 
41  0.1M HEPES- Sodium pH 
7.5 
10% (v/v) iso-Propanol, 
20% (w/v) PEG 4000 
42 0.05M Potassium 
dihydrogen Phosphate 
 20% (w/v) PEG 8000 
43   30% (w/v) PEG 1500 
44   0.2M Magnesium Formate 
45 0.2M Zinc Acetate 
dihydrate 
0.1M Sodium Cacodylate 
pH 6.5 
18% (w/v) PEG 8000 
46 0.2M Calcium Acetate 0.1M Sodium Cacodylate 18% (w/v) PEG 8000 
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hydrate pH 6.5 
47  0.1M Sodium Acetate 
trihydrate pH 4.6 
2M Ammonium Sulphate 
48  0.1M Tris Hydrochloride 
pH 8.5 
2M Ammonium dihydrogen 
Phosphate 
Table J3a: Hampton screen I components. 
 
 
 
J3B: Hampton screen II 
Tube Number Salt Buffer Precipitant 
1 2M Sodium Chloride   10% (w/v) PEG 6000 
2 0.5M Sodium Chloride; 
0.1M Magnesium 
Chloride hexahydrate 
 0.01M Hexadecyltrimethylammonium 
Bromide 
3   25% (v/v) Ethylene Glycol 
4   35% (v/v) Dioxane 
5 2M Ammonium Sulphate  5% (v/v) iso-Propanol 
6   1M Imidazole pH 7.0 
7   10% (w/v) PEG 1000; 10% (w/v) PEG 
8000 
8 1.5M Sodium Chloride  10% (v/v) Ethanol 
9  0.1M Sodium Acetate 
trihydrate pH 4.6 
2M Sodium Chloride 
10 0.2M Sodium Chloride 0.1M Sodium Acetate 
trihydrate pH 4.6 
30% (v/v) MPD 
11 0.01M Cobaltous 
Chloride hexahydrate 
0.1M Sodium Acetate 
trihydrate pH 4.6 
1M 1,6 Hexanediol 
12 0.1M CadmiumChloride 
dihydrate 
0.1M Sodium Acetate 
trihydrate pH 4.6 
30% (v/v) PEG 400 
13 0.2M Ammonium 
Sulphate 
0.1M Sodium Acetate 
trihydrate pH 4.6 
30% (w/v) PEG 2000mme 
14 0.2M Potassium Sodium 
Tartrate tetrahydrate 
0.1M tri-Sodium 
Citrate dihydrate pH 
5.6 
2M Ammonium Sulphate 
15 0.5M Ammonium 
Sulphate 
0.1M tri-Sodium 
Citrate dihydrate pH 
5.6 
1M Lithium Sulphate monohydrate 
16 0.5M Sodium Chloride 0.1M tri-Sodium 
Citrate dihydrate pH 
5.6 
2% (w/v) Ethylene Imine Polymer 
17  0.1M tri-Sodium 
Citrate dihydrate pH 
5.6 
35% (v/v) tert-Butanol 
18 0.01M Ferric Chloride 
hexahydrate 
0.1M tri-Sodium 
Citrate dihydrate pH 
5.6 
10% (v/v) Jeffamine M-600 
19  0.1M tri-Sodium 
Citrate dihydrate pH 
5.6 
2.5M 1,6 Hexanediol 
20  0.1M MES pH 6.5 1.6M Magnesium Sulphate heptahydrate 
21 0.1M Sodium dihydrogen 
Phosphate; 0.1M 
Potassium dihydrogen 
Phosphate 
0.1M MES pH 6.5 2M Sodium Chloride 
22  0.1M MES pH 6.5 12% (w/v) PEG 20000 
23 1.6M Ammonium 
Sulphate 
0.1M MES pH 6.5 10% (v/v) Dioxane 
24 0.05M Caesium Chloride  0.1M MES pH 6.5 30% (v/v) Jeffamine M-600 
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25 0.01M Cobaltous 
Chloride hexahydrate 
0.1M MES pH 6.5 1.8M Ammonium Sulphate 
26 0.2M Ammonium 
Sulphate 
0.1M MES pH 6.5 30% (w/v) PEG 5000mme 
27 0.01M Zinc Sulphate 
heptahydrate 
0.1M MES pH 6.5 25% (v/v) PEG 550mme 
28   1.6M tri-Sodium Citrate dihydrate pH 
6.5 
29 0.5M Ammonium 
Sulphate 
0.1M HEPES pH 7.5 30% (v/v) MPD 
30  0.1M HEPES pH 7.5 10% (w/v) PEG 6000; 5% (v/v) MPD 
31  0.1M HEPES pH 7.5 20% (v/v) Jeffamine M-600 
32 0.1M Sodium Chloride 0.1M HEPES pH 7.5 1.6M Ammonium Sulphate 
33  0.1M HEPES pH 7.5 2M Ammonium Formate  
34 0.05M Cadmium 
Sulphate hydrate 
0.1M HEPES pH 7.5 1M Sodium Acetate trihydrate 
35  0.1M HEPES pH 7.5 70% (v/v) MPD 
36  0.1M HEPES pH 7.5 4.3M Sodium Chloride 
37  0.1M HEPES pH 7.5 10% (w/v) PEG 8000; 8% (v/v) Ethylene 
Glycol 
38  0.1M HEPES pH 7.5 20% (w/v) PEG 10000 
39 0.2M Magnesium 
Chloride hexahydrate 
0.1M Tris pH 8.5 3.4M 1,6 Hexanediol 
40  0.1M Tris pH 8.5 25% (v/v) tert-Butanol  
41 0.01M Nickel (II) 
Chloride hexahydrate 
0.1M Tris pH 8.5 1M Lithium Sulphate monohydrate 
42 1.5M Ammonium 
Sulphate 
0.1M Tris pH 8.5 12% (v/v) Glycerol anhydrous  
43 0.2M Ammonium 
dihydrogen Phosphate 
0.1M Tris pH 8.5 50% (v/v) MPD 
44  0.1M Tris pH 8.5 20% (v/v) Ethanol 
45 0.01M Nickel (II) 
Chloride hexahydrate 
0.1M Tris pH 8.5 20% (w/v) PEG 2000mme 
46 0.1M Sodium Chloride 0.1M Bicine pH 9.0 20% (w/v) PEG 550mme 
47  0.1M Bicine pH 9.0 2M Magnesium Chloride hexahydrate 
48  0.1M Bicine pH 9.0 2% (v/v) Dioxane; 20% (w/v) PEG 
2000mme 10% (w/v) PEG 20000 
Table J3b: Hampton screen II components 
 
 
 
J4: PEG ion screen 
Tube Number Salt Precipitant 
1 0.2M Sodium Fluoride 20% (w/v) PEG 3350 
2 0.2M Potassium Fluoride 20% (w/v) PEG 3350 
3 0.2M Ammonium Fluoride 20% (w/v) PEG 3350 
4 0.2M Lithium Chloride anhydrous 20% (w/v) PEG 3350 
5 0.2M Magnesium Chloride hexahydrate 20% (w/v) PEG 3350 
6 0.2M Sodium Chloride 20% (w/v) PEG 3350 
7 0.2M Calcium Chloride dihydrate 20% (w/v) PEG 3350 
8 0.2M Potassium Chloride 20% (w/v) PEG 3350 
9 0.2M Ammonium Chloride 20% (w/v) PEG 3350 
10 0.2M Sodium Iodide 20% (w/v) PEG 3350 
11 0.2M Potassium Iodide 20% (w/v) PEG 3350 
12 0.2M Ammonium Iodide 20% (w/v) PEG 3350 
13 0.2M Sodium Thiocyanate 20% (w/v) PEG 3350 
14 0.2M Potassium Thiocyanate 20% (w/v) PEG 3350 
15 0.2M Lithium Nitrate 20% (w/v) PEG 3350 
16 0.2M Magnesium Nitrate hexahydrate 20% (w/v) PEG 3350 
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17 0.2M Sodium Nitrate 20% (w/v) PEG 3350 
18 0.2M Potassium Nitrate 20% (w/v) PEG 3350 
19 0.2M Ammonium Nitrate 20% (w/v) PEG 3350 
20 0.2M Magnesium Formate 20% (w/v) PEG 3350 
21 0.2M Sodium Formate 20% (w/v) PEG 3350 
22 0.2M Potassium Formate 20% (w/v) PEG 3350 
23 0.2M Ammonium Formate 20% (w/v) PEG 3350 
24 0.2M Lithium Acetate dihydrate 20% (w/v) PEG 3350 
25 0.2M Magnesium Acetate tetrahydrate 20% (w/v) PEG 3350 
26 0.2M Zinc Acetate dihydrate 20% (w/v) PEG 3350 
27 0.2M Sodium Acetate trihydrate 20% (w/v) PEG 3350 
28 0.2M Calcium Acetate hydrate 20% (w/v) PEG 3350 
29 0.2M Potassium Acetate 20% (w/v) PEG 3350 
30 0.2M Ammonium Acetate 20% (w/v) PEG 3350 
31 0.2M Lithium Sulphate monohydrate 20% (w/v) PEG 3350 
32 0.2M Magnesium Sulphate heptahydrate 20% (w/v) PEG 3350 
33 0.2M Sodium Sulphate decahydrate 20% (w/v) PEG 3350 
34 0.2M Potassium Sulphate 20% (w/v) PEG 3350 
35 0.2M Ammonium Sulphate 20% (w/v) PEG 3350 
36 0.2M di-Sodium tartrate dihydrate 20% (w/v) PEG 3350 
37 0.2M Potassium Sodium Tartrate tetrahydrate 20% (w/v) PEG 3350 
38 0.2M di-Ammonium Tartrate 20% (w/v) PEG 3350 
39 0.2M Sodium dihydrogen Phosphate monohydrate 20% (w/v) PEG 3350 
40 0.2M di-Sodium hydrogen Phosphate dihydrate 20% (w/v) PEG 3350 
41 0.2M Potassium dihydrogen Phosphate 20% (w/v) PEG 3350 
42 0.2M di-Potassium hydrogen Phosphate 20% (w/v) PEG 3350 
43 0.2M Ammonium dihydrogen Phosphate 20% (w/v) PEG 3350 
44 0.2M di-Ammonium hydrogen Phosphate 20% (w/v) PEG 3350 
45 0.2M tri-Lithium Citrate tetrahydrate 20% (w/v) PEG 3350 
46 0.2M tri-Sodium Citrate dihydrate 20% (w/v) PEG 3350 
47 0.2M tri-Potassium Citrate monohydrate 20% (w/v) PEG 3350 
48 0.2M di-Ammonium hydrogen Citrate 20% (w/v) PEG 3350 
Table J4: PEG ion screen components. 
 
 
 
J6a Newcastle screen 
1  50% (w/v) PEG 
400  
0.2 M Lithium Sulphate  0.1 M Sodium acetate pH 5.1  
2  20% (w/v) PEG 
3000  
0.1 M Sodium citrate pH 5.5  
3  20% (w/v) PEG 
3350  
0.2 M Diammonium hydrogen citrate pH 5.0  
4  30% (v/v) MPD  0.08 M Calcium chloride  0.1 M Sodium acetate pH 4.6  
5  20% (w/v) PEG 
3350  
0.2 M Magnesium formate pH 5.9  
6  20% (w/v) PEG 
1000  
0.2 M lithium sulphate  0.25 M 
Sodiumcitrate pH 
4.2  
0.25 M sodium dihydrogen 
phosphate pH 5.2  
7  20% (w/v) PEG 
8000  
0.1M CHES pH 9.5  
8  20% (w/v) PEG 
3350  
0.2 M Ammonium formate pH6.6  
9  20% (w/v) PEG 
3350  
0.2 M Ammonium chloride pH 6.3  
10  20% (w/v) PEG 
3350  
0.2 M Potassium formate pH 7.3  
11  50% (v/v) MPD  0.2 M Ammonium 
dihydrogen phosphate  
0.1M Tris pH 8.5  
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12  20% (w/v) PEG 
3350  
0.2 M Potassium nitrate pH 6.9  
13  0.8 M 
Ammonium 
sulphate  
0.1M Citric acid pH 4.0  
14  20% (w/v) PEG 
3350  
0.2 M Sodium  
thiocyanate pH 6.9  
 
15  20% (w/v) PEG 
6000  
0.1M Bicine pH 9.0  
16  10% (w/v) PEG 
8000  
8% (v/v) Ethylene glycol  0.1 M HEPES pH 7.5  
17  40% (v/v) MPD  5% (w/v) PEG 8000  0.1M Sodium cacodylate pH 7.0  
18  40% (v/v) 
Ethanol  
5% (w/v) PEG 1000  0.25 M Sodium 
citrate pH 5.2  
0.25 M Sodium dihydrogen 
phosphate pH 5.2  
19  8% (w/v) PEG 
4000  
0.1M Sodium acetate pH 4.6  
20  10% (w/v) PEG 
8000  
0.2 M Magnesium chloride  0.1 M Tris pH 7.0  
21  20% (w/v) PEG 
6000  
0.1M Citric acid pH 5.0  
22  50% (w/v) PEG 
200  
0.2 M Magnesium chloride  0.1 M Sodium cacodylate pH 6.6  
23  1.6 M Sodium citrate pH 6.5  
24  20% (w/v) PEG 
3350  
0.2 M Potassium citrate pH 8.3  
 
 
 
J6b Newcastle screen 
25  30% (v/v) MPD  0.02 M Calcium chloride  0.1M Sodium acetate pH 4.6  
26  20% (w/v) PEG 
8000  
0.2 M Sodium chloride  0.25 M Sodium 
citrate pH 4.2  
0.25 M Sodium dihydrogen 
phosphate pH 4.2  
    
27  20% (w/v) PEG 
6000  
1.0 M Lithium chloride  0.1 M Citric acid pH 4.0  
28  20% (w/v) PEG 
3350  
0.2 M Ammonium nitrate pH 6.3  
29  10% (w/v) PEG 
6000  
0.1M HEPES pH 7.0  
30  0.8 M Ammonium 
dihydrogen 
phosphate  
0.8 M Potassium dihydrogen 
phosphate  
0.1M HEPES pH 7.5  
31  40% (w/v) PEG 300  0.25 M Sodium citrate pH 
5.2  
0.25 M Sodium dihydrogen phosphate pH 5.2  
32  10% (w/v) PEG 
3000  
0.2 M Zinc acetate  0.1 M Sodium acetate pH 4.5  
33  20% (v/v) Ethanol  0.1 M Tris pH 8.5  
34  25% (v/v)1-2-
Propanediol  
0.1M Sodium potassium 
phosphate pH 6.8  
10% (v/v) glycerol  
35  10% (w/v) PEG 
20000  
2% (v/v) Dioxane  0.1M Bicine pH 9.0  
36  2.0 M Ammonium 
sulphate  
0.1M Sodium acetate pH 4.6  
37  10% (w/v) PEG 
1000  
10% (w/v) PEG 8000  
38  24% (w/v) PEG 
1000  
20% (v/v) Glycerol  
39  30% (v/v) PEG 400  0.2 M Magnesium chloride  0.1M HEPES pH 7.5  
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40  50% (w/v) PEG 200  0.2 M Sodium chloride  0.1 M Sodium potassium phosphate pH 7.2  
41  30% (w/v) PEG 
8000  
0.2 M Lithium sulphate  0.1M Sodium acetate pH 4.5  
42  70% (v/v) MPD  0.2 M Magnesium chloride  0.1 M HEPES pH 7.5  
43  20% (w/v) PEG 
8000  
0.1M Tris pH 8.5  
44  40% (v/v) PEG 400  0.2 M Lithium sulphate  0.1 M Tris pH 8.4  
45  40%(v/v) MPD  0.1M Tris pH 8.0  
46  25.5% (w/v) PEG 
4000  
0.17 M Ammonium sulphate  15% (v/v) Glycerol  
47  40% (w/v) PEG 300  0.2 M Calcium acetate  0.1M Sodium cacodylate pH 7.0  
48  14% (v/v) 
Isopropanol  
0.14 M Calcium chloride  0.07M Sodium 
acetate pH 4.6  
30% (v/v) glycerol  
 
 
J6c Newcastle screen 
49  16% (w/v)PEG 8000  0.04 M Potassium 
dihydrogen phosphate  
20% (v/v) Glycerol  
50  1.0 M Sodium citrate  0.1 M sodium cacodylate pH 6.5  
51  2.0 M Ammonium 
sulphate  
0.2 M Sodium chloride  0.1 M Sodium cacodylate pH 6.5  
52  10% (v/v) Isopropanol  0.2 M Sodium chloride  0.1 M HEPES pH 7.5  
53  1.26 M Ammonium 
sulphate  
0.2 M Lithium sulphate  0.1M Tris pH 8.5  
54  40% (v/v) MPD  0.1M CAPS pH 10.1  
55  20% (w/v)PEG 3000  0.2 M Zinc acetate  0.1M Imidazole pH 8.0  
56  10% (v/v) Isopropanol  0.2 M Zinc acetate  0.1M Sodium cacodylate pH 6.5  
57  1.0M Diammonium 
hydrogen phosphate  
0.1 M Sodium acetate pH 4.5  
58  1.6 M Magnesium 
sulphate  
0.1M MES pH 6.5  
59  10% (w/v)PEG 6000  0.1 M Bicine pH 9.0  
60  14.4% (w/v)PEG 8000  0.16 M Calcium acetate  0.08 M Sodium 
cacodylate pH 
6.5  
20% (v/v) glycerol  
61  10% (w/v)PEG 8000  0.1 M Imidazol pH 8.0  
62  30% (v/v) Jeffamine  0.05 M Caesiumchloride  0.1 M MES pH 6.5  
63  3.2 M Ammonium 
sulphate  
0.1 M Citric acid pH 5.0  
64  20% (v/v) MPD  0.1 M Tris pH 8.0  
65  20% (v/v) Jeffamine  0.1M HEPES pH 6.5  
66  50% (v/v) Ethylene glycol  0.2 M Magnesium chloride  0.1 M Tris pH 8.5  
67  10% (v/v) MPD  0.1 M Bicine pH 9.0  
68  0.2 M Ammonium 
sulphate  
0.1 M Sodium acetate pH 
4.6  
30% (w/v) PEG MME 2000  
69  0.2 M Ammonium 
sulphate  
0.1 M MES pH 6.5  30% (w/v) PEG MME 5000  
70  0.01 M Zinc sulphate  0.1 M MES pH 6.5  25% (w/v) PEG MME 550  
71  0.01 M Nickel chloride  0.1 M Tris pH 8.5  20% (w/v) PEG MME 2000  
72  0.1 M Sodium chloride  0.1 M Bicine pH 9.0  20% (w/v) PEG MME 550  
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J6d Newcastle Screen 
73  0.005 M Magnesium chloride  0.05 M HEPES pH 
7.0  
25% (w/v) PEG MME 550  
74  0.1 M Potassium chloride  0.015 M Magnesium 
chloride  
0.05 M Tris pH 7.5  10% PEG MME 550  
75  20% (v/v)1-4- Butandiol  0.1 M MES pH 6.0  0.2 M Lithium sulphate  
76  1 M Sodium potassium tartrate  0.1 M Imidazole pH 
8.0  
0.2 M Sodium chloride  
77  20% (v/v)1-4-Butandiol  0.1M Sodium acetate pH 4.5  
78  1M Sodium potassium tartrate  0.1 M CHES pH 9.5  0.2 M Lithium sulphate  
79  35% (v/v) Propanol  0.1 M Sodium cacodylate pH6.5  
80  35% (v/v) Propanol  0.1 M Tris pH 8.5  
81  3.5 M Sodium formate  
82  0.8M Succinic acid pH 7.0  
83  2.1 M Malic acid pH 7.0  
84  2.4 M Sodium malonate pH 7.0  
85  0.2 M Potassium chloride  0.05 M HEPES pH 
7.5  
35% (v/v) Pentaerythritol propoxylate  
86  0.005 M Ammonium sulphate  0.05 M Tris pH 6.5  30% (v/v) Pentaerythritol ethoxylate  
87  0.2 M Potassium bromide  25% (w/v) PEG MME 
2000 
0.1 M HEPES pH 7.5  
88  0.2M Potassium bromide  8% (w/v)PEG 20000  8% (w/v) PEG MME 
550  
0.1 M Tris pH 8.5  
89  1.0 M Potassium dihydrogen 
phosphate  
0.1 M Sodium citrate pH 4.6  
90  0.5 M Potassium dihydrogen 
phosphate  
0.1M HEPES pH 7.0  
91  20% (w/v)PEG 4000  0.005 M Cadmium 
chloride  
0.1 M Tris pH 8.0  
92  20% (w/v)PEG 4000  0.005 M Nickel 
chloride  
0.1 M MED pH 6.5  
93  0.8 M Sodium formate  10% (w/v) PEG 8000  10% PEG 1000  0.1 M imidazol pH 
8.0  
94  15% (w/v)PEG 4000  0.005 M Cadmium 
sulphate  
0.1 M Sodium cacodylate pH 6.5  
95  20% (w/v) PEG 600  0.005 M Cobalt 
chloride  
0.1 M HEPES pH 7.5  
96  2 M Ammonium sulphate  10% (v/v) Jeffamine  0.1 M Tris pH 8.0  
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J7a Index Screen 
1.   0.1 M Citric Acid pH 3.5, 2.0 M Ammonium Sulfate 
2.   0.1 M Na Acetate pH 4.5, 2.0 M Ammonium Sulfate 
3.   0.1 M Bis-Tris pH 5.5, 2.0 M Ammonium Sulfate 
4.   0.1 M Bis-Tris pH 6.5, 2.0 M Ammonium Sulfate 
5.   0.1 M HEPES pH 7.5, 2.0 M Ammonium Sulfate 
6.   0.1 M Tris pH 8.5, 2.0 M Ammonium Sulfate 
7.   0.1 M Citric Acid pH 3.5, 3.0 M Sodium Chloride 
8.   0.1 M Na Acetate pH 4.5, 3.0 M Sodium Chloride 
9.   0.1 M Bis-Tris pH 5.5, 3.0 M Sodium Chloride 
10. 0.1 M Bis-Tris pH 6.5, 3.0 M Sodium Chloride 
11. 0.1 M HEPES pH 7.5, 3.0 M Sodium Chloride 
12. 0.1 M Tris pH 8.5, 3.0 M Sodium Chloride 
13. 0.1 M Bis-Tris pH 5.5, 0.5 M Magnesium Formate 
14. 0.1 M Bis-Tris pH 6.5, 0.5 M Magnesium Formate 
15. 0.1 M HEPES pH 7.5, 0.3 M Magnesium Formate 
16. 0.1 M Tris pH 8.5, 0.3 M Magnesium Formate 
17. 1.4 M Sodium/Potassium Phosphate pH 5.6 
18. 1.4 M Sodium Potassium Phosphate pH 6.9 
19. 1.4 M Sodium Potassium Phosphate pH 8.2 
20. 0.1 M HEPES pH 7.5, 1.4 M Sodium Citrate 
21. 1.8 M tri-Ammonium Citrate pH 7.0 
22. 0.8 M Succinic Acid pH 7.0 
23. 2.1 M DL-Malic Acid pH 7.0 
24. 2.8 M Sodium Acetate pH 7.0 
25. 3.5 M Sodium Formate pH 7.0 
26. 1.1 M di-Ammonium Tartrate pH 7.0 
27. 2.4 M Sodium Malonate pH 7.0 
28. 35% v/v Tacsimate pH 7.0 
29. 60% v/v Tacsimate pH 7.0 
30. 0.1 M Sodium Chloride, 0.1 M Bis-Tris pH 6.5, 1.5 M Ammonium Sulfate 
31. 0.8 M K/Na Tartrate, 0.1 M Tris pH 8.5, 0.5% PEG MME 5000 
32. 1.0 M Ammonium Sulfate, 0.1 M Bis-Tris pH 5.5, 1% w/v PEG 3350 
33. 1.1 M Na Malonate pH 7.0, 0.1 M HEPES pH 7.0, 0.5% v/v Jeffamine ED-2001 pH 7.0 
34. 1.0 M Succinic Acid pH 7.0, 0.1 M HEPES pH 7.0, 1% w/v PEG MME 2000 
35. 1.0 M Ammonium Sulfate, 0.1 M HEPES pH 7.0, 0.5% w/v PEG 8000 
36. 15% v/v Tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 2% w/v PEG 3350 
37. 25% w/v PEG 
1500 
 
38. 0.1 M HEPES pH 7.0, 30% v/v Jeffamine M-600 pH 7.0 
39. 0.1 M HEPES pH 7.0, 30% v/v Jeffamine ED-2001 pH 7.0 
40. 0.1 M Citric Acid pH 3.5, 25% w/v PEG 3350 
41. 0.1 M Na Acetate pH 4.5, 25% w/v PEG 3350 
42. 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3350 
43. 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350 
44. 0.1 M HEPES pH 7.5, 25% w/v PEG 3350 
45. 0.1 M Tris pH 8.5, 25% w/v PEG 3350 
46. 0.1 M Bis-Tris pH 6.5, 20% w/v PEG MME 5000 
47. 0.1 M Bis-Tris pH 6.5, 28% w/v PEG MME 2000 
48. 0.2 M Ca Chloride, 0.1 M Bis-Tris pH 5.5, 45% v/v MPD 
49. 0.2 M Ca Chloride, 0.1 M Bis-Tris pH 6.5, 45% v/v MPD 
50. 0.2 M Ammonium Acetate, 0.1 M Bis-Tris pH 5.5, 45% v/v MPD 
51. 0.2 M Ammonium Acetate, 0.1 M Bis-Tris pH 6.5, 45% v/v MPD 
52. 0.2 M Ammonium Acetate, 0.1 M HEPES pH 7.5, 45% v/v MPD 
53. 0.2 M Ammonium Acetate, 0.1 M Tris pH 8.5, 45% v/v MPD 
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J7b Index Screen 
54. 0.05 M Ca Chloride, 0.1 M Bis-Tris pH 6.5, 30% v/v PEG MME 550 
55. 0.05 M Mg Chloride, 0.1 M HEPES pH 7.5, 30% v/v PEG MME 550 
56. 0.2 M K Chloride, 0.05 M HEPES pH 7.5, 35% v/v Pentaerythritol Propoxylate (5/4 
PO/OH) 
57. 0.05 M Ammonium Sulfate, 0.05 M Bis-Tris pH 6.5, 30% v/v Pentaerythritol 
Ethoxylate (15/4 EO/OH) 
58. 0.05 M Bis-Tris pH 6.5, 45% v/v PPG P 400 
59. 0.02 M Mg Chloride, 0.1 M HEPES pH 7.5, 22% w/v Polyacrylic Acid 5100 
60. 0.01 M Co Chloride, 0.1 M Tris pH 8.5, 20% w/v Polyvinylpyrrolidone K15 
61. 0.2 M Proline, 0.1 M HEPES pH 7.5, 10% w/v PEG 3350 
62. 0.2 M Trimethylamine N-oxide, 0.1 M Tris pH 8.5, 20% PEG MME 2000 
63. 0.1 M HEPES pH 7.0, 5% v/v Tacsimate pH 7.0, 10% w/v PEG MME 5000 
64. 0.005 M Co Chloride, 0.005 M Ni Chloride, 0.005 M Cd Chloride, Mg Chloride, 0.1 M 
HEPES pH 7.5, 12% w/v Polyethylene Glycol 3350 
65. 0.1 M Ammonium Acetate, 0.1 M Bis-Tris pH 5.5, 17% w/v PEG 10,000 
66. 0.2 M Ammonium Sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3350 
67. 0.2 M Ammonium Sulfate, 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350 
68. 0.2 M Ammonium Sulfate, 0.1 M HEPES pH 7.5, 25% w/v PEG 3350 
69. 0.2 M Ammonium Sulfate, 0.1 M Tris pH 8.5, 25% w/v PEG 3350 
70. 0.2 M Na Chloride, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3350 
71. 0.2 M Na Chloride, 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350 
72. 0.2 M Na Chloride, 0.1 M HEPES pH 7.5, 25% w/v PEG 3350 
73. 0.2 M Na Chloride, 0.1 M Tris pH 8.5, 25% w/v PEG 3350 
74. 0.2 M Li Sulfate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3350 
75. 0.2 M Li Sulfate, 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350 
76. 0.2 M Li Sulfate, 0.1 M HEPES pH 7.5, 25% w/v PEG 3350 
77. 0.2 M Li Sulfate, 0.1 M Tris pH 8.5, 25% w/v PEG 3350 
78. 0.2 M Ammonium Acetate, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3350 
79. 0.2 M Ammonium Acetate, 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350 
80. 0.2 M Ammonium Acetate, 0.1 M HEPES pH 7.5, 25% w/v PEG 3350 
81. 0.2 M Ammonium Acetate, 0.1 M Tris pH 8.5, 25% w/v PEG 3350 
82. 0.2 M Mg Chloride, 0.1 M Bis-Tris pH 5.5, 25% w/v PEG 3350 
83. 0.2 M Mg Chloride, 0.1 M Bis-Tris pH 6.5, 25% w/v PEG 3350 
84. 0.2 M Mg Chloride, 0.1 M HEPES pH 7.5, 25% w/v PEG 3350 
85. 0.2 M Mg Chloride, 0.1 M Tris Hydrochloride pH 8.5, 25% w/v PEG 3350 
86. 0.2 M K/Na Tartrate, 20% w/v PEG 3350 
87. 0.2 M Na Malonate pH 7.0, 20% w/v PEG 3350 
88. 0.2 M tri-Ammonium Citrate pH 7.0, 20% w/v PEG 3350 
89. 0.1 M Succinic Acid pH 7.0, 15% w/v PEG 3350 
90. 0.2 M Na Formate, 20% w/v PEG 3350 
91. 0.15 M DL-Malic Acid pH 7.0, 20% w/v PEG 3350 
92. 0.1 M Mg Formate, 15% w/v PEG 3350 
93. 0.05 M Zinc Acetate, 20% w/v PEG 3350 
94. 0.2 M Na Citrate, 20% w/v PEG 3350 
95. 0.1 M K Thiocyanate, 30% w/v PEG MME 2000 
96. 0.15 M K Bromide, 30% w/v PEG MME 2000 
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Appendix K : Growth curve of complemented mutants and controls 
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Appendix L  
 
Progenesis SameSpots Analysis of 2D-E images of Complemented mutants and Control.  
 
 
 pH 4                                                                                                                pH 7
 
  
 
Figure L1: Progenesis Comparison of S. equi 4047 WT/pVA838 versus 
ΔPrtm123/pVA838 – Cell Associated Protein Extract 
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Figure L2: Progenesis Comparison of S. equi 4047 WT/pVA838 versus 
ΔPrtm12/pVA838 – Cell Associated Protein Extract 
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Figure L3: Progenesis Comparison of S. equi 4047 WT/pVA838 versus ΔPrtm/pVA838 
– Cell Associated Protein Extract 
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Figure L4: Progenesis Comparison of S. equi 4047 ΔPrtm123/pVA838 versus 
ΔPrtm12/pVA838 – Cell Associated Protein Extract 
 
 
 
 
 
 
   
286 
 
pH 4           pH7 
 
Figure L5: Progenesis Comparison of S. equi 4047 ΔPrtm123/pVA838 versus 
ΔPrtm/pVA838 – Cell Associated Protein Extract 
 
   
287 
 
pH 4               pH7 
 
Figure L6: Progenesis Comparison of S. equi 4047 ΔPrtm/pVA838 versus 
ΔPrtm12/pVA838 – Cell Associated Protein Extract 
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Figure L7: Progenesis Comparison of S. equi 4047 WT/pVA838 versus 
ΔPrtm123/pVA838 –Secreted Protein Extract 
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Figure L8: Progenesis Comparison of S. equi 4047 WT/pVA838 versus 
ΔPrtm12/pVA838 –Secreted Protein Extract 
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Figure L9: Progenesis Comparison of S. equi 4047 WT/pVA838 versus ΔPrtm/pVA838 
– Secreted Protein Extract 
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Figure L10: Progenesis Comparison of S. equi 4047 ΔPrtm123/pVA838 versus 
ΔPrtm12/pVA838 –Secreted Protein Extract 
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Figure L11: Progenesis Comparison of S. equi 4047 ΔPrtm12/pVA838 versus 
ΔPrtm/pVA838 – Secreted Protein Extract 
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Figure L12: Progenesis Comparison of S. equi 4047 ΔPrtm/pVA838 versus 
ΔPrtm123/pVA838 –Secreted Protein Extract.
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